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Abstract 
 
 
In order to achieve efficient gene delivery, we have designed pKa modulatable oligopeptides 
(2COPs) by combining with lysine, histidine and cysteine residues which will bind DNA 
extracellularly, internalize via endocytosis, provide a tunable endosomal release mechanism, 
and provide a degradable backbone in order that the DNA can be released once in the 
cytoplasm. The reducible polycations (RPCs) were synthesized from 2COPs. The sizes, surface 
charges and the stability of RPC polyplexes under the simulated physiological conditions 
extra- and intracellularly suggested that these RPCs are promising vectors. In addition, the 
transfections revealed that the RPCs can facilitate endosomal buffering and intracellular 
reduction and are non-toxic to cells.  
 
The nuclear targeting signal (TAT) was incorporated into these vectors. The reducible 
copolycations (RcPCs) were synthesized via oxidative polymerisation between 2COPs and 
TAT. The RcPC polyplexes are ~100 nm, and are positively charged. Gel shift assay revealed 
that RcPCs have less potential than RPCs to be used as vectors as they are less stable 
extracellularly than the RPCs. In addition, chloroquine was required to enhance the 
transfection of RcPCs. Furthermore, there is no improvement in transfection of RcPC 
compared to RPCs. Therefore, this suggests that the incorporation of TAT does not improve 
the transfection.  
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1       INTRODUCTION 
Abstract  
 
This section overviews vectors used in gene delivery. The types of vectors, 
cellular barriers and the mechanism to overcome gene delivery are described, 
including a review of the previous research which has studied synthetic 
vectors, and the biological hurdles these vectors have to overcome to deliver a 
gene to the cell.  
 
1.1     Introduction to gene delivery 
 
Genes consist of bases that are specific sequences which encode instructions on how to 
produce proteins.[1] When genes are mutated so that the encoded proteins are unable to 
complete their normal functions genetic disorders can result.[2] Gene therapy is a challenging 
technique which could potentially be used to correct defective genes responsible for disease 
development. Since the completion of the Human Genome Project (HGP), gene therapy has 
become an increasingly important  technique which many research groups focus on.[3] There 
are two types of gene therapy, somatic gene therapy[4,5] and germline gene therapy.[6] The 
correction by the former approach can not be inherited by the offspring, whereas the latter 
corrects malfunction in eggs and sperm cells, thus these corrections can be passed down to the 
offspring. It has been claimed that the first clinical trial in gene therapy occurred in the 
1960s,[7-9] when Shope papilloma virus that encoded an enzyme arginase was injected into 
two patients which were suffering from hyperargininemia, a hereditary deficiency of enzyme 
arginase which leads to high level of arginine concentration in blood and celebrospinal fluid 
leading to severe mental retardation.  There have been increasingly more gene therapy clinical 
trials since 1989, as can be seen in Figure 1.1. 
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Figure 1.1.   Number of gene therapy clinical trails approved world wide between years 1989 - 2008.   
(Data from www.wiley.co.uk/genmed/clinical ) 
 
Human gene therapy (HGT) is aimed to correct defective genes by transferring a normal gene 
to the disease cells of a patient. There are several approaches to correct defective genes[10] 
such as (i) the insertion of a normal gene in nonspecific location within the genome, in order 
to replace the function of an abnormal gene,[7,11] (ii) gene exchange through homologous 
recombination in order to replace a nonfunctional gene with a normal gene,[12,13] (iii) an 
abnormal gene could be repaired to a normal gene through selective reverse mutation,[14] and 
(iv) a specific gene could be altered in order to regulate a gene to be turned on or off.[15]  
 
HGT involves multiple steps[3] including delivery to an organ, tissue targeting, cellular 
trafficking, regulation of gene expression, and modulating the biological activity of 
therapeutic proteins. In addition, safety[16] of the vector and gene product need to be 
understood. Most of these issues are not completely understood.  The gene carrier, which is 
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called a vector, must be utilized to deliver the normal gene, and is one of the important parts 
in human gene therapy process.  
 
1.1.1  Vectors for gene delivery   
 
The main objective in gene therapy is successful in vivo transfer of genetic materials to target 
cells of patient. The success or failure of gene therapy depends on the development and 
efficiency of the transfection of vectors. Vectors that have been developed for gene therapy 
approaches are divided into two major groups: viral vectors[17] and non-viral vectors (so-
called synthetic vector).[17]  
  
1.1.1.1 Viral vectors 
 
Viruses have evolved to deliver viral disease-causing genes to specific target cells and utilize 
the mechanisms of the host cell to multiply the new virus particles in a pathogenic manner.[18] 
In gene therapy, viruses are denatured, the viral gene removed, a therapeutic gene is added, 
followed by renaturation of the virus.[17] 
 
There are several types of viruses that have been used in gene therapy such as retroviruses, 
adenoviruses, adeno-associated viruses and herpes simplex viruses.[19] Retrovirus was the first 
to be used as a vector.[20] Retroviruses are RNA viruses that can be reverse transcribed to 
double-stranded DNA copies.[21] These copies of DNA can then be integrated into the human 
genome providing long term and heritable expression of the transduced gene. Major 
limitations of retrovirus are low titre, inability to transfect non-dividing cells and the risk of 
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insertional mutagenesis.[19] A sample of retrovirus is Human Immunodeficiency Virus (HIV). 
Adenoviruses are double-stranded DNA viruses which normally cause the common cold.[22] 
They can introduce their DNA into the nucleus of the cells. Unlike those of retrovirus, 
adenovirus DNA is not integrated into human genome, thus they are safer to use than 
retroviruses and can be produced in high titre. However, using the unintegrated property 
means adenoviral gene delivery is not permanent, and results in protein production for only a 
few days to a few weeks. Adeno-associated viruses (AAV) are believed to occur naturally in 
humans, existing without causing disease or immune response from the body.[22] Adeno-
associated viruses are small single-stranded DNA viruses that can insert their genetic material 
at a specific site on chromosome 19. However, this type of vector can only carry less than 5 
kb of DNA.  Herpes simplex viruses are double-stranded DNA viruses that can infect a 
particular cell type, neurons.[22]  
 
Using viral vectors for gene therapy is efficient. However, there are many hurdles[23] such as 
the limited amount of  DNA that viruses can carry (Table 1.1).[24]  
 
Table 1.1.  Properties of viruses used for gene therapy[24]
Virus Genetic material Genome size (kb) Insert size (kb) 
Retrovirus 
Adenovirus 
AAV 
HSV-1 
Poxvirus 
Linear single-stranded RNA 
Linear double-stranded DNA 
Linear single-stranded DNA 
Linear double-stranded DNA 
Linear double-stranded DNA 
7-11 
36 
4.7 
152 
130-280 
4 
8-9 
4.5 
30 
30 
 
 
References for Chapter 1 are on page 56-73. 10
Moreover, viral vectors can be toxic,[16] immune responses,[16] are difficult to manufacture at 
high titres, are expensive to produce and patient compliance is poor. An alternative way to 
address these drawbacks is with non-viral vectors as a result of (i) the ease of chemical 
manipulation, which can aid incorporation of essential vector features such as targeting 
ligands[25] and nuclear localization signal,[26] (ii) the higher capacity to deliver genetic 
material, (iii) lower toxicity, (iv) lower cost and easy scale-up processes, and (v) better patient 
compliance.[16,17] The summary of the advantages and limitations of viral and non-viral 
vectors also show in Table 1.2. 
 
 
Table 1.2 Advantages and limitations of viral and non-viral vectors[16,17,25-29] 
 
Advantages/Limitations Viral vectors Non-viral vector 
Advantages 
- higher transduction efficiency 
- long-term gene expression as some 
viruses can facilitate genetic 
integration into genome (retrovirus, 
AAV) 
- broad host range 
- some viruses are non-pathogenic    
  (AAV) 
- ease of manipulation 
- high flexibility on size of the delivered    
  transgene 
- safety 
- low cost 
- good patient compliance 
Limitations 
- cytotoxicity 
- immunogenicity 
- genetic material capacity limitation  
  (retrovirus, adenovirus, AAV) 
- Insertional mutagenesis (retrovirus) 
- difficulty to manufacture at high   
   titres 
- highly expensive to produce   
- poor patient compliance 
- poor transfection efficiency 
- transient gene expression 
- rapid plasma clearance (liposomes) 
- need targeting ligands for deliver to 
specific tissue such as transferin  
- need to escape from endosome 
- need nuclear localization signal for 
nuclear import in non-dividing cells 
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1.1.1.2 Non-viral vectors or synthetic vectors  
 
Currently, many researchers are interested in studying non-viral gene delivery systems,[30] 
since synthetic vectors are safer and are able to carry more copies of the gene than viral 
vectors. Furthermore, they can be manipulated more readily than viral vectors. Synthetic 
vectors are generally polycationic in nature, therefore, they can form complexes with the 
polyanionic phosphate backbone of the DNA or RNA. The net charge of these complexes is 
designed to be positive, which will enable the complexes to interact with the anionic nature of 
cell membranes, facilitating internalization into cells by syndecan-mediated endocytosis.[31] 
During the last decade efforts to design synthetic vectors have been made by taking advantage 
of the electrostatic self-assembly of nucleic acids with polycationic materials.[32] There are 
many types of synthetic vectors that have been used such as cationic lipids[33,34] and cationic 
polymers.[35-42] Polyamines are among the earliest compounds that were identified as DNA 
condensing agents.[43,44]  
 
1.1.1.2a Cationic lipids 
Cationic lipids that form liposomes have become one of the most studied non-viral 
vectors.[33,34] They condense with DNA via electrostatic interaction. Cationic liposomes are 
promising non-viral delivery systems for gene therapy, although the biochemical and 
biophysical mechanisms of these vectors with respect to gene transfection and expression are 
not thoroughly understood.[45] Most of the cationic lipids used as transfection reagents have 
three parts: (i) hydrophobic lipid anchor group which can be either a double chain 
hydrocarbon such as N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride 
(DOTMA),[46] 1,2-bis(oleoyloxy)-3-(timethylammonio)propane (DOTAP),[47] and dioctadecyl 
amino glycil spermine (DOGS, Transfectam®)[48] or a cholesterol derivative such as 3β[N-
(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol),[49] (ii) linker group such as 
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an ester, amide or carbamate, and (iii) a positively charge head group which interacts with the 
nucleic acid backbone (Figure 1.2).[50,51]  
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Figure 1.2.  Cationic lipids; a) N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA), 
b) 1,2-bis(oleoyloxy)-3-(timethylammonio)propane (DOTAP), c) dioctadecyl amino glycil 
spermine (DOGS), and d) 3β[N-(N′,N′-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol) 
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The model of DNA release from lipoplexes into the cytoplasm was proposed by Xu and 
Szoka[52] and called the flip-flop mechanism (Figure 1.3). The interaction between cationic 
lipids of lipoplexes and endogenous anionic lipids may promote membrane fusion and 
transport of DNA across the cell membrane. Thus, the key attribute of lipoplexes may be the 
ability of the lipid to dissolve into and undergo translational movement within lipid bilayers.  
 
Figure 1.3. Flip-flop mechanism to uptake  lipoplexes and subsequently release of DNA.[52]  After 
electrostatic interaction of cationic lipoplexes with the plasma membrane, lipoplexes are 
internalized by endocytosis (step 1) followed by the fusion of the lipid bilayers and a vesicle is 
formed if the membrane pinches off from the cell membrane (step 2). In the early endosome, 
membrane destabilization results in anionic lipids diffusing into the vesicle and forming a charge 
neutral ion pair with the cationic lipids (step 3). The DNA dissociates from the vesicle and enters 
the cytoplasm (step 4).  
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Reducible cationic lipids (RCLs) (Figure 1.4) have also been developed for gene transfer by 
incorporating disulfide bonds in either the hydrophilic or hydrophobic part of cationic lipids, 
or within an alkyl chain in order to enhance DNA release from lipoplexes after intracellular 
reduction.[34,53] The transfection by RCLs was 1000-fold greater than their analogues without 
disulfide bonds.[53]  
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Figure 1.4.   Reducible cationic lipids (RCLs) stuctures.[53] Lipids with disulfide bond within hydrophobic 
chain (a.b), and control lipid without disulfide bond (c) 
 
Water soluble cationic lipopolymer (WSLP) (Figure 1.5) has been synthesized by 
conjugating cholesterol choroformate directly to branched PEI 1800 Da.[54,55] The cholesterol 
was used as a lipophilic portion grafted onto branched PEI which serves as a hydrophilic head 
group. The mean size of WSLP/DNA complexes was approximately 70 nm. The transfection 
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efficiency of WSLP was higher than PEI 1800 Da, PEI 2500 Da, and naked DNA. 
Furthermore, WSLP is less toxic than PEI.[55]  
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Figure 1.5.   Water soluble cationic lipopolymer (WSLP)[54]  
 
1.1.1.2b Cationic polymers 
Cationic polymers have been widely studied as vectors for gene delivery. They include 
polyethylenimine (PEI)[35-40] and amine containing dendrimers[41,42] which complex with the 
gene. The complex is referred to as a polyplex.  
 
  (i) Polyethyleneimine (PEI) 
Branched PEI polymers contain primary, secondary and tertiary amino groups (Figure 1.6). 
This polymer has wide range of buffering capacity (pKa values of primary, secondary and 
tertiary amines are 9, 8 and 6-7, respectively) which allows varying degree of  protonation of 
the amine groups in the complex depending on the local pH.[56] The overall protonation level 
increases from 20 to 45% between pH 7 and 5.[57,58] This buffering property is very useful in 
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in vivo applications where it can lead to a release process from the endosome (proton sponge 
hypothesis).[36,58,59] PEI is inexpensive, easily available, and its potential use in gene delivery 
has generated much interest.[37,56,60,61]  
 
 a) Branched PEI       b) Linear PEI 
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Figure 1.6.   Polyethyleneimine (PEI) structures; a) branched PEI, and b) Linear PEI 
 
The combination of a cell-binding ligand and endosomolytic activity of PEI has been 
demonstrated which can lead to very efficient gene delivery systems.[62]  Some of which may 
be used for condensing and linking plasmid DNA to adenovirus particles.[63] However, PEI 
can cause significant in vivo toxicity in cultured cells. PEI is an organic polymer which can 
not be degraded by cellular enzymes. As a result, total body clearance of high molecular 
weight PEI is a slow process which leads to the accumulation of PEI in vivo.[38] To overcome 
this drawback, the introduction of disulfide bonds into low molecular weight PEI (800 Da) 
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through dimethyl-3,3’-dithiobispropionimidate•2HCl (DTBP) have been designed (Figure 
1.7) to promote reversion of high molecular weight polyplexes back to their low molecular 
weight counterparts which should  clear more easily from the body.[35]  PEI (1800 Da) has 
also been cross-linked with DTBP (CLPEI50%, molar ratio of cross-linker reactive group to 
PEI primary amine was 1:2) and was found that the polyplexes were reduced by GSH at a 
concentration of 3 mM.[64]   
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Figure 1.7.   Proposed reaction scheme of DTBP (dimethyl-3,3’-dithiobispropionimidate•2HCl)  cross-
linked PEI[35] 
 
It was found that the cytotoxicity of low molecular weight PEI (LMW-PEI, 5.4 kDa) was 
reduced by more than one order of magnitude compared with high molecular weight PEI 
(HMW-PEI, 25 kDa). Moreover, LMW-PEI was shown to increase the transfection efficiency 
in many types of cell lines.[37] The corporation of the fusogenic peptide (KALA, 
WEAKLAKALAKALAKHLAKALAKALKACEA) and PEI has also been modulated in 
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order to combine the endosomal escape and DNA condensation properties of PEI, as well as 
the cellular entry properties of KALA. The DNA polyplex was produced by condensing DNA 
with PEI as the core component and the outer layer linked with KALA. This tricomposite 
showed transfection efficiency better than that by either of KALA or PEI polyplexes alone.[60]   
 
  (ii) Dendrimers 
Dendrimers are a more recent class of cationic polymers that have been used as vectors for 
gene delivery.[41] A dendrimer[65] is a tree-like highly branched monodisperse polymer 
molecule. Dendrimers can be synthesized by two different routes which are convergent[66] and 
divergent[67] routes to form a tree-like architecture (Figure 1.8).  
 
 
 
Figure 1.8.  Dendrimer synthesis by convergent and divergent routes 
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Several different kinds of dendrimers have been synthesized,[68-70] for instance, 
polyamidoamine (PAMAM) is a dendrimer formed from the amidoamine monomer which is 
terminated with amine groups (Figure 1.9)[69] consist of highly ordered, three dimentional, 
hyperbranched arrays of dendrons. They are synthesized by iterative reaction sequences with 
methylacrylate and ethylenediamine.[65]  
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Figure 1.9. Structure of  polyamidoamine (PAMAM) dendrimer. (The core is shown in red (G0). Primary 
(G1) and  secondary (G2) generations are shown in blue and green, respectively) 
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Dendrimer size is designated by a generation number. After one reaction iteration on the 
initiator core, the dendrimer is a generation 0 dendrimer (G0), and with each subsequent 
reaction iteration, the generational number increases by one. PAMAM dendrimers have 
multiple terminal primary amine groups with pKa of approximately 9, thus at physiological 
pH these amine groups are protonated which gives a spheroidal polycation character and their 
tertiary amines have a pKa of 5.5.[71,72] The tertiary amines are able to buffer the endosome 
and prevent plasmid degradation. The capability of dendrimers in cell transfection depends on 
their size, structure and number of amino group on the surface.[41]   PAMAM dendrimers from 
G2-G10 were used to study their gene transfer properties in vitro.  The G6 dendrimer at 
charge ratio of 1:6 (-/+) produced maximal transfection levels at 1000-fold greater gene 
expression in CV-1 cells than that from PLL and 100-fold greater than that from DOTMA-
based lipoplexes.[71 A fusogenic peptide, GALA (WEAALAEALAEALAEHLAEALAEAL 
EAL(C)AA), was modified by replacing leucine (L) at position 28 with cysteine (C) and  
attaching it to a modified PAMAM (G5) dendrimer by disulfide bond formation (Figure 
1.10).[71] The combination of a fusogenic peptide and a dendrimer resulted in improving the 
transfection efficiency because GALA catalyzed the endosomal lysis leading the free 
drendriplex escaped to the cytoplasm.    
 
Figure 1.10.   The model of modified PAMAM attached to GALA via disulfide bond formation[71] 
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The investigation of in vitro transfection efficiencies of dendrimer complexes has also been 
studied by Tomlinson and colleagues.[73] The mean size of the complexes were shown to be 
monodisperse and below 200 nm at charge ratios of 1:0.25 to 1:6 (-/+). The maximum 
transfection efficiency was also observed with G5 and G6 dendrimer complexes at a charge 
ratio of 1:6 (-/+). The larger dendrimers resulted in significant cell toxicity.  
Polypeptides are also used as vector as will be described later. 
 
1.1.2  Cellular barriers to gene delivery 
 
There are several cellular barriers that need to be overcome in order for a gene to be delivered 
to the nucleus.[74,75]  The polyplexes have to protect the nucleic acids from degradation by 
nucleases[74] and the interactions with blood components extracellularly, which would result 
in the clearance of the polyplexes. Cells must be able to internalize the vector/DNA or RNA 
polyplexes in the form of an endosome by endocytosis.[76] When internalized into the 
cytoplasm the polyplexes must be able to escape from the endosomal compartment by the 
proton sponge mechanism.[58] Once released to the cytoplasm, the polyplexes have to unpack 
and release the nucleic acid.[75] If the polyplexes were formed with RNA, then it can be 
expressed transiently by the cell. If the polyplexes were formed with DNA, the transportation 
of DNA to the nucleus is essential. In the nucleus, the normal DNA replaces the abnormal 
DNA or is transcribed to mRNA which is exported to the cytoplasm, where it is translated to 
the therapeutic protein (Figure 1.11). Thus, the design of a vector carrying DNA needs to 
have several factors (i) gene binding, (ii) cell targeting, (iii) cell uptake, (iv) endosomal 
escape, (v) DNA release and (vi) nuclear localization. 
 
 
Figure 1.11.   Gene delivery by non-viral vector system.  Cationic polyplex interacts with anionic cell membrane then enters into cell by endocytosis (a). pH in endosome 
drop from 7 to 5 by proton and chloride ions accumulation (b) which cause water influx since the increasing of the osmolarity in the endosome, and result 
endosomal disrubtion eventually (c) The free polyplex in cytosol then has to unpack and release free nucleic acid (d) then DNA translocates to nucleus (e) for 
further DNA trancription (f) and mRNA translation (g). 
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In this section, extra- and intracellular barriers for gene delivery will be described.  
 
1.1.2.1 Extracellular barriers 
 
 1.1.2.1a Biodistribution and interaction in bloodstream 
In general, opsonization occurs in the bloodstream when foreign particles are coated by 
specific plasma proteins (opsonins), which allows macrophages to recognize and remove 
foreign particles from the bloodstream.[77]  The opsonization of hydrophobic particles has 
been shown to occur more quickly than hydrophilic particles due to the higher adsorbability 
of plasma proteins on the surfaces.[78] A study of liposome clearance from blood circulation 
by opsonization,[79] showed that hydrophobic particles are opsonized and taken up by fixed 
macrophages of liver and spleen with 80-90% efficiency within a few minutes of intravenous 
administration. Therefore, non-viral delivery systems must have a hydrophilic surface in order 
not to be opsonized. [80, 81]  
 
Particle size is also significant for survival in bloodstream. Particle diameters that are greater 
than 7 µm cause capillary blockage, regardless of their surface properties. [79] Whilst particle 
diameter less than 1 µm may circulate longer in  the bloodstream if there are no interactions 
with blood components or fixed macrophages.[79] Normally, a single plasmid could be 
condensed to approximately 25 nm in diameter.[82] However, the polyplexes mostly contain 
several plasmids which lead to sizes of 100-150 nm in diameter.[83] At physiological salt 
concentration (~0.1M),[84] however, the polyplexes tend to aggregate,[85] and they are bound 
with negative serum proteins resulting in larger sizes (200-1000 nm in diameter).[86,87] This 
aggregation results in mobility retardation of the polyplexes to the target cells.[81]  
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1.1.2.1b Cell targeting 
Synthetic vectors that are non-specific are able to transfer a gene in vitro, however, these 
vectors are unable to transfer genes in vivo, since they are non-specific to the target cells.[88, 89] 
In order to target the specific cells, the vector needs to be coupled with a ligand which is able 
to bind to a receptor on the cell surface.[25] The most widely used preexisting targeting ligands 
are based on endogenous molecules which are already present in the body such as folic 
acid[90] and transferrin.[91-95] The receptor of folic acid is overexpressed on a number of human 
tumors via folate receptor-mediated endocytosis.[90] Transferrin is a serum iron transport 
protein which delivers Fe(III) into cells via receptor-mediated endocytosis, and has become 
one of the most widely used ligands for targeting the synthetic vectors. For example, Wagner 
and colleagues[93] used conjugates of PLL-trasferrin to bind and condense DNA and deliver it 
to the transferrin receptor, where upon it enters the cell via endocytosis in vitro.  A galactose-
terminated (asialo-) glycoprotein, asialoorosomucoid (AsOR), is a ligand of 
asialoglycoprotein receptor of the liver, and was linked to polylysines in order to condense 
with DNA.  This glycosylated-PLL could carry the DNA to the liver in vivo via  receptor-
mediated gene delivery.[96]  
 
1.1.2.1c Cell uptake  
The uptake of most macromolecules or particles into cells by passive duffusion across the 
plasma membrane is limited by their solubility in the lipid bilayer. Endocytosis[76] is the 
process by which substances are internalized into cell (Figure 1.12). When a polyplex binds 
to the cell an extracellular portion of the plasma membrane is invaginated and pinched off 
forming a membrane–bounded vesicle called an endosome which encases the polyplex.[97] 
There are several pathways of endocytosis.  
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  a) Phagocytosis – or cell eating – is a form of endocytosis which occurs in 
phagocytes cells such as macrophages, dendritic cells and neutrophils to capture solid 
particles that are larger than 0.5 µm such as bacteria, phatogens and particulate antigens by 
pseudopodium (Figure 1.12a). The phagosome then fuses with the lysosome to hydrolyse the 
particles. The sizes of phagosomes vary from 0.5-4 µm.[98]  
   b) Pinocytosis – or cell drinking – occurs in almost all cells. Pinocytosis is the 
process that small particles or extracellular fluid are brought into cell by the invagination of 
the cell membrane which then pinches off to form endocytic vesicle called a pinosome 
(Figure 1.12b), which subsequently fuses with the lysosome to hydrolyse the particles. The 
size of micropinosome is 95-100 nm, whilst a macropinosome is 0.5-2 µm.[99]    
  c) Receptor-mediated endocytosis, in general, also called clathrin-dependent 
endocytosis,[100] is a major route of most cells to internalize molecules by strong binding of a 
ligand to a specific cell surface receptor leading to the invagination of coated pits which pinch 
off from the membrane to form a vesicle called an endosome (Figure 1.12c). The coated pit is 
a region of the membrane that is coated with clathrin for stability and to aid the transport 
process. Other examples of receptors, such as transferrin receptor and folate receptor, are cell 
uptaking via receptor- mediated endocytosis described in section 1.1.2.1b.   
  d) Syndecan-mediated endocytosis is an internalization process of positively 
charge polyplexes which adhere to the negatively charge heparan sulfate proteoglycans 
(HSGPs) of transmembrane syndecan expressed on surface of all adherent cells[101,102] via 
electrostratic interactions (Figure 1.12d).[103,104] Cationic polyplexes that enter into cell by 
this process are, for instance, protonated PEI[104] and PLL polyplexes.[103,104] 
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a) Phagocytosis b) Pinocytosis c) Recepter-mediated 
    endocytosis 
d) Syndecan-mediated    
    endocytosis 
 
Figure 1.12.   Endocytic pathways; a) Phagocytosis, b) Pinocytosis, c) Recepter-mediated endocytosis,  
    d) Syndecan-mediated endocytosis 
 
1.1.2.2 Intracellular barriers  
 
1.1.2.2a Endosomal escape 
As the pH decreases in the endosome from the early (pH ~6) to late (pH ~5-6) endosome, and 
finally fuses with the lysosomes (pH ~4.5) by the ATPase proton pumps,[105] many of the 
proteins and lipids begin to degrade in the late endosome. Therefore, after internalization into 
the cell, the polyplex has to be released from the endosome before reaching the late endosome 
state where it would be degraded.[97,106] A mechanism for endosomal polyplex release is based 
upon proton sponge hypothesis.[59] This postulates enhanced transgene delivery by polyplexes 
containing H+ buffering polyamines. As the pH in the endosome is buffered by the 
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polyplexes, the ATPase continues to pump protons into the endosome. This buffering leads to 
an influx of chloride counterions and increases the osmotic pressure, thus, inducing osmotic 
swelling by water influx into the vesicle and eventual lysis. The synthetic vectors that are able 
to release the polyplex by this mechanism are cationic polymers such as PEI,[36,107] since they 
have a capability to buffer the endosomal vesicle. PEI is able to condense DNA at 
physiological pH, but contains a proportion of tertiary amines that protonate only at lower pH. 
Thus, PEI becomes protonated in the endosome when the pH drop and causes the endosome 
disruption.[40] Figure 1.13 shows the mechanism of the proton sponge.  
 
 
Figure 1.13.  The proton sponge mechanism; a) Due to the pH buffeing in the endosome, the protons are 
continued to pump in the the vesicle resulting in Cl- influx and increase in the osmolarity inside 
the endosomal vesicle. b) Because of the osmolarity increase, water passes into the endosomal 
vesicle. (c) The increase of water volume results in the swelling of the endosomal compartment 
until it ruptures to release the polyplex into the cytoplasm which leads to nuclear uptake of DNA.     
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  - Endosomolytic compound 
Chloroquine (Figure 1.14), a low molecular weight drug used as a treatment for malaria,[108] 
has been also used in conjunction with the polyplexes.[107] Chloroquine is a weak base with 
pKa of 8.1 and 10.2 and is able to diffuse into low-pH compartments, whereupon it is 
protonated and buffers acidic vesicles, which aids the lysis of the endosome. At approximate 
concentration 100 µM, chloroquine causes substantial improvement in the transfection 
efficiency. Although cells may be exposed to relative low concentration of chloroquine (100 
µM) during the transfection, the concentration within cells is found to be much higher and this 
causes toxicity to cell and further increases in concentration causes substantial loss of cell 
viability.[109, 110] 
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Figure 1.14.  Structure of chloroquine 
 
There were developments of pH-dependent degradation polymer using polyacetals,[111,112] as it 
is degraded rapidly in endosomal pH (41% MW loss in 25 hours) resulting in non-toxic to 
cells. 
 
  1.1.2.2b Nuclear localization   
The DNA must be internalized into the nucleus in order to either replace the non-functional 
gene or transcribe to mRNA for furthering translation to the therapeutic protein.[113] The 
nuclear membrane is a barrier for most macromolecules that are greater than 40 kDa, unless 
they are able to interact with the nuclear pore active transport system.[113] Nuclear pore 
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complexes (NPCs) are macromolecular assemblies constructed from multiple copies of 
approximately 30 different proteins call nucleoporins.[114] Importins are the carriers to import 
protein into nucleus. Importin-β is mostly used as an import carrier, while importin-α is used 
as an adapter protein to import many proteins through NPCs. In order to locate the nucleus, 
the DNA strand needs to be combined with peptides referred to as nuclear localization signals 
(NLS) which can be recognized by the import carriers in the cytoplasm.[115,116] The 
mechanism of using the NLS peptides to translocate the DNA into the nucleus is shown in 
Figure 1.15.[114,117] Briefly, cargo proteins which contain NLS form complexes with the 
importin-α:β heterodimer (a, b). This heterotrimer then binds to the cytoplasmic filaments of 
NPCs (c) and translocate through the NPCs (d). Inside nuclearplasmic cargo proteins 
disassemble from importin complexes (e, f) and these importins are then recycled to the 
cytoplasm (g). The components involved in the nuclear protein import cycle shown in Table 
1.3.    
 
Table 1.3.  The components in nuclear protein import cycle and their functions 
Component Function 
Importin-α 
Importin-β 
Ran 
Ran-GAP 
NUP50 
CAS 
Adapter that link NLS-protein cargoes to importin-β 
Import factor that carriers protein cargoes through NPCs 
GTP binding protein 
RanGTPase activating protein 
Nucleoporin 50kDa that displaces protein cargoes bound to importin-α  
Nuclear export factor for importin-α 
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Bremner and colleagues[116] demonstrated that a peptide derived from human T cell leukemia 
virus type 1 (HTLV), MPKTRRRPRRSQRKRPPTWAHFPGFGQGSLC, was able to 
condense DNA and mediate levels of transgene expression up to 32-fold higher than PLL-
based polyplexes.[116] The single nuclear localized signal peptide (PKKKRKVEDPYC) 
modified from the NLS of simian virus 40 large tumor antigen was attached to DNA which 
was sufficient for translocation through the nuclear pore.[115] However, the use of SV40 NLS 
was the only apparent benefit when used in gene expression for non-dividing cells.[118]  
Figure 1.15.    Schematic representation of nuclear protein import cycle.  Importin-β form heterodimer with importin-α in cytoplasm (a) which then binds to the protein cargo 
containing nuclear localization signal (NLS) at the regonition site (b). The heterotrimer then binds to cytoplasmic filaments of the nuclear pore complex (NPC) (c), 
and subsequently translocate through the nuclear pore into the nucleoplasm (d). The Ran-GTP binds to the complex resulting in dissociation of importin-α complex 
and NLS-protein cargo is then replaced with NUP50 (e). CAS-RanGTP complex then binds to importin-α to release NUP50 (f) and enables CAS-RanGTP-improtin 
α complex to transport to the cytoplasm. Importin-β and improtin-α complex are recycled into the cytoplasm by the activation of RanGAP resulting in dissociation of 
improtins from the comlexes (g).  
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1.2  Non-viral gene delivery based on synthetic peptides 
 
A main advantage of a synthetic peptide-based DNA delivery system is its flexibility. For 
gene delivery, the composition of the polyplex can be easily modified in order to take 
advantage of specific peptide sequences to overcome extra- and intracellular barriers. As 
described previously, vectors need to bind the nucleic acid extracellularly in order to prevent 
the polyplex degradation. The vectors will then have to promote the endosomal escape after 
internalization into the cell via endocytosis (before it becomes a lysosome where the 
polyplexes are degraded).[97,106] Several peptide sequences are known that can cause pH 
selective endosomal lysis.[119] Furthermore, the intracellular release of DNA from polyplexes 
is necessary for further gene expression. The nuclear localization signal (NLS) has also shown 
to be an essential peptide for nuclear translocation to promote gene delivery.[116,118]  
 
Below, we review the various amino acids that have been incorporated into peptides for gene 
delivery and their function. 
 
1.2.1 Lysine-based peptides: Extracellular binding of DNA 
 
Lysine is one of the most utilized amino acid in gene delivery studies.[88,120-122] The reason 
being is that the primary amino side chain has a pKa of approximately 10.5 (Figure 1.16). The 
high pKa means that at physiological pH (~7.4)[123] the amine groups in a polylysine derivative 
will have a high degree of protonation. Thus, a polycation exists at physiological pH, 
allowing it to bind to DNA via electrostatic interactions. This binding means the polyplex will 
be stable extracellularly. PLL-Polyplexes are biodegradable, which is an advantage if using 
the polyplex in vivo. PLL is commercially available in various molecular weights ranging 
from approximately 1 kDa to 300 kDa. However, high molecular weight PLL shows high 
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levels of toxicity in vitro, and PLL-polyplexes without a targeting ligand has poor transfecting 
ability.[89, 124] The immunogenicity study of the D-isomer of  PLL showed that it induced the 
formation of antibodies; thus rendering it unsuitable for use as a vector.[125]  It is likely that 
PLL-polyplexes are cleared from the blood as a function of molecular weight. PLL20 (20 kDa 
PLL) polyplexes compared to PLL211 (211 kDa PLL) polyplexes displayed 20 times greater 
level clearance in blood after 30 minutes.[126] Wolfert and colleagues[127,128] studied the DNA 
polyplexes formed from PLL at two different molecular weights (3.9 and 244 kDa) as vectors. 
The sizes of polyplexes from PLL3.9 and PLL244 were in the range from 20-30 nm and 120-
300 nm, respectively. However, low molecular weight PLL significantly decreased 
cytotoxicity. PLL54 (54 kDa PLL) was used as vector to form polyplex with mRNA and found 
that it was too stable to release mRNA for further gene expression,[129]  whereas, using lower 
molecular weight PLL (3.4 kDa) improved the transfection, but it still required chloroquine. 
 
Fusogenic peptides are also used in order to increase the transfection efficiency of PLL.[130-132]   
For example, Lys based reducible polycations (RPCs) were oxidatively polymerized from 
CK16C and formed a DNA polyplex which contained a fusogenic peptide 
(GLFEALLELLESLWELLLEA). This polyplex was stable in an extracellular environment 
and could also release DNA intracellularly for nuclear translocation.[133] Targeting ligands, 
such as  transferring, were also conjugated to PLL to improve the transfection efficiency.[93] 
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Figure 1.16. Chemical structures of  amino acids used in peptides for gene delivery 
 
1.2.2 Histidine-based peptides:  Endosomal escape of DNA 
 
An important barrier to be addressed for in vivo gene delivery when using positively charged 
peptide-DNA polyplexes is that they find it difficult to escape from the endosome before it 
becomes a lysosome, because there is no proton sponge mechanism. The design of fusogenic 
peptides in order to make polyplexes that are able to disrupt the endosome was achieved by 
making use of histidine. Since the pKa of an imidazole group in the histidine side chain is 
approximately 6.0 (Figure 1.16),[134-136] it promotes buffering of endosomal pH and hence an 
influx of water, leading to an osmotic pressure in the endosome, leading to the endosome 
buffering, thus allowing the DNA polyplex to escape from the endosome into the cytoplasm 
(the proton sponge hypothesis).[58,137,138] Midoux and colleagues[139] designed a peptide 
containing several histidine residues (GLFHAIAHFIHGGWHGLIHGWYG). This peptide 
disrupted the endosomal membrane at a slightly acidic pH (pH 6.4). Subsequently, poly-L-
histidine (Mw 11 kDa) has been utilized as a gene vector and was shown to have desirable 
properties for gene delivery and was nontoxic to cells.[140]  
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1.2.3 Lysine and histidine-based peptides: Extracellular binding and endosomal escape 
of DNA 
 
There are many studies that focus on the combination of extracellular binding of DNA and 
endosomal escape of polyplexes in order to improve transfection efficiency. For instance, 
histidylated polylysine polyplexes show enhance transfection levels over PLL-polyplexes in 
the presence either of chloroquine or the fusogenic peptide.[130] N-Ac-poly(L-histidine)-graft-
poly-(L-lysine) (PLH-g-PLL) (Figure 1.17) was synthesized in order to combine the polyplex 
formation efficiency of PLL and endosomolytic efficiency of PLH.[141] The PLH-g-PLL 
polyplex enhanced gene expression. However, chloroquine was required for reasonable levels 
of gene expression.   
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Figure 1.17.  The structure of N-Ac-poly(L-Histidine)-graft-poly-(L-Lysine) (PLH-g-PLL)[141] 
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The aminated poly-L-histidine (Figure 1.18) has been reported to form polyplexes with DNA 
which led to endosomolysis.[142]  
 
H
N
O
N
N
N
H
O
NH
N
H
N
O
N
N
H2N
NH2
 
 
Figure 1.18.   The aminated poly-L-histidine synthesized by Asayama and colleague. [142]
 
A pH-responsive histidylated oligolysine -K[K(H)KKK]5-K(H)KKC- has been designed to 
incorporate into ligand-liposome polyplex in order to aid in endosomal escape and DNA 
condensation which improved the transfection efficiency of ligand-liposome polyplex 
itself.[143] The combination of liposomes and  branched co-polymers of histidine and lysine as 
vectors was shown to improve the gene expression 400-fold compared to the liposomes 
themselves.[120] Manickam and Oupicky[144] synthesized reducible copolypeptides (RCPPs) 
from bis-cysteine terminated histidine rich oligopeptide (CKHHHKHHHKC) and bis-cysteine 
terminated  nuclear localization signal (NLS, CGAGPKKKRKVC) via oxidative 
polymerization (see section 1.2.4). These RCPPs had enhanced trasfection levels of up to 10 
fold over PEI. 
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1.2.4  Cysteine-based peptides: Intracellular release of DNA 
 
The use of cysteine in biological systems has been primarily to bioconjugate molecules 
together via a covalent disulfide bond linkage.[88] The disulfide bond arises from the oxidation 
of two thiol (SH) groups as shown in Figure 1.19.  
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Figure 1.19.  The formation of a disulfide bond of two cysteine residues 
 
Polyplexes have been formed with disulfide bonds in the polymer backbone which are 
stabilized in the extracellular matrix, but are cleaved efficiently by high concentrations of 
intracellular glutathione (GSH), located in both cytoplasmic and nuclear compartments at 
concentrations of approximately 0.5 – 20 mM, leading to the vector degrading and efficient 
release of its DNA.[88,121,144] Reducible polycations (RPCs) have been synthesized from the 
Cys-(Lys)10-Cys by oxidative polymerization and used to form the polyplexes in combination 
with DOTAP which result in 187-fold higher transgene expression compared to non-reducible 
PLL.[89]  Mckenzie and colleagues[121] have also developed a reducible polycation by 
incorporating Lys, His and Cys residues, Cys-His-(Lys)6-His-Cys, resulting in improved gene 
transfection properties.  
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Cross-linked polymers via disulfide bonds were used to form the polyplexes that prevented an 
early dissociation of polyplexes inside the endosomes.[88,145] Thus, cross-linking peptides have 
been developed by inserting multiple cysteine residues into several 20 amino acid peptides 
(Table 1.4). Increased cross-linking via disulfide bond formation increased the stability of 
polyplexes and decreased the polyplex size.[88] However, the gene expression efficiency was 
inversely propotional to the number of the incorporated cysteine residues. In the study, 
peptides containing two cysteine residues (II) gave the highest gene expression. 
 
Table 1.4.  Cysteine containing peptides studied by Mckenzie and colleagues[88] 
Name Sequence 
CWK18
II 
III 
IV 
V 
Cys-Trp-Lys18  
Cys-Trp-Lys17-Cys  
Cys-Trp-Lys8-Cys-Lys8-Cys  
Cys-Trp-Lys5-Cys-Lys5-Cys-Lys5-Cys  
Cys-Trp-Lys4-Cys-Lys3-Cys-Lys3-Cys-Lys4-Cys  
 
 
1.2.5 Arginine-based peptides: Nuclear localisation 
 
The study of arginine has been interesting, since the pKa of the side chain in the arginine 
residue is approximately 12.5 (Figure 1.16), and is, therefore, fully protonated at 
physiological pH which promotes the electrostatic interaction with the nucleic acid. Arginine 
residues also play an important role  as protein transduction domains (PTDs) or cell 
penetrating peptides (CPPs) [137,146,147] which can facilitate uptake of the protein into the cells. 
For example the TAT-peptide 47-57 sequence, RKKRRQRRR, is the transduction domain, or 
region conveying the cell penetrating properties from HIV-1, and has recently been studied 
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for its properties as a vector.[148]  The result revealed that TAT peptides enhanced transfection 
activity of polyplexes and reduced cytotoxicity. However, they required chloroquine in order 
for the endosomal vesicles to burst. The condensation between oligomers of TAT peptides 
and DNA forms nanometric polyplexes. These TAT peptides improved the transfection 
efficiency 6-7 fold greater than poly-L-arginine.[149]   
 
1.3  Essential vector features for efficient non-viral gene delivery 
 
As described above, there are many biological barriers for non-viral gene delivery system, 
which result in less efficient transfection compared to viral vectors (described in table 1.2 and 
associated texts). Therefore, the design of a vector needs to have several features in order to 
achieve an efficient gene delivery system (Table 1.5):  
 
Table  1.5. Vector features for gene delivery 
Vector feature Function 
I 
II 
III 
IV 
V 
VI 
Bind DNA extracellularly 
Provide a cell targeting ligand 
Cell uptake via endocytosis 
Provide a tunable endosomal release mechanism 
Provide a degradable backbone in order that the DNA can be released once in the cytoplasm 
Provide a nuclear localization signal 
 
As reviewed above, there are several research groups that have focused on the combination of 
the above features in order to design a promising vector. The summary of those combining 
vector features are shown in Table 1.6. 
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Table 1.6.  The summary of vector features from previous research  
Vector features Reference 
I + II 
I + III + IV 
I + III + V 
I + III + VI 
I + II + III + IV 
I + III + IV + V 
I + III + IV + V + VI 
[93], [96] 
[60], [71], [130-132], [141-143] 
[89] 
[116] 
[62] 
[88], [121] 
[144] 
 
1.4  Can we extend the design of non-viral peptide vectors? 
 
As summarized in Table 1.6, the most common vectors that have been studied combined 2-4 
vector features. Therefore, a question arises as to how it might be possible to extend the 
capability of peptide vectors to 5 or more of the features. 
 
In order to examine this question, we should first examine the specific roles that several 
amino acids adopt in peptide vectors in order that we can rationally design new vectors. 
 
1.4.1    Lysine: extracellular stabilization (Vector feature I) 
 
Lysine has a pKa of approximately 10.5, thus at physiological pH (~7.4), it will be almost 
fully protonated. Thus, this will provide a strong interaction with the phosphate anions of the 
DNA backbone (Figure 1.20) leading to extracellular stability.  
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Figure 1.20  Polyplex formation via electrostratic interaction between nucleic acid and vector 
 
1.4.7 Cysteine: extracellular stabilization (Vector feature I) 
 
The terminal cysteine moieties provide functional groups that will allow polymerization of the 
oligopeptides via oxidation of the thiols (R-SH) to disulfides (R-S-S-R) to afford the 
intracellularly reducible polycations (RPCs). This polymerization will afford RPCs with 
enhanced binding to the DNA over shorter oligopeptides by virtue of the cooperativity of the 
extracellular binding.  
 
1.4.3 Lysine: endocytosis (Vector feature III) 
 
The surface charge of the polyplexes formed between the DNA and the RPCs is positive, 
which promotes electrostatic binding with the negatively charged heparan sulfate 
proteoglycan of transmembrane syndecan, [101, 102] which in turn leads to internalization into 
cells via endocytosis[103,104] Figure 1.21 illustrates the mechanism of polyplexes 
internalization via syndecan-mediated endocytosis : i) the cationic polyplex electrostraticlly 
binds to heparan sulfate proteoglycan (HSPGs) on cell suface, ii) then the cluster triggers the 
phosphorylation of syndecan and linker protein-mediated actin binding to cytoplasmic tail of 
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the syndecans, which in turn leads to actin binding to linker proteins, and iii) the constant 
formation of a growing network of cortical actin fibers or of tension fibers is sufficient to pull 
the polyplexes into cell. 
 
Figure 1.21.  Syndecan mediated endocytosis of cationic polyplexes 
 
1.4.4 Histidine: endosomal release (Vector feature IV) 
 
Histidine has an imidazole residue with a pKa of approximately 6, thus at physiological cell 
pH (~7.4) it will not be fully protonated and will have a buffering capacity when it is 
incorporated into the early endosome, whose pH is ~6. This buffering will promote 
endosomolysis as described earlier under the proton sponge hypothesis in section 1.1.2.2a 
(page 27) 
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1.4.5 Cysteine: intracellularly degradable (Vector feature V) 
 
The disulfide bonds will be cleaved upon release from the endosome by the relatively high 
concentration of cytoplasmic glutathione (Figure 1.22).[150] 
 
 
Figure 1.22.    The disulfide bond reduction by glutathione (GSH) catalyzed by glutathione reductase 
using NADPH to reduce oxidized glutathione (GSSG) 
 
The cleavage will result in only the oligopeptides binding to the DNA which will dissociate 
relative easily from the DNA, leaving naked DNA in the cytoplasm (Figure 1.23), which is 
free to be internalized into nucleus. 
 
 
Figure 1.23.      Polyplex dissociation by GSH to release DNA intracellularly 
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1.4.6 Nuclear targeting signal (Vector feature VI) 
 
Nuclear targeting signal (NLS) is the peptide that facilitates the nuclear transport through 
nuclear pore complexes[114-118] as described earlier in section 1.1.2.2b (page 29). Therefore, 
incorporation of NLS into non-viral vectors leads to promote nuclear import of transgene, 
which could make non-viral vector system more efficient. The most common NLS peptide 
derived from the simian virus 40 large tumor antigen (PKKKRKV).[115,116] In addition, TAT 
peptide derived from HIV-1 was also investigated as novel type of NLSs,[147] and could 
facilitate nuclear import faster than the SV40 NLS.[151]  
 
1.5 Design of new vectors 
 
 
Thus, considering the molecular design elements in the preceding sections (1.41-1.46) and 
considering the barriers for genes to be delivered to the cell nucleus (Figure 1.11), we have 
designed some new vectors by combining lysine, histidine and cysteine in various 
constitutional arrangements, and by incorporating TAT such that we could potentially have a 
vector with up to 5 features. 
   
Table 1.7 illustrates the oligopeptides which have been designed for the tasks above. They are 
10 mers containing lysine (K), histidine (H), and cysteine (C). Each one is terminated by 
cysteine residues (referred to as bis-cysteine containing oligopeptides (2COPs)) which are 
2COPs 1-6. 2COP 1 has 8 lysine, 2COPs 2-5 have 4 lysine and 4 histidine with an increased 
degree of “mixing” of the constitution, 2COP 6 has 8 histidine. Peptide 7 is a tris-cysteine 
containing oligopeptide (3COP) with 4 lysine residues. Bis-cysteine terminating TAT peptide 
was also designed as a vector in the study. 
 
 
Table 1.7.  Synthetic oligopeptides used in this study 
Oligopeptide Structure Oligopeptide Structure 
2COP 1 
(CK8C) 
 
2COP 5 
(CKHKHKHKHC) 
 
2COP 2 
(CK4H4C) 
 
2COP 6 
(CH8C) 
 
2COP 3 
(CK2H2K2H2C) 
 
3COP 7 
(CK2CK2C) 
 
2COP 4 
(CK2 2C) 
TAT 
(CRKKRR RRRC) HKHKH
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Strategies Designed vectors 
New strategies Chemical unit 
 
Advantage 
Vector 
features PLL RPC 1 Cross-linked RPCs 2-5 RPCs 2-5 RcPCs 2-5 
- pKa modulation 2COPs 2-5 (degree 
dilution of His and Lys) 
Proton sponge mechanism for endosomal 
escape of polyplex 
IV X X √ √ √ 
- Cross-linking disulfides 2COPs/3COP  Extra extracellular stability of polyplex I X X √ X X 
Known strategies Chemical unit        
- Electrostratic binding 
with DNA 
Lysine residues -Electrostratic binding of lysine side 
chains to DNA to aid extracellular 
stability  
-cell uptake via endocytosis 
I, III √ √ √ √ √ 
- Disulfide bond 
backbone 
Terminated cysteines -Extracellular stability of polyplex 
-Intracellular reduction of DNA into 
cytoplasm 
I, V X √ √ √ √ 
-NLS incorporation TAT incorporation Nuclear entry of DNA VI X X X X √ 
From the oligopeptides designed in Table 1.7, we can synthesize the new vectors by combination of new and known strategies described in 
Table 1.8.  
Table 1.8.  Strategies used in vector design and their advantage 
 
 
 
Section 1.6 describes in detail of hypothesis behind the strategies in term of how the various 
chemical molecules will control various processes during gene delivery. 
 
1.6 Hypothesis behind the vector design 
 
1.6.1   New strategies 
 
1.6.1.1   pKa modulation 
 
The mixing of the position of the constitution of the amino acid in 2COPs 2-5 will provide a 
subtle way of modulating the pKa of the imidazole residues. The degree of dilution of the 
histidine residues in the protonated lysine residues will make it increasingly more difficult for 
the imidazole nitrogen to become protonated, due to charge repulsion of the subphase protons 
by the protonated lysine residues as can be seen in Figure 1.24a. For –His-His-His-His- 
sequence (Figure 1.24b), it is shown that the amino groups on the imidazole ring are more 
easily protonated due to a lower degree of electrostratic repulsion by the distal protonated 
lysine residues.  
 
Therefore, the modulation of the pKa will provide a way to modulate the buffering capacity in 
the endosome (vector feature IV). RPCs 2-5, cross-linked RPCs 2-5, and RcPCs 2-5 (see 
Table 1.8) have buffering capacity in the endosome, thus these vectors do not require 
chloroquine to promote endosomal escape (Figure 1.27 c,d and e). On the other hand, PLL 
and RPC 1 that have no buffering properties and will need chloroquine to promote endosomal 
disruption. Hence we expect PLL and RPC 1 without CQ not to be released from the 
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endosome as there is no buffering capacity, and hence transfection will be poor (Figure 1.27 
a and b). 
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Figure 1.24.  The proton repulsion of the lysine and histidine based sequences; a) and -Lys-His-Lys-His- 
 b) -His-His-His-His- 
 
 
1.6.1.2   Cross-linking disulfide bonds 
 
Mckenzie and colleagues[88] developed the low molecular weight peptides (20 amino acids) 
by incorporating multiple cysteine residues into the peptides. After binding to plasmid DNA 
thiol groups of cysteine side chains spontaneously oxidize to form cross-linked disulfides 
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promoting extracellular stability of polyplexes. They also revealed that the cross-linked 
peptide polyplexes were 5-60 fold more efficient in transfection relative to uncross-linked 
peptide polyplexes. In addition, Mckenzie and colleagues[121] revealed that using low 
molecular weight peptide, CK2CK2C, to condense with DNA produced large particle (1668 
nm), and induced lower transfection level (10-100 fold) relative to CK8C polyplexes. 
However, in none of the previous publications have high molecular weight cross-linked 
disulfide polypeptides been used. Thus, in our study the tris-cysteine oligopeptide (3COP 7, 
CK2CK2C) will be used to form a cross-linked RPCs via disulfide bond formation (Figure 
1.25) with the 2COPs. These cross-linking backbones will provide further extracellular 
stabilization of the polyplex. Therefore, in combination between cross-linking backbones and 
pKa modulation in cross-linked RPCs 2-5 vectors could result with increase efficient 
transfection (Figure 1.27c). In addition, the linear polymer RPCs will also be synthesized by 
oxidative polymerization of 2COPs in order that the properties of cross-linked RPC and linear 
RPC can be compared. 
 
 
Figure 1.25.  Polyplex formation from reducible polycations (RPCs) and cross-linked RPC 
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1.6.2     Known strategies 
 
1.6.2.1   Electrostatic binding with DNA 
 
The lysine residue has been widely used in peptide vectors because of the positive side chain 
that results upon protonation, that can bind electrostatically to the negative charged phosphate 
groups in DNA backbone.[89,124,127] Therefore, our designed vectors (cross-linked RPCs, 
RPCs, and RcPCs) which have lysine residues incorporated will bind strongly to the DNA 
resulting in extracellular stability of polyplexes (vector feature I). In addition, the cationic 
polyplexes will electrostratically bind to the negative groups of heparan sulfate proteoglycans 
on cell surface which facilitates cell uptake via endocytosis (vector feature III).  
  
1.6.2.2 Disulfide bond backbone 
 
In recent years, reducible polycations (RPCs) have been synthesized by oxidative 
polymerization of oligopeptides that have terminated cysteine residues.[85,89,133,152] These 
RPCs resulted in extracellular stability of polyplexes (vector feature I), as well as intracellular 
reduction of polyplexes leading to DNA release in the cytoplasm (vector feature V). 
Therefore, the RPCs and RcPCs are likely to provide extracellular stability and an 
intracellular disassembles mechanism to provide polyplexes with efficient transfection 
(Figure 1.27d and e). In contrast, PLL polyplex does not have disulfide linkage, thus, it is 
unable to be reduced in the cytoplasm resulting in poor transfection level (Figure 1.27a).  
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In addition, the RcPCs 2-5 contain 2COPs and TAT in order to combine the extracellular 
binding with DNA (I), cell uptake (III), endosomal escape (IV), intracellular degradability 
(V) and nuclear targeting (VI) could induce excellent transfection levels (Figure 1.27e). 
 
Figure 1.26.   Reducible copolycations (RcPCs) synthesised by oxidative polymerisation between 2COPs 
and Bis-cysteine containing TAT oligopeptides 
 
NLS has been widely use in non-viral vectors[115,118,144] as described previously in section 
1.1.2.2b. The introduction of NLS into vectors could enhance the transfection level as the 
DNA is more likely to enter into nucleus in non-dividing cells (vector feature VI). Therefore, 
RcPC vectors (Figure 1.26) with TAT (NLS derived from HIV-1) should facilitate efficient 
transfection compare to other vectors that do not have TAT incorporation.  
 
1.6.2.3 NLS incorporation 
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Figure 1.27.  Schematic model of the transfection manner of RPCs and PLL polyplexes based on vector features I and III-VI: a) PLL, b) RPCs 1, c) cross-linked 
RPCs 2-5, d) RPCs 2-5 and e)  RcPCs 2-5 polyplexes.  
 
 
 
1.7 Overview of thesis 
 
This PhD thesis will be divided into 4 chapters as described below: 
 
(i) In chapter 3, the oligopeptides (2COPs 1-6 and 3COP 7) will be purified and 
characterised. The reducible polycations (RPCs 1-6) will be synthesized from 
2COPs 1-5 via disulfide bond formation by oxidative polymerisation. The DNA 
polyplexes from either RPCs or 2COPs will be produced and characterized in 
simulated extra – and intracellularly conditions based on vector features I and III-
V. In addition, the oxidative polymerisation of the cross-linked RPCs between 
2COPs and 3COP will also be studied. 
 
(ii) In chapter 4, the cell transfection of RPCs polyplexes based on vector feature I and 
III-V will be studied. The transfection of the RPCs polyplexes will be combined 
with the following compounds : 
-  Chloroquine (CQ) will be added into cell lines as its ability to buffer endosome 
and to enhance the transfection efficiency.   
-  Glutathione monoethyl ester (GSH-MEE), which is cell permeable and is 
converted to reduced gluthione intracellularly, will be added in order to boost 
intracellular GSH and enhance polypeptide vector cleavage of the disulfide 
bonds. 
- Buthionine sulfoximine (BSO), which is an inhibitor of intracellular GSH 
synthesis, will be used to deplete intracellular GSH, thus probing the reductive 
cleavage mechanism in the cells of the disulfide bonds. 
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(iii) In chapter 5, the reducible copolycations between 2COPs and TAT peptide 
(RcPCs) will be synthesized and characterized by randomly oxidative 
polymerisation in order to combine vector feature I and III-V of 2COPs and 
vector feature VI of TAT peptide.  
 
(iv) In Chapter 6, the cell transfection of RcPC polyplexes will be preformed in the 
same basis with Chapter 4 in order to compare with RPC polyplexes. 
 
The transfections will be carried out in two representative cell lines, human lung carcinoma 
epithelial cell (A549) and mouse brain endothelial cell (bEND3). These cell lines were chosen 
because for therapeutic applications it is important to consider transduction of both epithelial 
and endothelial cells. The A549 cells are the representative of most types of common cancer, 
while the bEND3 cells serve as a model for the surfaces that are accessible following the 
bloodstream administration of the polyplexes.  
 
PLL and PEI polyplexes at N:P 5 and 10, respectively were used as controls. 
 
 
 
 
 
 
References for Chapter 1 are on page 56-73. 
 
55
 
 
1.8 References 
 
 
1. Watson, J.D., and Crick, F.H.C. (1953). Genetical implications of the structure of 
deoxyribonucleic acid. Nature, 171, 964-967. 
2. Slavotinek, A., and Biesecker, L.G. (2003). Genetic modifiers in human development 
and malformation syndromes, including chaperone proteins. Human Molecular 
Genetics, 12, R45-50. 
3. Rubanyi, G.M. (2001). The future of human gene therapy. Molecular Aspects of 
Medicine, 22, 113-142. 
4. Williams, D.A., and Orkin, S.H. (1986). Somatic gene therapy; current status and 
future prospects. The Journal of Clinical Investigation, 77, 1053-1056. 
5. Dorin, J. (1996). Somatic gene therapy. British Medical Journal 312, 323-324. 
6. Nielsen, T.O. (1997). Human germline gene therapy. Mcgill Journal of Medicine, 3, 
126-132. 
7. Friedmann, T., and Roblin, R. (1972). Gene therapy for human genetic disease? 
Science, 175, 949-955. 
8. Rogers, S. (1959). Induction of arginase in rabbit epithelium by the Shope rabbit 
papilloma virus. Nature, 183, 1815-1816. 
9. Rogers, S., and Moore, M. (1963). Studies of mechanism of action of Shope rabbit 
papilloma virus. 1. Concerning nature of induction of arginase in infected cells. 
Journal of Experimental Medicine, 117, 521-542. 
10. Müller, H. (1987). Human gene therapy: possibilities and limitations. Cellular and 
Molecular Life Sciences 43, 375-378. 
References for Chapter 1 are on page 56-73. 
 
56
 
 
11. Philipp, C.N., Sollinger, H.W., and Alam, T. (2003). Hepatic insulin gene therapy in 
insulin-dependent diabetes mellitus. American Journal of Transplantation, 3, 1197-
1203. 
12. Lai, L.W., and Lien, Y.H.H. (1999). Homologous recombination based gene therapy. 
Nephron Experimental Nephrology, 7, 11-14. 
13. Wu, L.C., Sun, C.W., Ryan, T.M., Pawlik, K.M., Ren, J.X., and Townes, T.M. (2006). 
Correction of sickle cell disease by homologous recombination in embryonic stem 
cells. Blood, 108, 1183-1188. 
14. Flagler, K., Alexeev, V., Pierce, E.A., and Igoucheva, O. (2008). Site-specific gene 
modification by oligodeoxynucleotides in mouse bone marrow-derived mesenchymal 
stem cells. Gene Therapy, 15, 1035-1048. 
15. Bonaccorsi, L., Luciani, P., Nesi, G., Mannucci, E., Deledda, C., Dichiara, F., 
Paglierani, M., Rosati, F., Masieri, L., Serni, S., Carini, M., Proietti-Pannunzi, L., 
Monti, S., Forti, G., Danza, G., Serio, M., and Peri, A. (2008). Androgen receptor 
regulation of the seladin-1/DHCR24 gene: altered expression in prostate cancer. 
Laboratory Investigation, 88, 1049-1056. 
16. Raty, J.K., Lesch, H.P., Wirth, T., and Yla-Herttuala, S. (2008). Improving safety of 
gene therapy. Current Drug Safety, 3, 46-53. 
17. Boulaiz, H., Marchal, J.A., Prados, J., Melguizo, C., and Aranega, A. (2005). Non-
viral and viral vectors for gene therapy. Cellular and Molecular Biology, 51, 3-22. 
18. Cohen, S.S. (1963). Biochemistry of viruses. Annual Review of Biochemistry, 32, 83-
&. 
19. El-Aneed, A. (2004). An overview of current delivery systems in cancer gene therapy. 
Journal of Controlled Release, 94, 1-14. 
References for Chapter 1 are on page 56-73. 
 
57
 
 
20. Wei, C.M., Gibson, M., Spear, P.G., and Scolnick, E.M. (1981). Construction and 
isolation of a transmissible retrovirus containing the Src Gene of harvey murine 
sarcoma-virus and the thymidine kinase gene of herpes-simplex virus type-1. Journal 
of Virology, 39, 935-944. 
21. Coffin, J.M. (1979). Structure, replication, and recombination of retrovirus genomes - 
some unifying hypotheses. Journal of General Virology, 42, 1-26. 
22. Hermens, W.T.J.M.C., and Verhaagen, J. (1998). Viral vectors, tools for gene transfer 
in the nervous system. Progress in Neurobiology, 55, 399-432. 
23. Robbins, P.D., and Ghivizzani, S.C. (1998). Viral vectors for gene therapy. 
Pharmacology and Therapeutics, 80, 35-47. 
24. Wang, Y., and Yuan, F. (2006). Delivery of viral vectors to tumor cells: Extracellular 
transport, systemic distribution, and strategies for improvement. Annals of Biomedical 
Engineering, 34, 114-127. 
25. Schatzlein, A.G. (2003). Targeting of synthetic gene delivery systems. Journal of 
Biomedicine and Biotechnology, 2, 149-158. 
26. Chan, C.K., and Jans, D.A. (2002). Using nuclear targeting signals to enhance non-
viral gene transfer. Immunology and Cell Biology, 80, 119-130. 
27. Klasse, P.J., Bron, R., and Marsh, M. (1998). Mechanisms of enveloped virus entry 
into animal cells. Advanced Drug Delivery Reviews, 34, 65-91. 
28. Lehn, P., Fabrega, S., Oudrhiri, N., and Navarro, J. (1998). Gene delivery systems: 
Bridging the gap between recombinant viruses and artificial vectors. Advanced Drug 
Delivery Reviews, 30, 5-11. 
29. Whittaker, G.R. (2003). Virus nuclear import. Advanced Drug Delivery Reviews, 55, 
733-747. 
References for Chapter 1 are on page 56-73. 
 
58
 
 
30. Pouton, C.W., and Seymour, L.W. (2001). Key issues in non-viral gene delivery. 
Advanced Drug Delivery Reviews, 46, 187-203. 
31. Khalil, I.A., Kogure, K., Akita, H., and Harashima, H. (2006). Uptake pathways and 
subsequent intracellular trafficking in nonviral gene delivery. Pharmacological 
Reviews, 58, 32-45. 
32. Merdan, T., Kopecek, J., and Kissel, T. (2002). Prospects for cationic polymers in 
gene and oligonucleotide therapy against cancer. Advanced Drug Delivery Reviews, 
54, 715-758. 
33. Turk, M.J., Reddy, J.A., Chmielewski, J.A., and Low, P.S. (2002). Characterization of 
a novel pH-sensitive peptide that enhances drug release from folate-targeted liposomes 
at endosomal pHs. Biochimica Et Biophysica Acta-Biomembranes, 1559, 56-68. 
34. Tang, F.X., and Hughes, J.A. (1998). Introduction of a disulfide bond into a cationic 
lipid enhances transgene expression of plasmid DNA. Biochemical and Biophysical 
Research Communications, 242, 141-145. 
35. Gosselin, M.A., Guo, W.J., and Lee, R.J. (2001). Efficient gene transfer using 
reversibly cross-linked low molecular weight polyethylenimine. Bioconjugate 
Chemistry, 12, 989-994. 
36. Kichler, A., Leborgne, C., Coeytaux, E., and Danos, O. (2001). Polyethylenimine-
mediated gene delivery: a mechanistic study. Journal of Gene Medicine, 3, 135-144. 
37. Kunath, K., von Harpe, A., Fischer, D., Peterson, H., Bickel, U., Voigt, K., and Kissel, 
T. (2003). Low-molecular-weight polyethylenimine as a non-viral vector for DNA 
delivery: comparison of physicochemical properties, transfection efficiency and in 
vivo distribution with high-molecular-weight polyethylenimine. Journal of Controlled 
Release, 89, 113-125. 
References for Chapter 1 are on page 56-73. 
 
59
 
 
38. Boeckle, S., von Gersdorff, K., van der Piepen, S., Culmsee, C., Wagner, E., and 
Ogris, M. (2004). Purification of polyethylenimine polyplexes highlights the role of 
free polycations in gene transfer. Journal of Gene Medicine, 6, 1102-1111. 
39. Brus, C., Petersen, H., Aigner, A., Czubayko, F., and Kissel, T. (2004). Efficiency of 
polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block 
copolymers to protect oligonucleotides against enzymatic degradation. European 
Journal of Pharmaceutics and Biopharmaceutics, 57, 427-430. 
40. Boussif, O., Lezoualch, F., Zanta, M.A., Mergny, M.D., Scherman, D., Demeneix, B., 
and Behr, J.P. (1995). A versatile vector for gene and oligonucleotide transfer into 
cells in culture and in vivo - polyethylenimine. Proceedings of the National Academy 
of Sciences of the United States of America, 92, 7297-7301. 
41. Dufes, C., Uchegbu, I.F., and Schatzlein, A.G. (2005). Dendrimers in gene delivery. 
Advanced Drug Delivery Reviews, 57, 2177-2202. 
42. Stoddart, A. (2006). Gene delivery with dendrimers. Molecular Biosystems, 2, B10-
B10. 
43. Chattoraj, D.K., Gosule, L.C., and Schellman, J.A. (1978). DNA condensation with 
polyamines. 2. Electron-microscopic studies. Journal of Molecular Biology, 121, 327-
337. 
44. Gosule, L.C., and Schellman, J.A. (1976). Compact form of DNA induced by 
spermidine. Nature, 259, 333-335. 
45. Zhang, S.B., Xu, Y.M., Wang, B., Qiao, W.H., Liu, D.L., and Li, Z.S. (2004). 
Cationic compounds used in lipoplexes and polyplexes for gene delivery. Journal of 
Controlled Release, 100, 165-180. 
46. Felgner, P.L., Gadek, T.R., Holm, M., Roman, R., Chan, H.W., Wenz, M., Northrop, 
J.P., Ringold, G.M., and Danielsen, M. (1987). Lipofection - a highly efficient, lipid-
References for Chapter 1 are on page 56-73. 
 
60
 
 
mediated DNA-transfection procedure. Proceedings of the National Academy of 
Sciences of the United States of America, 84, 7413-7417. 
47. Simberg, D., Weisman, S., Talmon, Y., and Barenholz, Y. (2004). DOTAP (and other 
cationic lipids): Chemistry, biophysics, and transfection. Critical Reviews in 
Therapeutic Drug Carrier Systems, 21, 257-317. 
48. Behr, J.P., Demeneix, B., Loeffler, J.P., and Mutul, J.P. (1989). Efficient gene-transfer 
into mammalian primary endocrine-cells with lipopolyamine-coated DNA. 
Proceedings of the National Academy of Sciences of the United States of America, 86, 
6982-6986. 
49. Gao, X., and Huang, L. (1991). A novel cationic liposome reagent for efficient 
transfection of mammalian-cells. Biochemical and Biophysical Research 
Communications, 179, 280-285. 
50. Mahato, R.I. (2005). Water insoluble and soluble lipids for gene delivery. Advanced 
Drug Delivery Reviews, 57, 699-712. 
51. Mahato, R.I., Rolland, A., and Tomlinson, E. (1997). Cationic lipid-based gene 
delivery systems: Pharmaceutical perspectives. Pharmaceutical Research, 14, 853-
859. 
52. Xu, Y.H., and Szoka, F.C. (1996). Mechanism of DNA release from cationic 
liposome/DNA complexes used in cell transfection. Biochemistry, 35, 5616-5623. 
53. Wetzer, B., Byk, G., Frederic, M., Airiau, M., Blanche, F., Pitard, B., and Scherman, 
D. (2001). Reducible cationic lipids for gene transfer. Biochemical Journal, 356, 747-
756. 
54. Han, S.O., Mahato, R.I., and Kim, S.W. (2001). Water-soluble lipopolymer for gene 
delivery. Bioconjugate Chemistry, 12, 337-345. 
References for Chapter 1 are on page 56-73. 
 
61
 
 
55. Lee, M., Rentz, J., Han, S.O., Bull, D.A., and Kim, S.W. Water-soluble lipopolymer 
as an efficient carrier for gene delivery to myocardium. Gene Therapy, 10, 585-593. 
56. Lungwitz, U., Breunig, M., Blunk, T., and Gopferich, A. (2005). Polyethylenimine-
based non-viral gene delivery systems. European Journal of Pharmaceutics and 
Biopharmaceutics, 60, 247-266. 
57. Suh, J., Paik, H.J., and Hwang, B.K. (1994). Ionization of poly(ethylenimine) and 
poly(allylamine) at various pHs. Bioorganic Chemistry, 22, 318-327. 
58. Behr, J.P. (1997). The proton sponge: A trick to enter cells the viruses did not exploit. 
Chimia, 51, 34-36. 
59. Sonawane, N.D., Szoka, F.C., and Verkman, A.S. (2003). Chloride accumulation and 
swelling in endosomes enhances DNA transfer by polyamine-DNA polyplexes. 
Journal of Biological Chemistry, 278, 44826-44831. 
60. Min, S.H., Lee, D.C., Lim, M.J., Park, H.S., Kim, D.M., Cho, C.W., Yoon, D.Y., and 
Yeom, Y.I. (2006). A composite gene delivery system consisting of polyethylenimine 
and an amphipathic peptide KALA. Journal of Gene Medicine, 8, 1425-1434. 
61. Li, D., Tang, G.P., Li, J.Z., Kong, Y., Huang, H.L., Min, L.J., Zhou, J., Shen, F.P., 
Wang, Q.Q., and Yu, H. (2007). Dual-targeting non-viral vector based on 
polyethylenimine improves gene transfer efficiency. Journal of Biomaterials Science-
Polymer Edition, 18, 545-560. 
62. Kircheis, R., Kichler, A., Wallner, G., Kursa, M., Ogris, M., Felzmann, T., 
Buchberger, M., and Wagner, E. (1997). Coupling of cell-binding ligands to 
polyethylenimine for targeted gene delivery. Gene Therapy, 4, 409-418. 
63. Baker, A., Saltik, M., Lehrmann, H., Killisch, I., Mautner, V., Lamm, G., Christofori, 
G., and Cotten, M. (1997). Polyethylenimine (PEI) is a simple, inexpensive and 
References for Chapter 1 are on page 56-73. 
 
62
 
 
effective reagent for condensing and linking plasmid DNA to adenovirus for gene 
delivery. Gene Therapy, 4, 773-782. 
64. Wang, Y.X., Chen, P., and Shen, J.C. (2006). The development and characterization 
of a glutathione-sensitive cross-linked polyethylenimine gene vector. Biomaterials, 
27, 5292-5298. 
65. Dufes, C., Uchegbu, I.F., and Schatzlein, A.G. (2005). Dendrimers in gene delivery. 
Advanced Drug Delivery Reviews, 57, 2177-2202. 
66. Lee, J.W., Kim, J.H., Kim, B.-K., Kim, J.H., Shin, W.S., and Jin, S.-H. (2006). 
Convergent synthesis of PAMAM dendrimers using click chemistry of azide-
functionalized PAMAM dendrons. Tetrahedron, 62, 9193-9200. 
67. Martin, I.K., and Twyman, L.J. (2001). The synthesis of unsymmetrical PAMAM 
dendrimers using a divergent/divergent approach. Tetrahedron Letters, 42, 1119-1121. 
68. Loup, C., Zanta, M.A., Caminade, A.M., Majoral, J.P., and Meunier, B. (1999). 
Preparation of water-soluble cationic phosphorus-containing dendrimers as DNA 
transfecting agents. Chemistry a European Journal, 5, 3644-3650. 
69. Tomalia, D.A., Baker, H., Dewald, J., Hall, M., Kallos, G., Martin, S., Roeck, J., 
Ryder, J., and Smith, P. (1985). A new class of polymers - starburst-dendritic 
macromolecules. Polymer Journal, 17, 117-132. 
70. Svenson, S. (2009). Dendrimers as versatile platform in drug delivery applications. 
European Journal of Pharmaceutics and Biopharmaceutics, 71, 445-462. 
71. Haensler, J., and Szoka, F.C. (1993). Polyamidoamine cascade polymers mediate 
efficient transfection of cells in culture. Bioconjugate Chemistry, 4, 372-379. 
72. Maiti, P.K., Cagin, T., Lin, S.T., and Goddard, W.A. (2005). Effect of solvent and pH 
on the structure of PAMAM dendrimers. Macromolecules, 38, 979-991. 
References for Chapter 1 are on page 56-73. 
 
63
 
 
73. Tomlinson, E., and Rolland, A.P. (1996). Controllable gene therapy - Pharmaceutics 
of non-viral gene delivery systems. Journal of Controlled Release, 39, 357-372. 
74. Ruponen, M., Honkakoski, P., Ronkko, S., Pelkonen, J., Tammi, M., and Urtti, A. 
(2003). Extracellular and intracellular barriers in non-viral gene delivery. Journal of 
Controlled Release, 93, 213-217. 
75. Davis, M.E. (2002). Non-viral gene delivery systems. Current Opinion in 
Biotechnology, 13, 128-131. 
76. Besterman, J.M., and Low, R.B. (1983). Endocytosis: a review of mechanisms and 
plasma membrane dynamics. Biochemical Journal, 210, 1-13. 
77. Owens Iii, D.E., and Peppas, N.A. (2006). Opsonization, biodistribution, and 
pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 
307, 93-102. 
78. Norman, M.E., Williams, P., and Illum, L. (1992). Human serum albumin as a probe 
for surface conditioning (opsonization) of block copolymer-coated microspheres. 
Biomaterials, 13, 841-849. 
79. Patel, H.M. (1992). Serum opsonins and liposomes - their interaction and 
opsonophagocytosis. Critical Reviews in Therapeutic Drug Carrier Systems, 9, 39-90. 
80. Carlisle, R.C., Etrych, T., Briggs, S.S., Preece, J.A., Ulbrich, K., and Seymour, L.W. 
(2004). Polymer-coated polyethylenimine/DNA complexes designed for triggered 
activation by intracellular reduction. Journal of Gene Medicine, 6, 337-344. 
81. Dash, P.R., Read, M.L., Fisher, K.D., Howard, K.A., Wolfert, M., Oupicky, D., Subr, 
V., Strohalm, J., Ulbrich, K., and Seymour, L.W. (2000). Decreased binding to 
proteins and cells of polymeric gene delivery vectors surface modified with a 
multivalent hydrophilic polymer and retargeting through attachment of transferrin. 
Journal of Biological Chemistry, 275, 3793-3802. 
References for Chapter 1 are on page 56-73. 
 
64
 
 
82. Fink, T.L., Klepcyk, P.J., Oette, S.M., Gedeon, C.R., Hyatt, S.L., Kowalczyk, T.H., 
Moen, R.C., and Cooper, M.J. (2006). Plasmid size up to 20 kbp does not limit 
effective in vivo lung gene transfer using compacted DNA nanoparticles. Gene 
Therapy, 13, 1048-1051. 
83. Lai, E., and van Zanten, J.H. (2001). Monitoring DNA/poly-L-lysine polyplex 
formation with time-resolved multiangle laser light scattering. Biophysical Journal, 
80, 864-873. 
84. Petersson, K., Ilver, D., Johansson, C., and Krozer, A. (2006). Brownian motion of 
aggregating nanoparticles studied by photon correlation spectroscopy and 
measurements of dynamic magnetic properties. Analytica Chimica Acta, 573-574, 
138-146. 
85. Read, M.L., Singh, S., Ahmed, Z., Stevenson, M., Briggs, S.S., Oupicky, D., Barrett, 
L.B., Spice, R., Kendall, M., Berry, M., Preece, J.A., Logan, A., and Seymour, L.W. 
(2005). A versatile reducible polycation-based system for efficient delivery of a broad 
range of nucleic acids. Nucleic Acids Research, 33, e86. 
86. Ogris, M., Brunner, S., Schuller, S., Kircheis, R., and Wagner, E. (1999). PEGylated 
DNA/transferrin-PEI complexes: reduced interaction with blood components, 
extended circulation in blood and potential for systemic gene delivery. Gene Therapy, 
6, 595-605. 
87. Dash, P.R., Read, M.L., Barrett, L.B., Wolfert, M., and Seymour, L.W. (1999). 
Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes 
for gene delivery. Gene Therapy, 6, 643-650. 
88. McKenzie, D.L., Kwok, K.Y., and Rice, K.G. (2000). A potent new class of 
reductively activated peptide gene delivery agents. Journal of Biological Chemistry, 
275, 9970-9977. 
References for Chapter 1 are on page 56-73. 
 
65
 
 
89. Read, M.L., Bremner, K.H., Oupicky, D., Green, N.K., Searle, P.F., and Seymour, 
L.W. (2003). Vectors based on reducible polycations facilitate intracellular release of 
nucleic acids. Journal of Gene Medicine, 5, 232-245. 
90. Wang, S., and Low, P.S. (1998). Folate-mediated targeting of antineoplastic drags, 
imaging agents, and nucleic acids to cancer cells. Journal of Controlled Release, 53, 
39-48. 
91. Wagner, E., Curiel, D., and Cotten, M. (1994). Delivery of drugs, proteins and genes 
into cells using transferrin as a ligand for receptor-mediated endocytosis. Advanced 
Drug Delivery Reviews, 14, 113-135. 
92. Zenke, M., Steinlein, P., Wagner, E., Cotten, M., Beug, H., and Birnstiel, M.L. (1990). 
Receptor-mediated endocytosis of transferrin polycation conjugates - an efficient way 
to introduce DNA into hematopoietic cells. Proceedings of the National Academy of 
Sciences of the United States of America, 87, 3655-3659. 
93. Wagner, E., Zenke, M., Cotten, M., Beug, H., and Birnstiel, M.L. (1990). Transferrin-
polycation conjugates as carriers for DNA uptake into cells. Proceedings of the 
National Academy of Sciences of the United States of America, 87, 3410-3414. 
94. Daniels, T.R., Delgado, T., Rodriguez, J.A., Helguera, G., and Penichet, M.L. (2006). 
The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the 
treatment of cancer. Clinical Immunology, 121, 144-158. 
95. von Gersdorff, K., Sanders, N.N., Vandenbroucke, R., De Smedt, S.C., Wagner, E., 
and Ogris, M. (2006). The internalization route resulting in successful gene expression 
depends on polyethylenimine both cell line and polyplex type. Molecular Therapy, 14, 
745-753. 
96. Wu, G.Y., and Wu, C.H. (1988). Receptor-mediated gene delivery and expression in 
vivo. Journal of Biological Chemistry, 263, 14621-14624. 
References for Chapter 1 are on page 56-73. 
 
66
 
 
97. Wattiaux, R., Laurent, N., Wattiaux-De Coninck, S., and Jadot, M. (2000). 
Endosomes, lysosomes: their implication in gene transfer. Advanced Drug Delivery 
Reviews, 41, 201-208. 
98. Mitra, B.N., Yasuda, T., Kobayashi, S., Saito-Nakano, Y., and Nozaki, T. (2005). 
Differences in morphology of phagosomes and kinetics of acidification and 
degradation in phagosomes between the pathogenic Entamoeba histolytica and the 
non-pathogenic Entamoeba dispar. Cell Motility and the Cytoskeleton, 62, 84-99. 
99. Bishop, N.E. (1997). An update on non-clathrin-coated endocytosis. Reviews in 
Medical Virology, 7, 199-209. 
100. Mousavi, S.A., Malerod, L., Berg, T., and Kjeken, R. (2004). Clathrin-dependent 
endocytosis. Biochemical Journal, 377, 1-16. 
101. Kim, C.W., Goldberger, O.A., Gallo, R.L., and Bernfield, M. (1994). Members of the 
syndecan family of heparan-sulfate proteoglycans are expressed in distinct cell-
specific, tissue-specific, and development-specific patterns. Molecular Biology of the 
Cell, 5, 797-805. 
102. Bernfield, M., Gotte, M., Park, P.W., Reizes, O., Fitzgerald, M.L., Lincecum, J., and 
Zako, M. (1999). Functions of cell surface heparan sulfate proteoglycans. Annual 
Review of Biochemistry, 68, 729-777. 
103. Mislick, K.A., and Baldeschwieler, J.D. (1996). Evidence for the role of proteoglycans 
in cation-mediated gene transfer. Proceedings of the National Academy of Sciences of 
the United States of America, 93, 12349-12354. 
104. Kopatz, I., Remy, J.S., and Behr, J.P. (2004). A model for non-viral gene delivery: 
through syndecan adhesion molecules and powered by actin. Journal of Gene 
Medicine, 6, 769-776. 
References for Chapter 1 are on page 56-73. 
 
67
 
 
105. Forrest, M.L., and Pack, D.W. (2002). On the kinetics of polyplex endocytic 
trafficking: Implications for gene delivery vector design. Molecular Therapy, 6, 57-66. 
106. Wiethoff, C.M., and Middaugh, C.R. (2003). Barriers to nonviral gene delivery. 
Journal of Pharmaceutical Sciences, 92, 203-217. 
107. Akinc, A., Thomas, M., Klibanov, A.M., and Langer, R. (2005). Exploring 
polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. 
Journal of Gene Medicine, 7, 657-663. 
108. Foley, M., and Tilley, L. (1997). Quinoline antimalarials: Mechanisms of action and 
resistance. International Journal for Parasitology, 27, 231-240. 
109. Monsigny, M., Roche, A.C., Midoux, P., and Mayer, R. (1994). Glycoconjugates as 
carriers for specific delivery of therapeutic drugs and genes. Advanced Drug Delivery 
Reviews, 14, 1-24. 
110. Cheng, J.J., Zeidan, R., Mishra, S., Liu, A., Pun, S.H., Kulkarni, R.P., Jensen, G.S., 
Bellocq, N.C., and Davis, M.E. (2006). Structure-function correlation of chloroquine 
and analogues as transgene expression enhancers in nonviral gene delivery. Journal of 
Medicinal Chemistry, 49, 6522-6531. 
111. Tomlinson, R., Klee, M., Garrett, S., Heller, J., Duncan, R., and Brocchini, S. (2002). 
Pendent chain functionalized polyacetals that display pH-dependent degradation: A 
platform for the development of novel polymer therapeutics. Macromolecules, 35, 
473-480. 
112. Tomlinson, R., Heller, J., Brocchini, S., and Duncan, R. (2003). Polyacetal-
doxorubicin conjugates designed for pH-dependent degradation. Bioconjugate 
Chemistry, 14, 1096-1106. 
113. Pouton, C.W., Wagstaff, K.M., Roth, D.M., Moseley, G.W., and Jans, D.A. (2007). 
Targeted delivery to the nucleus. Advanced Drug Delivery Reviews, 59, 698-717. 
References for Chapter 1 are on page 56-73. 
 
68
 
 
114. Stewart, M. (2007). Molecular mechanism of the nuclear protein import cycle. Nature 
Reviews Molecular Cell Biology, 8, 195-208. 
115. Zanta, M.A., Belguise-Valladier, P., and Behr, J.P. (1999). Gene delivery: A single 
nuclear localization signal peptide is sufficient to carry DNA to the cell nucleus. 
Proceedings of the National Academy of Sciences of the United States of America, 96, 
91-96. 
116. Bremner, K.H., Seymour, L.W., Logan, A., and Read, M.L. (2004). Factors 
influencing the ability of nuclear localization sequence peptides to enhance nonviral 
gene delivery. Bioconjugate Chemistry, 15, 152-161. 
117. Pante, N., and Aebi, U. (1996). Toward the molecular dissection of protein import into 
nuclei. Current Opinion in Cell Biology, 8, 397-406. 
118. Collins, E., Birchall, J.C., Williams, J.L., and Gumbleton, M. (2007). Nuclear 
localisation and pDNA condensation in non-viral gene delivery. Journal of Gene 
Medicine, 9, 265-274. 
119. Plank, C., Oberhauser, B., Mechtler, K., Koch, C., and Wagner, E. (1994). The 
influence of endosome disruptive peptides on gene transfer using synthetic virus-like 
gene transfer Systems. Journal of Biological Chemistry, 269, 12918-12924. 
120. Chen, Q.R., Zhang, L., Stass, S.A., and Mixson, A.J. (2001). Branched co-polymers of 
histidine and lysine are efficient carriers of plasmids. Nucleic Acids Research, 29, 
1334-1340. 
121. McKenzie, D.L., Smiley, E., Kwok, K.Y., and Rice, K.G. (2000). Low molecular 
weight disulfide cross-linking peptides as nonviral gene delivery carriers. 
Bioconjugate Chemistry, 11, 901-909. 
122. Cho, Y.W., Kim, J.D., and Park, K. (2003). Polycation gene delivery systems: escape 
from endosomes to cytosol. Journal of Pharmacy and Pharmacology, 55, 721-734. 
References for Chapter 1 are on page 56-73. 
 
69
 
 
123. Leng, M., and Felsenseld, G. (1966). The perferential interactions of polylysine and 
polyarginine with specific base sequenes in DNA. Proceedings of the National 
Academy of Sciences of the United States of America, 56, 1325-1332. 
124. Zauner, W., Ogris, M., and Wagner, E. (1998). Polylysine-based transfection systems 
utilizing receptor-mediated delivery. Advanced Drug Delivery Reviews, 30, 97-113. 
125. Vermeersch, H., and Remon, J.P. (1994). Immunogenicity of poly-D-lysine, a 
potential polymeric drug carrier. Journal of Controlled Release, 32, 225-229. 
126. Ward, C.M., Read, M.L., and Seymour, L.W. (2001). Systemic circulation of poly(L-
lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: 
differential circulation in mice and rats and the implications for human gene therapy. 
Blood, 97, 2221-2229. 
127. Wolfert, M.A., and Seymour, L.W. (1996). Atomic force microscopic analysis of the 
influence of the molecular weight of poly(L)lysine on the size of polyelectrolyte 
complexes formed with DNA. Gene Therapy, 3, 269-273. 
128. Wolfert, M.A., Dash, P.R., Nazarova, O., Oupicky, D., Seymour, L.W., Smart, S., 
Strohalm, J., and Ulbrich, K. (1999). Polyelectrolyte vectors for gene delivery: 
Influence of cationic polymer on biophysical properties of complexes formed with 
DNA. Bioconjugate Chemistry, 10, 993-1004. 
129. Bettinger, T., Carlisle, R.C., Read, M.L., Ogris, M., and Seymour, L.W. (2001). 
Peptide-mediated RNA delivery: a novel approach for enhanced transfection of 
primary and post-mitotic cells. Nucleic Acids Research, 29, 3882-3891. 
130. Midoux, P., and Monsigny, M. (1999). Efficient gene transfer by histidylated 
polylysine pDNA complexes. Bioconjugate Chemistry, 10, 406-411. 
References for Chapter 1 are on page 56-73. 
 
70
 
 
131. Zhang, X.H., Sawyer, G.J., Dong, X.B., Qiu, Y., Collins, L., and Fabre, J.W. (2003). 
The in vivo use of chloroquine to promote non-viral gene delivery to the liver via the 
portal vein and bite duct. Journal of Gene Medicine, 5, 209-218. 
132. Erbacher, P., Roche, A.C., Monsigny, M., and Midoux, P. (1996). Putative role of 
chloroquine in gene transfer into a human hepatoma cell line by DNA lactosylated 
polylysine complexes. Experimental Cell Research, 225, 186-194. 
133. Parker, A.L., Eckley, L., Singh, S., Preece, J.A., Collins, L., and Fabre, J.W. (2007). 
(LYS)(16)-based reducible polycations provide stable polyplexes with anionic 
fusogenic peptides and efficient gene delivery to post mitotic cells. Biochimica Et 
Biophysica Acta-General Subjects, 1770, 1331-1337. 
134. Gasparovic, C., Barba, I., Born, J., Barton, S., Arus, C., and Mann, P. (1998). A study 
of imidazole-based nuclear magnetic resonance probes of cellular pH. Analytical 
Biochemistry, 261, 64-72. 
135. Uster, P.S., and Deamer, D.W. (1985). pH-dependent fusion of liposomes using 
titratable polycations. Biochemistry, 24, 1-8. 
136. Wang, C.Y., and Huang, L. (1984). Polyhistidine mediates an acid-dependent fusion 
of negatively charged liposomes. Biochemistry, 23, 4409-4416. 
137. Cho, Y.W., Kim, J.D., and Park, K. (2003). Pollycation gene delivery systems: escape 
from endosomes to cytosol. Journal of Pharmacy and Pharmacology, 55, 721-734. 
138. Pichon, C., Roufai, M.B., Monsigny, M., and Midoux, P. (2000). Histidylated 
oligolysines increase the transmembrane passage and the biological activity of 
antisense oligonucleotides. Nucleic Acids Research, 28, 504-512. 
139. Midoux, P., Kichler, A., Boutin, V., Maurizot, J.C., and Monsigny, M. (1998). 
Membrane permeabilization and efficient gene transfer by a peptide containing several 
histidines. Bioconjugate Chemistry, 9, 260-267. 
References for Chapter 1 are on page 56-73. 
 
71
 
 
140. Daniel W. Pack, D.P.R.L. (2000). Design of imidazole-containing endosomolytic 
biopolymers for gene delivery. Biotechnology and Bioengineering, 67, 217-223. 
141. Benns, J.M., Choi, J.S., Mahato, R.I., Park, J.S., and Kim, S.W. (2000). pH-Sensitive 
cationic polymer gene delivery vehicle: N-Ac-poly(L-histidine)-graft-poly(L-lysine) 
comb shaped polymer. Bioconjugate Chemistry, 11, 637-645. 
142. Asayama, S., Sekine, T., Hamaya, A., Kawakami, H., and Nagaoka, S. (2005). 
Poly(L-histidine) with several aminoethyl groups for a new pH-sensitive DNA carrier. 
Polymers for Advanced Technologies, 16, 567-570. 
143. Yu, W., Pirollo, K.F., Yu, B., Rait, A., Xiang, L.M., Huang, W.Q., Zhou, Q., Ertem, 
G., and Chang, E.H. (2004). Enhanced transfection efficiency of a systemically 
delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated 
oligolysine peptide. Nucleic Acids Research, 32, e48. 
144. Manickam, D.S., and Oupicky, D. (2006). Multiblock reducible copolypeptides 
containing histidine-rich and nuclear localization sequences for gene delivery. 
Bioconjugate Chemistry, 17, 1395-1403. 
145. Trubetskoy, V.S., Budker, V.G., Hanson, L.J., Slattum, P.M., Wolff, J.A., and 
Hagstrom, J.E. (1998). Self-assembly of DNA-polymer complexes using template 
polymerization. Nucleic Acids Research, 26, 4178-4185. 
146. Tung, C.H., and Weissleder, R. (2003). Arginine contianing peptides as delviery 
vectors. Advanced Drug Delivery Reviews, 55, 281-294. 
147. Truant, R., and Cullen, B.R. (1999). The arginine-rich domains present in human 
immunodeficiency virus type 1 TAT and Rev function as direct importin beta-
dependent nuclear localization signals. Molecular and Cellular Biology, 19, 1210-
1217. 
References for Chapter 1 are on page 56-73. 
 
72
 
 
148. Manickam, D.S., Bisht, H.S., Wan, L., Mao, G.Z., and Oupicky, D. (2005). Influence 
of TAT-peptide polymerization on properties and transfection activity of TAT/DNA 
polyplexes. Journal of Controlled Release, 102, 293-306. 
149. Rudolph, C., Plank, C., Lausier, J., Schillinger, U., Muller, R.H., and Rosenecker, J. 
(2003). Oligomers of the arginine-rich motif of the HIV-1 TAT protein are capable of 
transferring plasmid DNA into cells. Journal of Biological Chemistry, 278, 11411-
11418. 
150. Meister, A. (1988). Glutathione metabolism and its selective modification. The 
Journal of Biological Chemistry, 263, 17205-17208. 
151. Nitin, N., LaConte, L., Rhee, W., and Bao, G. (2009). TATpeptide is capable of 
importing large nanoparticles across nuclear membrane in digitonin permeabilized 
cells. Annals of Biomedical Engineering, 1-10. 
152. Stevenson, M., Ramos-Perez, V., Singh, S., Soliman, M., Preece, J.A., Briggs, S.S., 
Read, M.L., and Seymour, L.W. (2008). Delivery of siRNA mediated by histidine-
containing reducible polycations. Journal of Controlled Release, 130, 46-56. 
 
 
References for Chapter 1 are on page 56-73. 
 
73
  
 
 
 
 
 
 
CHAPTER 2 
Materials and Methods 
 
 
 
 
 
 
 
 
 
   74
 CONTENTS 
List of Figures 
List of Tables 
 
2 MATERIALS AND METHODS   
2.1 Suppliers of materials 79
2.2 Source of nucleic acids, oligopeptides and cell lines 79 
         2.2.1    Source of nucleic acids 79 
 2.2.2  Source of oligopeptides 80 
         2.2.3 Source of cell lines 80 
2.3 Oligopeptide purification and characterization 81  
2.4 pKa determination of oligopeptides 86  
2.5 Reducible polycations (RPCs) formation 87  
   2.5.1 Oxidative polymerisation to form RPCs 87
     2.5.2 Formation of cross-linked RPCs 88
 2.5.3 Formation of reducible copolypeptides (RcPCs) and reducible polyTAT 
 (RP-TAT)           89 
2.5.4 Gel Permeation Chromatography (GPC) 90 
2.5.5 Polymer purification      90 
2.5.6 Polydispersity index (PDI) of polycations   91 
2.6 Amino acid analysis of RcPCs 92
2.7 Formation of polyplexes 93
 2.7.1 Calculation of charge ratio   93
     2.7.2 Formation of polyplexes 94
2.8 Physicochemmical characterisation of polyplexes 94 
2.8.1    Analysis of polyplex diameter by photon correlation spectroscopy (PCS)    94 
 2.8.2 Analysis of polyplex surface charge by zeta potential 95 
2.8.3    Atomic force microscopy   95 
 2.8.4    Agarose gel electrophoresis of DNA   96
 2.8.5       Gel shift assay 96 
2.8.5.1    Polyaspatic aicd assay 96 
2.8.5.2    Glutathione and NaCl assay 97 
2.9 Cell culture 97
   75
  2.9.1 Maintainance of established cell lines   98
 2.9.2 Determination of viable cell number   98 
      2.10  Biological studies of polyplexes 99 
  Cell    2.10.1 transfection in vitro 99
 2.10.2 Luciferase assay    100 
2.10.3 Advanced protein assay                                                                                100 
2.10.4  MTS cell proliferation assay                                                                         101 
2.10.5  Intracellular glutathione analysis                                                                  102 
2.11  Expression of data                                                                                                103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   76
 List of Figures 
 
Figure  2.1. Map of pCMV-Luc (5.9 kb)       80 
Figure  2.2. Structures of lysine and histidine      86 
Figure  2.3.  pKa determination by plotting the change of chemical shift  
         against the pH values       87 
Figure 2.4.   PLL standard plotted between Log MW and GPC retention time  90 
Figure 2.5.   Amino acid standard at 200 nmol ml-1 (EZ:faast kits, phenomenex, UK)  
run with GC         92 
Figure 2.6.  Amino acid standard plotted between the concentration of amino acid  
  and the peak area obtained from GC      93 
Figure 2.7.    BSA standard plotted between BSA concentration and absorbance          101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   77
 List of Tables 
 
Table 2.1.  Oligopeptides used in this work      81 
Table 2.2. Specific masses and volumes of peptides and reagents used in oxidative 
polymerization to synthesize RPCs      88 
Table 2.3. Specific masses and volumes of peptides and reagents used in oxidative 
polymerization to synthesize RP-TAT and RcPCs    89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   78
 2   MATERIALS AND METHODS 
Abstract 
In this chapter the experimental principles and procedures used during the 
course of this thesis are described. The techniques employed ranged from 
chemical characterization of synthesised peptides, formation of reducible 
polycations (RPCs) and reducible copolycations (RcPCs) and their DNA 
polyplexes through to determination of gene transfection studies of RPCs- and 
RcPCs-based vectors in endothelial (bEND3) and epithelial (A549) cell lines.  
 
2.1    Suppliers of materials 
 
All materials were purchased from Sigma-Aldrich, Fisher Scientific or Applied Biosystems, 
in the UK unless otherwise stated. All solvents were laboratory reagent grade or anhydrous, 
with the exception for HPLC analysis, where HPLC grade solvents were used. All water was 
distilled, followed by purification to 18 MΩ.cm using an Elga water purifier. 
 
2.2   Source of nucleic acids, oligopeptides and cell lines 
 
2.2.1   Source of nucleic acid 
 
The expression vector used in all of the transfection studies was pCMV-Luc, a luciferase gene 
expression plasmid that contains CMV promoter and enhancer regions (Figure 2.1). Plasmid 
DNA was grown in Escherichia coli, and all nucleic acids were amplified by standard 
techniques followed by purification using preparation kits (Qiagen, Crawley, UK) or 
otherwise stated, and finally stored at -18oC in appropriate aliquot concentrations (1.2 mg/ml) 
   79
 prior to use. The concentration and purity of DNA was checked on a spectrophotometer at 
A260/A280 absorbance wavelengths.  
 
Figure 2.1.   Map of pCMV-Luc (5.9 kb) 
 
2.2.2 Source of oligopeptides 
 
All of the oligopeptides were synthesized by Alta Biosciences (Birmingham, UK) and Peptide 
protein research Ltd (Wickham, UK) using standard Fmoc method. Oligoeptides used in the 
studies are shown in Table 2.1. 
 
2.2.3 Source of cell lines 
 
A549 (human lung carcinoma cells) and bEND3 (mouse brain carcinoma cells) were used in 
this study and were obtained from ATCC unless otherwise stated. Both cell lines were 
   80
 maintained and grown in Dulbecco’s modified Eagles media (DMEM, Gibco-BRL, Paisley, 
UK) supplemented with 2 mM L-glutamine and 10 % foetal calf serum (FCS). The media was 
supplemented with penicillin and streptomycin to prevent bacterial contamination of the cell 
lines 
 
Table 2.1 Oligopeptides used in this work  
 
Oligopeptide 
 
Sequencea
Calculated 
Mass  (g mol-1) b
2COPs (bis-cysteine containing oligopeptides) 
1 
2 
3 
4 
5 
6  
TAT 
 
3COP (tris-cysteine containing oligopeptides) 
7 
 
CK8C 
CK4H4C 
CK2H2K2H2C 
CK2HKHKH2C 
CKHKHKHKHC 
CH8C 
CRKKRRQRRRC 
 
 
CK2CK2C 
 
1249.70 
1285.56 
1285.56 
1285.56 
1285.56 
1321.43 
1545.10 
 
 
839.42 
a C = Cysteine, K = Lysine, H = Histidine, R = Arginine, Q = Glutamine 
b Molecular weight from the calculation 
 
2.3   Oligopeptide purification and characterization 
 
The crude oligopeptides 1-7 and TAT were purified by preparative RP-HPLC. Briefly, all 
crude peptides were analyzed by analytical RP-HPLC eluted with the gradient 0-100% of 
MeCN/water (60:40) plus 0.05% TFA for 60 minutes. The methods used in analytical RP-
HPLC were then written separately for separating all peaks for each oligopeptide sample. 
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 Analytical RP-HPLC runs were preformed on a Luna (Phenomenex), C18, 250 mm × 4.6 mm 
ID, with 10 μm pore size column. The crude oligopeptides (~1mg) were dissolved in water 
(100 μl) and a 10 μl aliquot was injected at 1.0 ml/min flow rate and the UV absorbance at 
210 nm was mornitored.  After finding the suitable method, all fractions were collected and 
their mass was determined by ElectroSpray Mass Spectrometry (TOF-ESI MS, Micromass, 
UK). Preparative RP-HPLC (Phenomenex), C18 with 250 mm × 21.2 mm ID and 10 μm pore 
size, was utilized for oligopeptide purification. An aqueous solution of the crude 
oligopeptides (20 mg in 700 μl of water) were injected onto the column using of MeCN plus 
0.05% TFA as an elution solvent at 10 ml/min flow (see below). The methods applied for 
purifying oligopeptides were those used in analytical HPLC. Fractions of the oligopeptides 
were collected, concentrated by rotary evaporation, lyophilized, purged with nitrogen or 
helium and stored dry at -20°C. The lyophilized samples were then analyzed by ESI-MS. The 
structures of the purified oligopepides were determined using 1H NMR 500 MHz (Bruker 
AC500) using deuterated solvents and the residual solvent as the lock. Purity of purified 
peptides was further analyzed by analytical RP-HPLC (preparative HPLC of crude peptides, 
analytical HPLC and 1H NMR of purified peptides are shown in appendix).   
 
Dr. Parvez Iqbal and Dr. Neil Spencer (School of Chemistry, University of Birmingham) 
characterized the 2COPs and TAT by 1H NMR. 
 
2COP 1 (CK8C) 
Preparative HPLC eluting time: ~24 minutes with MeCN (1%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 60 minutes 
Mass (g mol-1): 1249.9 [M]+, 625.4 [M+H]+2, 417.3 [M+H]+3 
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1H NMR δ (ppm) (D2O): 4.61 (t, J = 5.23Hz, 1H, -CO-CH-N-), 4.36-4.24 (m, 9H, -CO-CH-
N-), 2.98 (t, J = 6.99 Hz, 20H, CH-C3H6-CH2-NH2, -CH2-SH), 1.79-1.66 (m, 32H, CH-CH2-
CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.45-1.42 (m, 16H, CH-CH2-CH2-CH2-
CH2-NH2) 
 
2COP 2 (CK4H4C) 
Preparative HPLC eluting time: ~35 minutes with the gradient of MeCN (0-5%) plus TFA 
(0.05%) for the first 30 minutes, and with MeCN+TFA (5%) for further 10 minutes as an 
elution solvent at 10 ml/min flow rate  
Mass (g mol-1): 1285.9 [M]+, 643.4 [M+H]+2, 429.3 [M+H]+3 
1H NMR δ (ppm) (D2O): 8.63-8.61 (m, 4H, Im, -N=CH-NH-), 7.32-7.27 (m, 4H, Im, -C-CH-
N-), 4.69-4.63 (m, 4H, -CO-CH-N-), 4.54 (t, 1H, J = 5.73 Hz,-CO-CH-N-), 4.35 (t, J = 5.73 
Hz, 1H, -CO-CH-N-), 4.33-4.21 (m, 4H, -CO-CH-N-), 3.21-3.10 (m, 10H, -NH-CH-CH2-,-
CH2-SH), 3.07-2.92 (m, 10H, CH-C3H6-CH2-NH2, -CH2-SH), 1.74-1.66 (m, 16H, CH-CH2-
CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.45-1.38 (m, 8H, CH-CH2-CH2-CH2-
CH2-NH2) 
 
2COP 3 (CK2H2K2H2C) 
Preparative HPLC eluting time: ~32-34 minutes with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes 
Mass (g mol-1): 1285.7 [M]+, 643.3 [M+H]+2, 429.2 [M+H]+3 
1H NMR δ (ppm) (D2O:H2O=1:9): 8.63-8.62 (m, 4H, Im, -N=CH-NH-), 7.31-7.26 (m, 4H, 
Im, -C-CH-N-), 4.67-4.64 (m, 4H, -CO-CH-N-), 4.49 (t, 1H, J = 5.59 Hz,-CO-CH-N-), 4.34-
4.21 (m, 5H, -CO-CH-N-), 3.25-3.10 (m, 10H, -NH-CH-CH2-, -CH2-SH), 3.08-2.89 (m, 10H, 
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 CH-C3H6-CH2-NH2, -CH2-SH), 1.77-1.65 (m, 16H, CH-CH2-CH2-CH2-CH2-NH2, CH-CH2-
CH2-CH2-CH2-NH2), 1.45-1.35 (m, 8H, CH-CH2-CH2-CH2-CH2-NH2) 
 
2COP 4 (CK2HKHKH2C) 
Preparative HPLC eluting time: ~32-34 minutes with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes 
Mass (g mol-1): 1285.7 [M]+, 643.3 [M+H]+2, 429.2 [M+H]+3 
1H NMR δ (ppm) (D2O:H2O=1:9): 8.64-8.62 (m, 4H, im, -N=CH-NH-), 7.32-7.28 (m, 4H, im, 
-C-CH-N-), 4.69-4.63 (m, 4H, -CO-CH-N-), 4.53 (t, 1H, J = 5.66 Hz,-CO-CH-N-), 4.35 (m, 
1H, -CO-CH-N-), 4.33-4.27 (m, 4H, -CO-CH-N-), 3.26-3.03 (m, 10H, -NH-CH-CH2-,-CH2-
SH), 2.98-2.90 (m, 10 H, CH-C3H6-CH2-NH2, -CH2-SH), 1.76-1.65 (m, 32H, CH-CH2-CH2-
CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.43-1.35 (m, 8H, CH-CH2-CH2-CH2-CH2-
NH2) 
 
2COP 5 (CKHKHKHKHC) 
Preparative HPLC eluting time: ~35-37 minutes with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes 
Mass (g mol-1): 1285.8 [M]+, 643.3 [M+H]+2, 429.2 [M+H]+3 
1H NMR δ (ppm) (D2O:H2O=1:9): 8.64-8.63 (m, 4H, Im, -N=CH-NH-), 7.34-7.30 (m, 4H, 
Im, -C-CH-N-), 4.69-4.63 (m, 4H, -CO-CH-N-), 4.55 (t, 1H, J = 5.62 Hz,-CO-CH-N-), 4.33-
4.24 (m, 5H, -CO-CH-N-), 3.22-3.07 (m, 10H, -NH-CH-CH2-, -CH2-SH), 3.01-2.94 (m, 10 H, 
CH-C3H6-CH2-NH2, -CH2-SH), 1.74-1.64 (m, 16H, -CH-CH2-CH2-CH2-CH2-NH2, -CH-CH2-
CH2-CH2-CH2-NH2), 1.45-1.38 (m, 8H, -CH-CH2-CH2-CH2-CH2-NH2) 
 
2COP 6 (CH8C) 
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 Preparative HPLC eluting time: ~37 minutes with the gradient of MeCN (0-10%) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate for 40 min  
Mass (g mol-1): 1321.9 [M]+, 661.4 [M+H]+2, 441.3 [M+H]+3
1H NMR δ (ppm) (D2O): 8.64-8.63 (m, 8H, Im, -N=CH-NH-), 7.28-726 (m, 8H, Im, -C-CH-
N-), 4.73-4.63 (m, 8H, -CO-CH-N-), 4.45 (t, 1H, J = 5.38 Hz,-CO-CH-N-), 4.17 (t, J = 5.37 
Hz, 1H, -CO-CH-N-), 3.00-2.84 (m, 20H, -NH-CH-CH2-, -CH2-SH) 
 
3COP 7 (CK2CK2C) 
Preparative HPLC eluting time: ~19 minutes with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes 
Mass (g mol-1): 840.5 [M]+, 420.7 [M+H]+2 
1H NMR δ (ppm) (D2O:H2O=1:9): 4.54-4.49 (m, 2H, -CO-CH-N-), 4.36-4.31 (m, 4H, -CO-
CH-N-), 3.13-2.90 (m, 14H, CH-C3H6-CH2-NH2, -CH2-SH), 1.81-1.66 (m, 16H, CH-CH2-
CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.45-1.42 (m, 8H, CH-CH2-CH2-CH2-
CH2-NH) 
 
TAT (CRKKRRQRRRC) 
Preparative HPLC eluting time: ~32 minutes with the gradient of MeCN (0-20%) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate for 60 min 
Mass (g mol-1): 783.9 [M+H]+2, 515.6 [M+H]+3
1H NMR δ (ppm) (D2O:H2O=1:9):  8.78 (d, J = 6.41 Hz, 1H, -CH-CO-NH-), 8.48 (m, 9H, -
CH-CO-NH-), 7.52 (m, 4H, -CH-CH2-CH2-CH2-NH2), 7.18-7.16 (m, 6H, -CH-CH2-CH2-
CH2-NH-CNH-NH2, -N-CH-CH2-NH2,), 4.34-4.24 (m, 4H, -CO-CH-N-), 3.20-3.16 (m, 12H, 
-CH-CH2-CH2-CH2-NH-CNH-NH2), 3.10 (dq, 2H, J = 17.42 Hz, 5.50 Hz, -N-CH-CH2-SH), 
3.04-2.98 (m, 6H, -CH-CH2-CH2-CH2-CH2-NH2, -N-CH-CH2-SH), 2.34 (t, J = 8.14 Hz, 2H, -
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 CH-CH2-CH2-CO-NH2), 2.06-1.92 (m, 2H, -CH-CH2-CH2-CO-NH2), 1.82-1.61 (m, 32H, CH-
CH2-CH2-CH2-CH2-NH2, -CH-CH2-CH2-CH2-NH-CNH-NH2), 1.44-1.36 (m, 4H, CH-CH2-
CH2-CH2-CH2-NH2) 
 
2.4  pKa determination of the olipeptides  
 
NMR titration was used for the determination of the pKa values of the histidine moieties. 10 
mg of each peptide was dissolved in deuterated water (D2O) (0.75 ml). An aliquot of NaOD 
solution (100 mM, 20 μl) was added to the peptide solution and then mixed by vortex for 2 
minutes. The pH values were measured using a thin stem stainless pH reference probe (ISFET 
electrode). The NMR spectra were recorded using 1H NMR (500 MHz). The NMR sample 
was left in the NMR instrument for 10 minutes at 27°C. The chemical shifts of Hε of lysine 
residues and H5 and H6 of the imidazole rings of histidine residues (Figure 2.2) were 
measured as a function of pH.  
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Figure 2.2.  Structures of lysine (a) and histidine (b) 
 
The pKa values were determined by plotting the change of chemical shift against the pH 
values (Figure 2.3) 
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 Dr. Parvez Iqbal (School of Chemistry, University of Birmingham) performed the NMR 
experiments to calculate the pKa. The NMR spectra examples from the NMR titration 
experiments are shown in appendix (section 8.3, Figure 8.25-8.27)  
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Figure 2.3.  pKa determinations by plotting the change of chemical shift against pH  
 
2.5    Reducible polycations (RPCs) formation   
2.5.1  Oxidative polymerisation to form RPCs 
 
The purified oligopeptides were dissolved in PBS (0.5X PBS, pH 7.4, 70 µl) and 30% DMSO 
(60 µl) (~70 fold molar excess in respect to thiol groups) to form 200 µl total volume 
mixtures at 18, 30 and 60 mM oligopeptide concentration (Table 2.2).  The reactions were 
incubated at ambient or 40°C and the reaction progress was monitored by measuring the 
increase in molecular weight of the resulting polymers by gel permeation chromatography 
(section 2.5.4) as a function of time. Aliquots (5 µl) of the reaction were removed and 
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 terminated using fresh prepared aminoethanethiol (AET, 17 µM, 40 µl), unless otherwise 
stated, every 2 hours for the first 12 hours then 24, 30, 36 and 48 hours. 
 
Table 2.2.   Specific masses and volumes of peptides and reagents used in oxidative polymerization to   
  synthesize RPCs 
RPCs 2COPs used 
Concentration of 
2COPs (mM) 
Mass of peptide used 
 (mg) 
Vol of PBS 
(µl) 
Vol of DMSO 
(µl) 
RPC 1 2COP 1 18 4.5 140 60 
  30 7.5 140 60 
  60 15.0 140 60 
RPC 2 2COP 2 18 4.6 140 60 
  30 7.7 140 60 
  60 15.4 140 60 
RPC 3 2COP 3 18 4.6 140 60 
  30 7.7 140 60 
  60 15.4 140 60 
RPC 4 2COP 4 18 4.6 140 60 
  30 7.7 140 60 
  60 15.4 140 60 
RPC 5 2COP 5 18 4.6 140 60 
  30 7.7 140 60 
  60 15.4 140 60 
RPC 6 2COP 6 18 4.6 140 60 
  30 7.9 140 60 
  60 15.8 140 60 
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 2.5.2 Formation of cross-linked RPCs 
 
The reaction mixtures were performed at 30 mM concentration of 2COP 1-5 containing 3COP 
7 at 4 and 32% mole fraction in PBS (0.5X PBS, 70 µl) and 30% DMSO (30 µl). The 
reactions were incubated at ambient and the reaction progress was monitored by measuring 
the increase in molecular weight of resulting polymer by gel permeation chromatography 
(section 2.5.4). Aliquots (5 µl) of the reaction were removed and terminated using fresh 
prepared aminoethanethiol (AET, 17 µM, 8 mol % excess, 40 µl), unless otherwise stated, 
every 2 hours for the first 12 hours then 24, 30, 36 and 48 hours. 
 
2.5.3 Formation of reducible copolycations (RcPCs) and reducible polyTAT (RP-TAT) 
 
Reducible copolycations (RcPCs) were produced from 2COPs 1-5 and the TAT oligopeptide. 
2COPs (30 mM) and TAT solution (30 mM) in 5x PBS and 30% DMSO at 2COPs:TAT 
molar ratios of 1:1 for RcPCs 1-5 and also 1:3 for RcPC 5 (Table 2.3) were incubated at 
ambient for 48 hours. In addition, the reducible polymer from TAT (RP-TAT) was 
synthesized from 60 mM TAT solution in 5x PBS and 30% DMSO, and was incubated at 
ambient form 48 hours. The progress of the polymerisation was measures by monitoring the 
increase in molecular weight of resulting polymer by gel permeation chromatography (section 
2.5.4) 
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Table 2.3.   Specific masses and volumes of peptides and reagents used in oxidative polymerization to 
synthesize RP-TAT and RcPCs 
RP-TAT/RcPCs 2COP:TAT Molar ratio 
Mass of peptide used 
 (mg) 
Vol of PBS 
(µl) 
Vol of DMSO 
(µl) 
RP-TAT TAT - 18 140 60 
RcPC 1 2COP 1:TAT 1:1 7.5:9.3 140 60 
RcPC 2 2COP 2:TAT 1:1 7.7:9.3 140 60 
RcPC 3 2COP 3:TAT 1:1 7.7:9.3 140 60 
RcPC 4 2COP 4:TAT 1:1 7.7:9.3 140 60 
RcPC 5 2COP 5:TAT 1:1 7.7:9.3 140 60 
RcPC 5 2COP 5:TAT 1:3 3.9:14.0 140 60 
 
 
2.5.4 Gel permeation chromatography (GPC) 
 
The molecular weight distributions of the quenched polymerization reactions (section 2.5.1 
and 2.5.2) were analyzed by size exclusion chromatography (SEC). The SEC analysis was 
performed using HPLC with CATSEC-300 (250 mm x 4.5 mm ID) column (Hichrom, UK) 
eluted with 200 mM NaCl with 0.1% TFA. 10 µl of the samples were injected with 0.5 
ml/min flow rate (20 µl injecting loop) using a UV detector system at 220 nm. Commercially 
available poly-L-lysine (PLL) (Sigma, UK) samples (5.6, 8.3, 21.3, 62.1 and 128.5 kDa) were 
used to estimate the molecular weight (Figure 2.4).  
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Figure 2.4.  PLL standard plotted between Log MW and GPC retention time 
 
2.5.5 Polymer purification 
 
The reaction mixtures from section 2.5.1 and 2.5.2 were diluted in HEPES (15 ml, 15 mM, 
pH 7.4). The RPCs, RcPCs and RP-TAT were purified on centrifugal filter concentrators with 
molecular weight cut-off of 10,000 (Centricon Plus 2, Amicon Biosperation, Millipore, 
cellulose membrane, UK).  The solution was spun down to 150 μl at 4000 rpm (repeated three 
times for this procedure). For the final time of the centrifugation, the sample was spun down 
until a final volume of 400-500 µl obtained. After purification of the polymers, the molecular 
weight of the polymers and the removal of DMSO and other impurities were verified by GPC 
(section 2.5.4).  
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 2.5.6 Polydispersity index (PDI) of polycations 
 
SEC-MALLS (size exclusion chromatography coupled to multi-angle laser light scattering) 
was used to detect absolute molecular weights and molecular weight distributions. The Wyatt 
Technology (Santa Barbara, USA)  DAWN® HELEOS multi-angle laser light scattering 
photometer was coupled to TSK Gel G6000PW and G4000PW columns  protected by a 
similarly packed guard column (Anachem Ltd., Luton, UK) and pre-equilibrated for at least 1 
hour  at 30°C before sample measurement. The eluent was aqueous acetic acid (0.5 M) and 
aqueous sodium nitrate (0.1 M) and the injection volume was 100 μl. A value for the 
refractive index change with concentration dn/dc of 0.155 was used. Polypeptide molar 
masses and polydispersities were analyzed using software Astra V 5.3.2.16. This 
measurement was carried out by Dr. Gordon Morris (National Centre for Macromolecular 
Hydrodynamics, Division of Food Sciences, School of Biosciences, University of 
Nottingham)  
 
2.6 Amino acid analysis of RcPCs 
 
Ratios of the 2COP and TAT sequences of RcPCs 1-5 were determined using amino acid 
analysis. RcPCs were hydrolysed by liquid phase hydrolysis by adding HCl (6N) with 4% of 
thioglycolic acid (100 µl) into polypeptide (500 µg).  The reaction mixtures were placed in a 
heating block in a tightly capped vial at 110oC for 22 hr, to cleave the peptide bonds. The 
sample was then placed at -20oC for 24 h, unless stated otherwise. The samples were 
neutralised and analysed using EZ:faast kits (phenomenex, UK). An amino acid calibration 
standard (50, 100 and 200 nmol ml-1) (Figure 2.5) was run with gas chromatography (GC) to 
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 allow quantification of the amount of unknown amino acids found in each sample, thereby 
enabling calculation of the % recovery of amino acids within the sample to be determined.  
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Figure 2.5.  Amino acid standard at 200 nmol ml-1 (EZ:faast kits, Phenomenex, UK) run with GC 
 
The amino acid standards were plotted between the concentration of amino acid and the peak 
area obtained from GC (Figure 2.6). 
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Figure 2.6. Amino acid standard plotted between the concentration of amino acid and the peak area  
obtained from GC 
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 2.7    Formation of polyplexes 
2.7.1    Calculation of charge ratio 
 
An average mass of DNA per phosphate group is 325 Da and an average mass of PLL per 
amino group is 208. Hence, to obtain a theoretical charge ratio of PLL:DNA at 1:1, a 
weight/weight (w/w) ratio of 1:0.64 was required. For oligopeptides, PEI, RPCs and TAT-
RPCs, the ratio of N:P  was used rather than charge ratio, since the charge ratio is dependent 
on pH, and therefore, difficult to calculate accurately and only a proportion of the amino 
groups are fully ionised. The N:P ratio is defined as: N is the number of amino groups in the 
polycation, and P is the number phosphate groups in the DNA. The N:P ratio calculations 
have been used and will be discussed in detail in the appropriate chapters.  
 
2.7.2 Formation of polyplexes 
 
The addition of the 2COPs, RPCs, RcPCs and RP-TAT as well as PLL and PEI, oligopeptides 
and RPCs to a solution of DNA results in an electrostatic interaction between the oppositely 
charged components resulting in partial charge neutralisation and hydrophobic collapse of the 
DNA into discrete nanomolecular sized polyplexes. Plasmid DNA was dissolved in 10 mM 
HEPES buffer, pH 7.4 (1 ml, 40 µg/ml DNA). Plasmid DNA solution (500 µl) was added into 
a polypropylene microcentrifuge tube. The amount of polycation to produce the polyplexes at 
the desired N:P ratios was dissolved in 10 mM HEPES buffer (1 ml) at pH 7.4 and then added 
(500 µl) into the plasmid DNA solution to give the final concentration at 20 μg/ml of plasmid 
DNA. The resulting suspension of polyplexes was mixed by inverting the tube 5 times. The 
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 polyplexes were allowed to equilibrate overnight at ambient temperature, unless otherwise 
stated. 
2.8   Physicochemical characterisation of polyplexes 
2.8.1    Analysis of polyplex diameter by photon correlation spectroscopy (PCS) 
 
The hydrodynamic diameters of the polyplexes were measured by dynamic light scattering 
(DLS) using a Zetasizer 3000 (Malvern Instruments, Worcestershire, UK), equipped with a 50 
mW internal laser. Measurements were taken at 25oC at an angle of 90o to the incident light 
using disposable polymethacrylate cuvette. The machine was calibrated using latex spheres 
(204 nm diameter). Polyplexes for PCS measurements were prepared in 10mM HEPES buffer 
at pH 7.4 (1 ml)(section 2.7.2) in triplicate and analysed by monomodal analysis (where n = 3 
(total of 30 sub-runs)).  
 
2.8.2 Analysis of polyplex surface charge by zeta potential 
 
The polyplex solution was diluted with 10 mM HEPES buffer at pH 7.4 (3 ml) before 
injecting into the Zetamaster (Malvern Instruments, Worcestershire, UK) instrument. 
Measurements were taken at 25 oC and repeated 10 times. Before each measurement the flow 
cell was washed through with 18 ΩM.cm water (5 ml). 
 
2.8.3 Atomic force microscopy 
 
An AFM liquid cell and oxidation-sharpened NP-S tips on a V-shaped, silicon nitride 
cantilever, with a spring constant of around 0.1 N/m (Nanoprobe, Veeco Instruments) and 
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 resonant frequency between 9 and 10 kHz were used. All AFM imaging was carried out 
using a Tapping Mode on a Veeco Nanoscope (IIIa) MultiMode system (Veeco 
Instruments, Santa Barbara, CA). Topographical images were taken at 512X512 pixel 
resolution, plane-flattened, and analyzed by the computer program Nanoscope Software v 
5.12. 
 
The polyplexes were incubated at room temperature prior to immobilization onto freshly 
cleaved muscovite mica (Agar Scientific,Essex, UK) and being imaged directly in liquid. 
 
For time-course experiments, the polyplexes (120 µl, 97.8 µg/ml) were deposited on 
freshly cleaved NiCl  modified mica and incubated for 10 minutes before being washed 
twice with deionized water (2 x 200 µl). An aliquot of the fluid (100 µl) in the cell was 
then exchanged with GSH (20mM, 100 µl). The time for this exchange was defined as 
time zero and images were then captured according to stated times. 
2
The AFM experiments were carried out by Mahmoud Soliman (School of Pharmacy, 
University of Nottingham, UK) 
 
2.8.4 Agarose gel electrophoresis of DNA 
 
All agarose gel electrophoresis used Horizon 11.14 horizontal gel tanks (Gibco BRL, 
Invitrogen Life Technologies, Paisley, UK). Low melting point agarose gel (Gibco, BRL) was 
prepared at 1 % in TBE buffer (50 mM Tris, 50 mM boric acid, 0.8 mM EDTA, 0.5X TBE). 
Ethidium brominde (5 µl, 10 mg/ml) was added into melted gel (100 ml).  The agarose gel 
was poured into the casting tray and allowed to set at room temperature before TBE (0.5X 
TBE) was added as running buffer. TBE buffer (0.5X) was used as the electrophoresis 
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 running buffer. The samples were loaded into wells and the gel was run at 110 V (Biorad, 
UK) for 60 mins. The Typhoon gel scanner set at 533 nm/610 nm wavelengths and 550V was 
used to scan the gel and the quantity of DNA in particular bands analysed using 
ImageQuantTM software. Gels visualised on the transilluminator and the image captured using 
a Polaroid camera (Analysis software, FluorChem 8800, Alpha Innotech). 
 
2.8.5 Gel shift assay  
 
2.8.5.1 Polyaspartic assay 
 
The simulated extracellular stability of the polyplexes was studied using polyaspatic acid 
(PAA). The polyplex solutions were prepared by mixing with PAA at 250 times of the 
plasmid DNA concentration. The gel was run (section 2.8.4) at 110 volt for 60 minutes in 
0.5x TBE. The pCMV-Luc was loaded into gel in the equal amount with the plasmid DNA in 
the polyplex samples as control. 
 
  2.8.5.2  Glutathione and NaCl assay 
 
The intracellular stability of polyplexes was studied using glutathione (GSH) and NaCl for 
monitoring the reduction of the disulfide bonds. The polyplex solutions were prepared by 
mixing with 5mM. The mixtures were incubated at ambient for 1 hr before adding 0.15 M, 0.5 
M or 1 M NaCl.  The gel was run (section 2.8.4) at 110 volt for 60 minutes in 0.5x TBE. The 
pCMV-Luc was loaded onto the gel in the equal amount with the plasmid DNA in the 
polyplex samples as control. 
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 2.9    Cell culture 
 
All cell cultures were preformed using biological safety class II laminar flow cabinet (Class II 
Microbiological Safety Cabinet, Envair Ltd, UK), cleaned with 70 % ethanol before and after 
use. Cells were maintained in an incubator (MCO-17AIC, Sanyo, UK) at 37oC with a constant 
CO2 level of 5 %. Cells were maintained and grown in Dulbecco’s modified Eagles media 
(DMEM, Gibco-BRL, Paisley, UK) supplemented with L-glutamine (2mM) and 10 % foetal 
calf serum (FCS). The media was supplemented with penicillin and streptomycin to prevent 
the bacterial contamination to the cell lines. Phosphate buffered saline (1x PBS, Gibco-BRL, 
Paisley, UK) was used for washing cells. All media and PBS buffer were stored at 4oC.  
 
2.9.1 Maintenance of established cell lines 
 
Cells were grown as a monolayer in 75 cm3 flasks containing of DMEM with 10% FCS (10 
ml) at 37oC, 5% CO2. The culture medium was replaced every 3-4 days to avoid depletion of 
essential nutrients and build up of toxic metabolites. Cells were routinely passaged at 80 % 
confluence at a ratio of 1:10 to prevent overgrowth and loss of surface contact. To the sub-
culture, the medium was removed and the cells were washed briefly with 1x PBS buffer (10 
ml). The cells were suspended by trypsinising by adding trypsin/EDTA (5 ml; 0.05/0.02 %, 
respectively) and incubated at 37oC, 5% CO2 for 5 mins. Cells were resuspended in fresh 
media and aliquoted (10 ml) into fresh flasks, unless otherwise stated. 
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 2.9.2 Determination of viable cell number 
 
An aliquot of the cell suspension (20 µl) was added to aqueous trypan blue solution (20 µl). 
Only viable cells take up the trypan blue dye, thereby allowing the number of viable cell 
numbers to be determined microscopically by discounting blue cells using a haemocytometer 
of fixed volume. The cell concentration was calculated as the equation below.  
 
( ) ( )sampleinmixtureoriginalofvolume dilutionsampleofvolumechamberofvolumecountedchamberofpropotion countedcellofnumber ××  
 
2.10 Biological studies of polyplexes 
2.10.1 Cell transfection in vitro 
 
Cells were prepared in 96 well plates (104 cells per well) in DMEM (100 µl) containing 10% 
FCS and 1% penstrep. The cells were allowed to adhere for 18 hours at 37°, 5% CO2. The 
media was removed from the wells and the cells were washed with PBS (100 µl) and replaced 
with the serum free DMEM (50 µl). The polyplex solutions (25 µl) were mixed with serum 
free DMEM (25 µl) then added 50 µl of the mixture to each well of the cells (3 replicates 
were performed for each polyplex). The polyplexes were incubated at 37°C with 5% CO2 for 
4 hours then removed from the wells. The cells were washed with PBS (100 µl) and replaced 
with DMEM (100 µl) containing 10% FCS and 1% penstrep. The plates were incubated at 
37°C with 5% CO2 for a further 44 hours. The media was removed from the wells and the 
cells were washed with PBS (100 µl) and replaced with 1x cell lysis buffer (50 µl). The plates 
were kept at -80°C for at least 30 minutes and then thawed at room temperature. The cell 
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 lysate were further analyzed by luciferase assay (section 2.10.2) to obtain the relative light 
units (RLU), and the amount of protein produced by the advanced protein assay (section 
2.10.3). Thus, the gene expression will be shown in relative light units per milli gram of 
protein (RLU/mg protein).  
 
In some experiments, cells were incubated in the DMEM (100 µl) containing chloroquine 
(100 µM), glutathione monoethyl ester (5 mM) or buthionine sulfoximin (100 µM) at 37°C 
with 5% CO2  for 1, 3 and 24 hours, respectively. The cells were washed with PBS before 
transfecting with the polyplexes.  
 
2.10.2 Luciferase assay 
 
The luciferase assay is used to determine the luminescence produced by luciferase enzyme in 
the cell lysate (section 2.10.1).  
 
The cell lysate (25 µl) was added into the appropriate Rohren tube. The luminescence of the 
samples was analysed automatically by the luminormeter (EG and G Berthold, Bundoora, 
Australia) using the luciferase assay reagent (25 µl) (Promega, Madison, WI, USA). 
Luminescence was integrated over 10 sec and normalised to total cell protein, obtained using 
the advanced protein assay (section 2.10.3).  
 
2.10.3 Advanced protein assay 
 
The advanced protein assay is a colorimetric method for determining the protein 
concentration of cell lysate. It was performed in a 96 well plate.  
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 The cell lysate (5 µl) was added into each well (triplicate per sample) and the advanced 
protein assay reagent (250 µl, 1x APAR) (Totam Biologicals, Northampton, UK) was added 
into sample. The absorbance was measured at 590 nm using the Victor plate reader (Wallec, 
Perkin Elmer Life Sciences, UK). Blank was also performed by adding 1x lysis buffer (5 µl) 
instead of protein sample. The absorbance of each measurement was deducted from the blank.  
Bovine serum albumin (BSA) at different concentrations (7.8, 15.6, 31.2, 62.5, 125, 250 and 
500 µg ml-1) was used to produce a standard curve (Figure 2.7). 
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Figure 2.7.   BSA standard plotted between BSA concentration and absorbance  
 
2.10.4 MTS cell proliferation assay 
 
MTS cell proliferation assay is a colourimetric method to identify the cytotoxic potential of a 
test agent. The active agent of this assay is [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphophenyl)-2H-tetrazolium, inner salt] (Owen’s reagent or 
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 MTS). The MTS agent is bioreduced by NADPH and NADH produced by dehydrogenase 
enzymes in metabolically active cells, producing a yellow/orange formazan product. The 
amount of formazan product is directly proportional to the number of living cells. Thus, the 
cell proliferation or death can be quantified by reading the plate at 490 nm.  
 
After cell transfection for 96 hrs, cells were washed with PBS (200 µl) and reaction media 
(120 µl), containing DMEM (100 µl) with 10% FCS and MTS reagent (20 µl) (Promega, 
Madison, WI, USA) was added to the cells. Cells were incubated at 37°C with 5% CO2 for 45 
minutes. The quantity of formazan product was measured by the amount of absorbance at 490 
nm. A blank was also performed by adding the reaction media into empty wells. The 
absorbance was read using the Victor plate reader (Wallace, Perkin Elmer Life Sciences, UK). 
Each measurement was deducted from the blank before calculating the percentage cell 
viability.  
 
2.10.5 Intracellular glutathione analysis 
 
Monochlorobimane (mBCl) fluorometric method was used to measure the intracellular GSH 
in this thesis. Adding the membrane-permeant mBCl into culture medium leads the 
intracellular GSH to form GSH-mBCl adduct which can be measured fluorometrically.  
 
A stock solution of mBCl (8mM) was prepared in DMSO and stored at -80°C. The working 
solution of mBCl was prepared immediately before using by adding PBS to give the 800 µM 
final concentration.  
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 Following the cell incubation with chemical agents such as GSH-MEE, BSO or CQ at 
appropriate time (section 2.10.1), the cells were washed with PBS (100 µl) and the mBCl (5 
µl, 800 µM) was added into DMEM (95 µl), then added into cells to give final concentration 
at 40 µM. The cells were incubated at 37°C with 5% CO2 for 60 min. The fluorescence of the 
cells was measured at λex 355 nm and λem 460 using the Victor plate reader (Wallace, Perkin 
Elmer Life Sciences, UK). A blank was also performed by measuring the cell fluorescence 
before adding fluorescent probe mBCl. Each measurement was deducted from the blank 
before calculating the relative fluorescence.  
 
2.11 Expression of data 
 
All error bars shown represent the mean and standard deviation of the data from three 
independent experiments. 
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CHAPTER 3 
 
Synthesis and characterization of 
oligopeptides, reducible polycations (RPCs) 
and polyplexes 
 
 
 
 
 
 
References for Chapter 3 are on page 160-163. 
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3  SYNTHESIS AND CHARACTERIZATION OF 
OLIGOPEPTIDES, REDUCIBLE POLYCATIONS (RPCs) 
AND POLYPLEXES 
 Abstract 
 
As described previously there are several barriers to be overcome to deliver a 
gene in vitro and in vivo, which provided the key features to achive the 
efficient gene delivery including. In this chapter, the synthetic oligopeptides 
were designed by combining with lysine, histidine and cysteine residues which 
will bind DNA extracellularly, internalise via endocytosis, provide a tunable 
endosomal release mechanism and provide a degradable backbone in order 
that the DNA can be released once in the cytoplasm. The design, synthesize, 
characterize moleculary and biologically of pKa modulatable oligopeptides 
and reducible polycations (RPCs) will be described. The sizes, surface 
charges and the stability of RPC polyplexes under the simulated physiological 
conditions extra- and intracellularly suggested that these RPCs are the 
promising vectors for gene delivery, especially the low molecular weight 
RPCs. 
 
3.1 Introduction  
 
 
For efficient gene delivery, DNA or RNA must be taken across a number of formidable 
biological barriers. In the case of DNA, delivery is to the cell nuclei, while for RNA only 
cytoplasmic delivery is required. For both nucleic acids, a challenging step is to cross the cell 
membrane and gain entry into cellular cytoplasm which can be achieved via endocytosis.[1,2] 
Cationic polymers can be used as non-viral gene carriers by condensing nucleic acids with 
polycations to form polyelectrolyte complexes, known as ‘polyplexes’.[3] When internalized 
into the cytoplasm, via endocytosis, the polyplexes must be able to escape from endosomal 
compartments: and a means to do this is via a buffering capacity as the pH in the maturing 
endosome drops – this is known as the proton sponge hypothesis.[4] This hypothesis 
specifically describes the buffering action of polyethylenimine (PEI)/DNA polyplexes in the 
endosome during acidification and subsequent lysis of the endosome, due to an influx of 
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water due to the change in osmolarity.  This hypothesis can be extended to describe the 
activity of polyplexes which contain other basic groups which are capable of buffering the 
endosome.[5] 
 
In recent years, lysine (K) and histidine (H) have been incorporated into vectors on account of 
their varying abilities to deliver genes in vitro and in vivo,[6-13] which in turn may stem from 
their varying basicities. The degree of success of these vectors may be related to the ability of 
the polycation to buffer acidification in the endosome sufficiently. For example, polyplexes 
formed from poly(L)lysine (PLL) are not very efficient for gene delivery when used alone 
because the primary amine on the side chain of lysine has a pKa of ~10.5, and thus, is highly 
protonated at physiological pH (~7.4),[14] and is therefore unable to buffer the pH effectively. 
Therefore, an endosomolytic agent, chloroquine, is used to increase the transfection efficiency 
of PLL.[7] The rational for the addition of the chloroquine is that it is a weaker base with pKa 
of 8.1 and 10.2 and is able to diffuse into low-pH compartments, whereupon it is protonated 
and buffers acidic vesicles, which aids the lysis of the endosome.[15] Thus, the lack of 
buffering capacity of the protonated amine groups in PLL results in low transfection activity 
of the polyplexes, without chloroquine. Therefore, histidine residues have been incorporated 
into synthetic peptides in order to enhance endosomal release, since the pKa of an imidazole 
group in the histidine side chain is approximately 6.0.[16] It was found that poly(L)histidines 
were able to promote buffering in endosomal compartments allowing the polyplexes to escape 
from the endosome via the proton sponge hypothesis.[17-21]  
 
The use of cysteines in bioconjugates is a well-known strategy for linking molecular 
fragments together via a covalent disulfide bond, and is an appealing option in gene delivery 
chemistries owing to the ready reversibility of the disulfide bonds by the reducing agent 
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intracellular glutathione (GSH).[9,22] Polyplexes have been formed with disulfide bonds in the 
polymer backbone which are stabilized in the extracellular matrix,[23,24] but are cleaved 
efficiently by high concentration of intracellular glutathione, leading to the vector falling apart 
and efficient release of the DNA. These polyplexes are also reasonable gene delivery agents.  
 
3.2 Objectives 
 
In this chapter, we focus on producing a vector from synthetic oligopeptides, that 
incorporrate 3 amino acids – lysine, histidine and cysteine – in order to combine the 
vector features as described previously in Chapter 1 (Table 1.5). Thus, the vectors should 
address several of the key features  highlighted on page 40. 
   - bind DNA extracellularly (I),   
   - cell uptake via endocytosis (III),   
   - provide a tunable endosomal release mechanism (IV),  
  - and provide a degradable backbone in order that the DNA can be released  
       once in the cytoplasm (V).  
 
The design of the oligopeptides (Table 3.1) used in this study was described in section 
1.5.  
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Table 3.1. The synthetic oligopeptides used in this study 
Oligopeptide Sequencea
Bis-(cysteine containing oligopeptides) (2COPs) 
1 
2 
3 
4 
5 
6 
Tris-(cysteine contaning oligopeptides) (3COP) 
7 
 
CK8C 
CK4H4C 
CK2H2K2H2C 
CK2HKHKH2C 
CKHKHKHKHKHC 
CH8C 
 
CK2CK2C 
 a C = Cysteine, K = Lysine, H = Histidine 
 
 
3.3 Methodology 
 
 
The experimental processes in this chapter will be divided into 5 sections as described 
below and show in diagrammatically in Figure 3.1 and 3.2.  
 
   (i) The purification and characterisation of the oligopeptides: The crude 
oligopeptides 2COPs and 3COPs were purified and characterized (Figure 3.1 and 3.2a-b, 
step 1) using high perfomance liquid chromatography (HPLC), electrospray mass 
spectrometry (ESI-MS) and nuclear magnetic resonance (NMR). The pKa values of the 
oligopeptides were then determined using 1H NMR titration. 
 
   (ii) The formation and characterization of RPCs: The reducible polycations 
(RPCs) were synthesized via oxidative polymerisation from 2COPs (Figure 3.1, step 2). 
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The characterisation of RPCs was carried out using gel permeation chromatography 
(GPC) and multi-angle laser light scattering (MALLS).  
 
   (iii) The formation and characterization of RPCs polyplexes: The formation 
of RPCs polyplex with the DNA was performed in a condensation reaction (Figure 3.1, 
step 4), and the stability of the polyplexes under extra- and intracellularly simulated 
conditions was carried out (Figure 3.1, step 5-7). 
 
   (iv) The formation and characterisation of oligopeptide polyplexes: 2COPs 
1-5 were used to form the polyplexes with the DNA (Figure 3.2a, step 2) in order to 
compare their characteristic with RPCs polyplexes. The characterization of 2COPs 
polyplexes was carried out using dynamic light scattering (DLS) (Figure 3.2a, step 3).  
 
   (v) The synthesis of cross-linked RPCs: The cross-linked RPCs were 
synthesized via oxidative polymerisation between 2COPs and 3COPs (Figure 3.2b, step 
step 2) in order to compare with the synthesis of the linear RPCs. The characterization of 
the cross-linked RPCs was performed using GPC (Figure 3.2b, step 3).  
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Figure 3.1.   Schematic overview of characterisation and analysis of oligopeptides and polyplexes in this chapter 
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3.2.   Schematic overview of experiperimental processes of a) 2COPs and polyplexes and b) 3COPs and cross-linked RPC 
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3.4    Results and discussion 
 
3.4.1  Oligopeptide purification and characterization (Figure 3.1 and Figure 3.2a-b, 
Step 1) 
 
 
Crude samples of oligopeptides 1-7 synthesized by Alta Bioscience (Birmingham, UK) using 
Fmoc procedure were purified by preparative reverse phase HPLC as described in section 2.3. 
The final purity of each oligopeptide was determined by analytical reverse phase HPLC, the 
experimental and calculated mass was determined by electrospray-MS and is shown in Table 
3.2. The purity of all oligopeptides was between 97.35-99.64 % by analytical RP-HPLC. The 
purified oligopeptides were then characterized by 1H NMR (500 MHz) and ESI-MS to 
comfirm their structures (section 2.3).  
Table 3.2.  The purity and mass of purified oligopeptides 
 
Oligopeptide 
 
Sequencea
 
Purity (%) b
Experimental Mass 
[M]+ (g mol-1) c
Calculated 
Mass  (g mol-1) d
2COPs 
1 
2 
3 
4 
5 
6 
3COP 
7 
 
CK8C 
CK4H4C 
CK2H2K2H2C 
CK2HKHKH2C 
CKHKHKHKHKHC 
CH8C 
 
CK2CK2C 
 
99.59 
97.42 
98.45 
97.35 
97.41 
97.56 
 
99.64 
 
1249.90 
1285.90 
1285.70 
1285.70 
1285.80 
1321.90 
 
840.50 
 
1249.70 
1285.56 
1285.56 
1285.56 
1285.56 
1321.43 
 
839.42 
a C = Cysteine, K = Lysine, H = Histidine   
b Purity determined by analytical RP-HPLC (see appendix) 
c Mass analyzed by ESI-MS 
d Mass from the calculation 
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3.4.2 Determination of the pKa of the oligopeptides (Figure 3.1 and Figure 3.2a-b,   
Step 1) 
 
 
The pKa values of the purified oligopeptides was determined using 1H NMR titration (section 
2.4). The pKa values were calculated by plotting the change in chemical shift of reporter 
proton resonances against pH (Figure 3.3). At 50% of the height of the change in chemical 
shift the equilibrium position of protonated and unprotonated amino groups is 1:1. Thus, the 
pH at this point is referred as the pKa.   
 
1 H
 N
M
R
 C
he
m
ic
al
 s
hi
ft 
(p
pm
) 
pH 
50% of the height  
 
of the chemical shift 
Calculated pKa
 
Figure 3.3.   pKa calculation by 1H NMR titration plotting the change in chemical shift of reporter proton 
resonances against pH 
 
For 2COP 1 and 3COP 7 the lysine moieties pKa were measured by observing the Hε proton 
of the side chain (Table 3.3). Whilst,  2COPs 2-6, the H5 and H6 proton on the imidazole ring 
were monitored as shown in Figure 3.4 and Table 3.3. The NMR spectra examples from the 
NMR titration experiments are shown in the appendix (section 8.3, Figure 8.25-8.27). 
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Figure 3.4.   pKa determination of oligopeptides 1-7 
by  plotting the change in chemical shift 
from H5, H6 or Hε against pH 
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The determination of the pKa of the lysine residues in 2COPs 2-5 is not possible because of 
overlapping proton resonance with the β-methylene group of the histidine. However, the pKa 
of the lysine is so much greater (~10.5) than the physiological pH (~7.4), leading to it being 
highly protonated at pH 7.4. Hence small pH shifts will not affect the DNA binding 
significantly. 
  
Table 3.3. pKa value of oligopeptides determined by 1H NMR titration (500 MHz) 
Histidine                                 Lysine 
  
 
 
                  
pKa
 
Oligopeptide 
β 
α 
γ 
δ ε 
H2N
OH
O
NH2
α 
β 
H2N
OH
O
N
HN
H5
H6
H5 H6 Hε Average 
2COPs 
CK8C (1) 
CH4K4C (2) 
CH2K2H2K2C (3) 
CH2KHKHK2C (4) 
CHKHKHKHKC (5) 
CH8C (6) 
 
3COP 
CK2CK2C (7) 
 
- 
6.18 
6.15 
6.10 
6.14 
6.2 
 
 
- 
 
- 
6.22 
6.17 
6.12 
6.04 
6.3 
 
 
- 
 
10.51 
- 
- 
- 
- 
- 
 
 
10.81 
 
10.51 
6.20 
6.16 
6.11 
6.09 
6.25 
 
 
10.81 
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For 2COP 1 and 3COP 7 the pKa of the lysine residue were 10.51 and 10.81, respectively. For 
2COPs 2-6 the pKa of the histidine residues were 6.20, 6.16, 6.11, 6.09 and 6.25, respectively. 
As expected the pKa of the imidazole residues in the histidine decreases from 2COPs 2-5 
(Figure 3.5), due to charge repulsion of the subphase protons by the protonated lysine 
residues as described in section 1.6.1.1 and Figure 1.24. 
 
6.05
6.1
6.15
6.2
2COP 2 2COP 3 2COP 4 2COP 5
Oligopeptide
A
ve
ra
ge
 p
K
a
 
Figure 3.5.  Average pKa of histidine-containing oligopeptides 
 
 
In addition, as can be seen in Figure 3.4, at physiological pH (pH 7.4) 2COP 1 is fully 
protonated as there is no chemical shift of Hε at pH less than 8, whereas there is only partial 
protonation in 2COPs 2-6. Furthermore, the 2COPs 2-6 are still not fully protonated at 
endosomal pH (pH ~5), suggesting that 2COPs 2-6 will have a buffering capacity in the 
endosome leading to endosomal disruption via the proton sponge mechanism.[4] 
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3.4.3 Formation and characterization of reducible polycations (RPCs)  (Figure 3.1, 
Step 2, 3) 
 
2COPs 1-6 were oxidative polymerized to form linear polymers via disulfide bond formation 
(referred to reducible polycations, RPCs) (section 2.5.1). The polymerization is shown for 
2COP 2 in Figure 3.6.  
HS
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O OH O OH
i) Oligopeptide concentration (18, 30, 60 mM)
   in PBS buffer, pH 7.4, with 30% DMSO
   - 2COP 1-6 (18, 30, 60 mM) incubated at ambient
   - 2COP 1 (18 mM) incubated at 40oC
ii) Quenched with AET (17 μM)
4 4
4 4 4 4n
 
 
Figure 3.6. The oxidative polymerization procedure of 2COP 2 (CK4H4C) 
 
We investigated for 2COPs 1-6 the effect of concentration of the oligopeptides on the degree 
of polymerization, and for 2COP 1, we investigated the effect of temperature (ambient and 
40°C) 
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The growth of the RPCs molecular weights was monitored by gel permeation chromatography 
(GPC) (section 2.5.4). At various time intervals 5 μl aliquots were removed and quenched 
with aminoethanethiol (AET, 17 µM, 40 µl). This aliquot was analysed by GPC eluting with 
200 mM NaCl with 0.1% TFA, in order to get the molecular weight against PLL standards 
(5.6, 8.3, 21.3, 62.1 and 128.5 kDa). The GPC chromatogram examples of some 
polymerization reactions are shown in the appendix (Figure 8.28-8.30). 
 
3.4.3.1  Polymerization as a function of oligopeptide concentration  
 
The polymerizations were performed at three 2COP concentrations (18, 30 and 60 mM 
(ambient temperature)) and the molecular weights were determined as a function of time. This 
data is shown in Figure 3.7.  Due to the nature of the step growth polymerization 
mechanism,[25] in which monomers react to form dimers, then trimers, oligomers and finally 
long chain polymers, unsurprisingly, to produce the higher the molecular weight of the RPCs 
the higher concentration of 2COPs is needed in order to increase the chance of interacting to 
the adjacent monomers. At 2COP concentrations of 18, 30 and 60 mM, the relative 
conversions are 40, 60 and 80 %, respectively (data not shown). We propose at the lower 
2COP concentration there may be a competing oxidation forming R-SO-O-,[26,27] resulting in 
the lower polymerization yields, for example, at lower peptide concentration reaction there is 
more chance of thiol groups to be oxidized to R-SO-O-  which resulted in less conversion of 
monomers. All 2COPs showed the same general pattern of the RPC growth. During the first 
12 hr the RPC molecular weight grew slowly and increased rapidly after 12 hr. The maximum 
molecular weight of the RPCs generally reduced after 36 hrs.  
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a) 2COP 1 (CK8C) b) 2COP 2 (CK4H4C) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7. Oxidative polymerization of 2COPs (bis-cysteine containing peptides) at various peptide       
concentrations incubated at ambient. [18mM         , 30mM           and 60mM         ] 
The molecular weight was analyzed by GPC using PLL at 5.6, 8.3, 21.3, 62.1 and 128.5 kDa as 
standard curve (all data are an average of the triplicate experiments). 
c) 2COP 3 (CK2H2K2H2C) d) 2COP 4 (CK2HKHKH2C) 
e) 2COP 5 (CKHKHKHKHC) f) 2COP 6 (CH8C)  
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The maximum RPC molecular weight for all 2COPs at 18 mM, 30mM and 60mM are 
approximately 25-45, 30-65, and 50-90 kDa, respectively, as can be seen in Figure 3.8. 
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Figure 3.8.  Oxidative polymerization compared between all 2COPs at different concentrations         
incubated at ambient.  All data are an average of triplicate experiments. 
      [peptide 1         , 2         , 3    X    , 4     X    , 5        , and 6         ]  
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3.4.3.2  Polymerization as a function of temperature for 2COP 1 (ambient and 
40°C) 
 
The reaction mixtures were incubated at ambient and 40°C. Unsurprisingly the 
polymerization at 40°C proceeds more rapidly than that at ambient, reaching a molecular 
weight of approximately 45 kDa after 4 hr, followed by a decrease in molecular weight 
(~25% over 70 hrs) (Figure 3.9a). The ambient  polymerization  reaches  approximately the 
same maximum molecular weight, but after ~24 hr, at which point there is 3% decrease of the 
RPC molecular weight. Both temperatures proceed only to ~37% (40°C) and 41% (ambient) 
yield (Figure 3.9b). The remaining ~60% of material that is eluted has a retention time of 
2COP 1. The GPC chromatograms are shown in the appendix (Figure 8.30). 
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Figure 3.9.   Oxidative polymerization of 2COP 1 (CK8C) at 18 mM concentration reacted at ambient     
 and 40°C           ; a) molecular weight growth, and b) relative area of polymer yield 
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3.4.3.3   RPCs  stability in HEPES buffer 
 
The purified RPCs were stored in the HEPES buffer at -20°C for a period of 2-3 days and 
then reanalyzed by GPC. All the RPCs were stable, except for the RPC formed from 2COP 6, 
which degraded to form a material of molecular weight less than 10 kDa (data not shown). 
 
3.4.4    Formation and characterization of polyplexes  
 
The polyplexes were prepared by mixing the plasmid DNA (pCMV-Luc or pEGFP-C1) in 
HEPES buffer with the vectors (RPCs or oligopeptides) in HEPES buffer. The ratio of 
protonated basic groups (lysine and imidazole) of the vectors to the negative phosphate group 
on the DNA backbone is defined as the N:P ratio. Previously, RPCs (RPC(59) (CH3K3H3C, 59 
kDa) and RPC (113) (CH6K3H6C, 113 kDa) [8]  revealed an N:P ratio of 5:1 gave polyplexes of 
~100 nm diameter, which were non toxic to cells (95% cell viability). Therefore, the 
experiments here were carried out at N:P ratio of 5:1, with controls PLL and PEI at N:P ratios 
of 5:1 and 10:1, respectively, as these represented the most effective system in the 
literature.[28,29]  High N:P ratios were not tested for toxicity and transfection because N:P 
ratios grater than 10:1 lead to high level of cell death and result in decrease in transfection,[30] 
because of a high free concentration of the polycations. 
 
3.4.4.1  Weight per charge and N:P ratio calculation 
 
 
The weight per charges (wpc) were calculated on the actual mass of the oligopeptides 
(2COPs), taking into consideration the counterion associated with the protonation of the 
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amino groups on the lysine and histidine residues at physiological pH. During the synthesis, 
the 10 mer peptides were deprotected in an acidic cocktail containing trifluoroacetic acid 
(TFA), which acts as the counterion forming a TFA salt. Therefore, the number of TFA 
counterions of 2COP 1-5 is 9, due to the TFA counterion forming a salt molecule with the 4 
ammonium ions and 4 imidazolium ions of the 2COP backbone and the protonated N-
terminus of the oligopeptide. The following calculation was used to determine the wpc of all 
oligopeptides in this study.  
 
wpc = 
pHicallogphysioatgroupshistidinelysinebasicprotonatedofnumber
TFAofMWscounterionTFAofnumberpeptideofMW
)/(
)()( ×+
 
 
MW of TFA    = 114 g/mol 
TFA counterion   = CF3COO – 
 
For example, in the case of 2COP 1 (CK8C), as can be seen in Figure 3.4a, there is no change 
in chemical shift of Hε at pH 7.4 which mean the amino groups on the side chain of lysine 
residues are fully protonated at physiological pH. Therefore, the number of positive amino 
groups of this 2COP 1 is 9. 
 
In the cases of 2COPs 2-5, the basic nitrogen atom on the imidazole rings of histidine residues 
are not fully protonated. However, there is a change in the chemical shift of H5 and H6 at pH 
7.4, as can be seen in Figure 3.4b-e, which means there is a degree of protonation of the 
histidine side chain. Therefore, the number of protonated amino groups of the histidine based 
sequences was calculated from the average percentage of the chemical shift changing at pH 
7.4 of H5 (b) and H6 (b’) (Figure 3.10). 
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a 
b 
a' 
b’ 
pH 7.4 
H5
H6
   a , a’ = 100% protonation 
   b, b’ = Fraction of protonated imidazole groups at pH 7.4 
 
Figure 3.10.   The chemical shift change between pH 2-10  
 
Weight per charge (wpc) of 2COPs 1-5 is shown in Table 3.4. 
 
Table 3.4.  Weight per charge (wpc) of  2COPs  
 
2COPs 
 
Number of TFA 
counterions 
Number of positive 
charges 
at pH 7.4 
Peptide Mw  
(g mol-1) 
wpc 
 (g mol-1) 
CK8C (1) 
CK4H4C (2) 
CK2H2K2H2C (3) 
CK2HKHKH2C (4) 
CKHKHKHKHKHC (5) 
9 
9 
9 
9 
9 
9 
5.7 
5.2 
5.4 
5.3 
1249.90 
1285.90 
1285.70 
1285.70 
1285.80 
252.8 
405.6 
444.6 
428.1 
436.2 
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The wpc value is used to calculate the N:P ratio, which is the number of possible protonatable 
basic groups with respect to the negative phosphate groups on the backbone of the nucleic 
acid. The concentration of 2COPs or RPCs calculated to form the polyplexes at final 
concentration of plasmid DNA at 20 µg/ml and at the N:P ratios used in this study is shown 
by the following equation.  
 
Peptides conc. (µg ml-1) = wpcPN
groupphosphateperDNAofmassaverage
DNAplasmidofionconcentratFinal ×× :  
 
Final concentration of plasmid DNA              = 20 µg ml-1
Average mass of DNA per phosphate group  = 325 g mol-1 
wpc    = weight per charge 
 
3.4.4.2  RPC polyplex formation and characterization (Figure 3.1, step 4-7) 
 
3.4.4.2a  Diameter and zeta potential of polyplexes (Figure 3.1, Step 4-5) 
Polyplexes were formed from RPCs 1-5 as described in section 2.7.1 and 2.7.2 at N:P 5. PEI 
(25 kDa) and PLL (70 kDa) were used as controls to form the polyplexes at N:P 10 and 5 by 
leaving the condensation mixtures overnight at ambient temperature. The resultant polyplex 
dispersion was analyzed by zeta potential and dynamic light scattering (Table 3.5). 
 
Zeta potentials were positive in all cases, which will allow the polyplexes to promote the 
internalization via syndecan-mediated endocytosis[31] (Figure 1.22) by electrostatic 
interaction between the positively charged polyplexes and the negatively charged cell 
membrane. 
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Table 3.5.   Properties of RPCs and their polyplexes  
RPCs/ polymer 
Average 
pKa
MW 
(kDa)a
Polydispersity 
indexb
N:P 
ratio 
Zetapotential 
(mV)c
Polyplex size 
(nm)d
RPC 1  
(CK8C)  
10.51 111.4 1.119     5 
       
      10.0  ±  10.9 
     
    132.1  ±    4.5 
RPC 2 
 (CK4H4C) 
6.20   118.0 1.142 5 
      
      14.3  ±    9.7 
     
      98.3  ±    0.6 
RPC 3 
 (CK2H2K2H2C) 
6.16   115.1 1.167 5 
     
      13.5  ±    7.2 
     
      99.8  ±    0.9 
RPC 4 
 (CK2HKHKH2C) 
6.11   102.9 1.063 5 
 
        5.8  ±    3.6 
    
     101.1  ±    2.8 
RPC 5 
(CKHKHKHKHC) 
6.09     94.8 1.125 5 
     
      17.4  ±   11.3 
 
      95.5  ±    1.1 
PEI - 25 - 10        3.4   ±     0.2     108.7  ±    8.6 
PLL - 70 - 5       11.3  ±     9.0       81.0  ±    0.9 
a   Molecular weight of RPCs was analyzed by GPC using CATSEC300 column compared to PLL standard. 
b  Polydispersity index (PDI) of RPCs was measured by size exclusion chromatography (Anachem Ltd., Luton,     
   UK) coupled with multi-angle laser light scattering photometer (Wyatt Technology (Santa Barbara, USA). 
c   Zetapotential was measured by using  Zetamaster (Malvern Instruments, Worcestershire, UK).  
d  Hydrodynamic diameters of the polyplexes were measured by dynamic light scattering using a Zetasizer 3000 
(Malvern Instruments, Worcestershire, UK). 
 
The diameters by DLS for each RPC/DNA polyplex were in the range between 95.5-132.1 nm 
(Table 3.5). However, the polyplexes of RPCs 2-5 were all smaller than for RPC 1, 
suggesting better compaction through the introduction of histidine residues. On first 
inspection this result is counter-intuitive as RPC 1 is more highly charged and one might 
expect tight compaction, as a result of the greater electrostatic interaction. However, the 
incorporation of histidine residues, which are only slightly protonated at physiological pH 
(pH 7.4)(Figure 3.4) results in the polymer chains maybe having a shorter persistence length 
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(Figure 3.11a) that may result in better compaction of the histidine containing polyplexs over 
RPC 1 with it is more potentially rigid structure (Figure 3.11b).  
 
a) -Lys-His-Lys-His- 
 Shorter persistance lenght 
 
 
 
 
 
b) –Lys-Lys-Lys-Lys- 
  
 
 
 
 
 
 
 
 
 
Figure  3.11.    Length persistency of the lysine and histidine based sequences; a) -Lys-His-Lys-His  
and b) -Lys-Lys-Lys-Lys 
3.4.4.2b  Shape of polyplexes (Figure 3.1, Step 5) 
Polyplexes imaged in a solution AFM cell on mica all revealed nanoparticulate matter with 
diameters as indicated by DLS. Comparing the AFM images for RPC 1 (Figure 3.12a and b) 
against RPC 2-5 (Figure 3.12c-f), it can be seen that RPC 1 architectures are less symmetric 
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and appear to have a ‘halo’ around the bright core. These images would suggest and support 
the lower degree of compact for RPC 1, as its ‘halo’ is likely to be non-condensed DNA (see 
Figure 3.16 and associated text). 
 a) RPC 1 b) RPC 1 
c) RPC 2 d) RPC 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
e) RPC 4 f) RPC 5 
 
 
 
 
 
 
Figure 3.12.   Aqueous phase atomic force microscopy of RPCs polyplexes at N:P 5. Images show 
polyplexes of pEGFP-C1 with (a,b) RPC 1; (c) RPC 2 ; (d) RPC 3 ; (e) RPC 4 ; and (f) RPC 5. 
Note that RPC 1 polyplex (CK8C) displays several morphologies consistent with the more rigid 
structure of the fully protonated polylysine backbone at pH 7.4, as seen clearly in plate b) at 
higher magnification. (Studied by Mahmoud Soliman at School of Pharmacy, University of 
Nottingham, UK) 
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3.4.4.2c  Extracellular stability studies of polyplexes (Figure 3.1, Step 6) 
The stability of polyplexes can be investigated by studying the polyelectrolyte exchange 
reaction. The simple method to determine the stabilisation of polyplexes is to evaluate the 
suseptibility to disruption by polyanions. Therefore, polyaspartic acid (PAA) was used as a 
model polyanions to investigate the stability of polyplexes against polyelectrolyte exchange 
reaction. [32,33] The results (Figure 3.13) without PAA all RPCs, PEI and PLL were able to 
form stable polyplexese as shown by no loss of DNA in the gel electrophoresis assay (lane 
a1-g1). Furthermore, the polyplexes formed with RPCs 2-5 were found to be stable even after 
incubating with PAA (lane b2-e2), and were more stable than the polyplex formed with RPC 
1 (lane a2), PEI (lane f2) and PLL (lane g2). The rational of lower stability of RPC 1 
(slightly released DNA with PAA, lane a2) fits with the hypothesis of the higher length 
persistency of the polymer chain resulting in less compaction with DNA (as described in 
section 3.4.4.2a and Figure 3.11) leading to PAA competitively replacing the DNA with 
greater than RPC 2-5. Thus, RPC/DNA binding is not entirely due to electrostratic interaction, 
but also due to some steric contribution, such as molecular entanglement. 
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b) a) 
 
Figure 3.13.    Gel shift assay with (a) and without (b) polyaspartic acid (PAA) of polyplexes formed from 
RPCs 1-5 (N:P 5), PEI (N:P 10) and PLL (N:P 5).  Polyaspartic acid at 250 times of DNA 
concentration was mixed into the polyplex solution. Lanes a1-g1on the left panel are for 
polyplexes without incubating with PAA. Lanes a2-g2 on the right panel are for polyplexes 
incubated with PAA. pCMV-Luc was used to run as standard DNA. Agarose gel electrophoresis 
was run using 1% agarose gel with EtBr (0.5 µg.ml) at 110 V for 60 mins in 0.5x TBE buffer.  
 
 
3.4.4.2d   Intracellular reduction studies of polyplexes (Figure 3.1, Step 7) 
  (i)  Gel shift assay with salt and GSH 
Another key aspect of the vector design criteria was the inbuilt release mechanism aimed 
at destabilising vector-DNA association through the cleavage of the disulfide bonds 
forming the polypeptide. Thus, the stability against physiological concentrations of salt 
and a biological reducing agent, glutathione, was assessed. GSH is thought to be present 
in the cytoplasm at concentrations varying between 5-20 mM dependent on the cell cycle, 
thus  5 mM GSH was used in these studies.[34] Gel electrophoresis assays were carried out 
on polyplexes with NaCl (0.15, 0.5 and 1 M) to evaluate primary binding stability in the 
presence of electrolytes, with GSH and GSH with NaCl to assess polyplex destabilisation 
(Figure 3.14).  
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Figure 3.14.    DNA binding and release demonstrated by agarose gel electrophoresis (gel shift assays). All 
polyplexes formed at N:P 5. Top panel: polyplexes of RPCs 1-3 with pDNA; bottom panel shows 
RPCs 4, 5 compared against non-cleavable polypeptide poly(lysine). Gel shift assays 
demonstrate tight binding of DNA and stability to dissociation by NaCl solutions (lanes a-d for 
all RPCs) but release of DNA following addition of GSH (lanes f-h) for RPCs 1-5 . Agarose gel 
electrophoresis was run using 1% agarose gel with EtBr (0.5 µg.ml) at 110 V for 60 mins in 0.5x 
TBE buffer 
 
The percentage of DNA release against salt concentration in the presence of GSH (5 mM) 
in plotted in Figure 3.15. 
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Figure 3.15.    Percentage of DNA release from RPCs 1-5 after incubating with GSH (5mM) in 
combination with NaCl (0, 0.15, 0.5 and 1 M) 
   [RPC 1         , RPC 2          , RPC 3         , RPC 4    x   , RPC 5         ]             
 
These gel shift assays reveals   
    (a)  RPC 1 produced polyplexes that were both stable in salt alone 
and GSH alone. Data presented later (Figure 3.16) suggested that the GSH does indeed 
cleave the RPC 1. Thus we concluded the short oligopeptide 2COP 1 that probably results, 
after GSH treatment, binds strongly to DNA, and therefore does not release it in the gel. 
Indeed even salt and GSH in combination does not release the DNA from RPC 1/2COP 1 
(Figure 3.15). This result is in contrast to RPCs 2-5 (described below) presumably due to 
the higher charge of 2COP 1, that results in much stronger electrostatic bindng to the 
DNA. 
 
    (b)  RPCs 2-5 produced the polyplexes that were stable in salt (0.15-
1 M) as can be seen from lanes b-d of RPCs 2-5. Furthermore, these RPCs polyplexes 
were also stable in GSH alone (5mM) (lane e of RPCs 2-5). Importantly, however, 
addition of GSH (5mM) in the presence of salt destabilised the polyplexes, leading to 
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release of the DNA in all cases (lane f-h of RPCs 2-5 and Figure 3.15). Thus, the 
combination of GSH under physiological salt concentrations was able to both cleave the 
polydisulfide bonds in the polyplexes leading to lower a molecular weight peptides that 
had a lower affinity for the DNA in the salt solution, leading to disassociate of the 
polyplexes. 
 
    (c)  poly L-lysine (PLL), the non-cleavable RPC 1 analogue, used as 
a control, was found not to release DNA in salt alone, GSH alone and in combination as 
can be seen in lanes b-d, e and f-h of PLL, respectively, as would be expected. 
 
   (ii)  AFM analysis of degradation by GSH 
Disassembly of the polyplexes under reducing conditions was apparent in aqueous phase 
AFM imaging in the presence of GSH. Polyplexes formed from RPC 1 with pEGFP-C1 were 
imaged sequentially following the addition of the reducing agent and marked changes were 
observed in the structures of the individual polyplexes over a period of 220 minutes (Figure 
3.16 a-d). Initially the polyplexes appeared a compact spherical structure (Figure 3.16a). 
However, after 25 minutes expose to GSH (20mM), the polyplexes became less dense, and 
DNA strands were observed to protrude from the core (Figure 3.16). After prolonged times 
(Figure 3.16c-d), a DNA ‘halo’ is visible and the core area is diminished, although complete 
DNA release is not observed for RPC 1. This ‘ halo’ suggested that interactions of the 
cationic components with DNA were diminishing with time, and that condensation of the 
DNA by the vector components was less effective, in line with the earlier gel shift results, 
which suggest disulfide bond cleavage. 
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a) RPC 1 (0 min) b) RPC 1 (25 min) 
c) RPC 1 (90 min) d) RPC 1 (220 min) 
Figure 3.16.   Aqueous phase atomic force microscopy of RPC 1 polyplexes at N:P 5 showing effect of 
reduction by GSH (20 mM). Images (a-d) show individual RPC 1-pEGFP-C1 polyplexes 
immediately after addition of glutathione and after 25, 90 and 220 minutes, respectively. (Studied 
by Mahmoud Soliman at School of Pharmacy, University of Nottingham, UK) 
 
Polyplexes formed from RPC 2 and 3 with pEGFP-C1 were also imaged before (Figure 3.17a 
and c) and 4 hrs after addition of GSH (20 mM) (Figure 3.17b and d). Polyplexes are fewer 
in number after incubating with GSH for both RPCs, and strands of free DNA are visible for 
both RPCs after incubating with GSH (images b,d arrows).  
 
 
 
 
 
 
 
References for Chapter 3 are on page 160-163. 
 
138
 
 
 a) RPC 2 (before GSH added) b) RPC 2 (220 mins after GSH) 
 
 
 
 
 
 d) RPC 4 (220 mins after GSH) c) RPC 3 (before GSH added) 
 
 
 
 
 
 
Figure 3.17.    Aqueous phase atomic force microscopy of RPC 2, 3 polyplexes at N:P 5 showing effect of 
reduction by GSH (20 mM).  Image (a,b) and (g,h) depicts RPC 2 and RPC 3 polyplexes with 
pEGFP-C1, respectively, before GSH added and after 220 minutes of incubating with GSH. 
(Studied by Mahmoud Soliman at School of Pharmacy, University of Nottingham, UK) 
 
The control experiments with non-cleavable PLL vectors did not show polyplex breakdown 
under the same conditions (NaCl, GSH) over a time period of 223 minutes (Figure 3.18). 
Compared to RPC 1 in Figure 3.16, the core area of PLL polyplex did not diminish with time, 
as would be expected there are no disulfide bonds that the GSH might cleave. 
 
Thus, the gel shift assay (Figure 3.14) and AFM data have established RPCs 2-5 vectors 
release the DNA under physiological reducing conditions, whereas RPC 1 and PLL do not.  
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 a) 0 min b) 40 min c) 59 min 
d) 80 min e) 153 min f) 223 min 
 
 
 
 
 
 
 
 
 
 
 
 
Scale bar 200 nm,  z = 10 nm 
 
Figure 3.18.   Aqueous phase atomic force microscopy of PLL/DNA polyplexes at N:P 5 showing effect of 
reduction by GSH (20 mM) at the different times. (Studied by Mahmoud Soliman at School of 
Pharmacy, University of Nottingham, UK)  
 
   (iii)  Dynamic light scattering analysis of degradable by GSH 
Further confirmation of RPCs polyplex breakdown under reducing conditions was obtained 
by dynamic light scattering after incubating RPCs polyplexes with GSH (20mM) over a time 
period of 210 minutes (Figure 3.19).  
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Figure 3.19.   Diameters of RPC polyplexes 1-5 following incubation with 20 mM glutathione 
   [RPC 1         , RPC 2          , RPC 3         , RPC 4    x   , RPC 5         ]             
 
The model in Figure 3.20 explains why this should occur. The GSH cleaves the disulfide 
bonds and leads to unpacking of the polyplexes and thus expansion. This model is 
corroborated with the DLS experiments (Figure 3.19).  
 
 
Figure 3.20.    Model of polyplex reduction by GSH 
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In summary, the PLL polyplex is disassembled by PAA (Figure 3.21a) to a greater extend 
than RPC 1 (Figure 3.21b). Presumably, this is because PLL has a higher persistence length 
than RPC 1. This reduction in persistence length of RPC 1 is a result of the reduction in 
charge repulsion of the protonated lysine groups either side of the reducible disulfide bond 
from the cysteines, allow the s-s bond to act as a molecular hinge.  Whereas, RPCs 2-5 are 
stable to PAA (Figure 3.21c) because of the greater compaction of the polyplexes, which we 
hypothesized, is a result of the lower persistence length of RPCs 2-5 over RPC 1 and PLL. 
 
PLL polyplex is unable to be disassembled by GSH and NaCl due to the lack of the disulfide 
bonds (Figure 3.21a). RPC 1 polyplex is cleaved by GSH (Figure 3.21b). However, the short 
2COP 1 that results still binds strongly to the DNA resulting in it being unable to release the 
DNA. RPC 2-5 polyplexes are cleavable by GSH and NaCl and the resulting 2COPs are less 
strongly bound to the DNA, than 2COP 1, and hence the DNA is released (Figure 3.21c). 
 
Therefore, with these stability models, RPCs 2-5 could be promising vectors for non-viral 
gene delivery system. 
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Figure 3.21.  The models of PLL and RPC polyplexes after treating with PAA or GSH+NaCl: a) PLL, b) RPC 1 and c) RPCs 2-5  
 
 
3.4.4.3 Formation of polyplexes with lower molecular weight RPCs (Figure  
3.1, step 4-7) 
 
 
3.4.4.3a  Diameter and zeta potential of polyplexes (Figure 3.1, Step 3-
4) 
DNA polyplexes were prepared from the lower molecular weight (~50 kDa) RPCs at N:P 
ratio 5 in order to compare their properties with the high molecular weight (~100 kDa) RPCs 
(Table 3.6).  
 
Table 3.6. Properties of RPCs at different molecular weight and their polyplexes formed at N:P  5 
 
RPCs 
MW 
(kDa)a
Polydispersity 
indexb
Diameter 
(nm)c
Zeta potential 
(mV)d
  53.9 1.563      99.9  ±    8.3        16.8  ±  11.0 
          
RPC 1 
(CK8C)  111.4 1.119    132.1  ±    4.5        10.0  ±  10.9 
            60.8 1.339      98.4  ±    0.7        10.1  ±  14.0 RPC 2 
 (CK4H4C) 118.0 1.142      98.3  ±    0.6        14.3  ±    9.7 
 40.4 1.318      94.7  ±    1.5 
       
       15.5  ±  15.5 
         
RPC 3 
 (CK2H2K2H2C) 115.1 1.167      99.8  ±    0.9        13.5  ±    7.2 
48.5 1.279    101.1  ±    2.2 
       
         5.3  ±    5.7 
       
RPC 4 
 (CK2HKHKH2C) 102.9 1.063    101.1  ±    2.8          5.8  ±    3.6 
 42.3 1.292      90.7  ±    3.4        12.6  ±   12.3     RPC 5 
(CKHKHKHKHC)  94.8 1.125      95.5  ±    1.1        17.4  ±   11.3 
a  Molecular weight of RPCs was analyzed by GPC using CATSEC300 column compared to PLL standard. 
b Polydispersity index (PDI) of RPCs was measured by size exclusion chromatography (Anachem Ltd., Luton,     
   UK) coupled with multi-angle laser light scattering photometer (Wyatt Technology (Santa Barbara, USA). 
c  Hydrodynamic diameters of the polyplexes were measured by dynamic light scattering using a Zetasizer 3000    
   (Malvern Instruments, Worcestershire, UK). 
d  Zetapotential was measured by using  Zetamaster (Malvern Instruments, Worcestershire, UK). 
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As can be seen in Table 3.6, the diameters for all N:P ratios for each RPC/DNA polyplex at 
lower molegular weight were in the range between 90.7-101.1 nm, compared to the 
polyplexes produced from higher molecular weight RPCs were in the range between 95.5-
132.1 nm. The polyplex diameters and zeta potential values of RPC polyplexes which formed 
from the RPCs at the different molecular weight were similar in all cases. Thus, revealing 
reduction in molecular weight of the RPCs greater than 50% do not affect the diameter and 
surface charge of the polyplexes.  
 
3.4.4.3b  Extracellular stability studies of polyplexes (Figure 3.1, 
Step  5) 
The extracellular stability of the polyplexes of lower molecular weight RPCs was also studied 
using the gel shift assay by incubating the polyplexes with polyaspartic acid (PAA) as shown 
in Figure 3.22.  PEI polyplexes at N:P 10 and PLL polyplexes at N:P 5 were used as a 
control. 
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 a) b) 
 
 
Figure 3.22.   Gel shift assay with (a) and without (b) polyaspartic acid (PAA) of polyplexes formed from  
low molecular weight RPCs 1-5 (N:P 5) ,PEI (N:P 10) and PLL (N:P 5).  Polyaspartic acid at 
250 times of DNA concentration was mixed into the polyplex solution. Lanes a1-g1on the left 
panel are for polyplexes without incubating with PAA. Lanes a2-g2 on the right panel are for 
polyplexes incubated with PAA. pCMV-Luc was used to run as standard DNA. Agarose gel 
electrophoresis was run using 1% agarose gel with EtBr (0.5 µg.ml) at 110 V for 60 mins in 
0.5xTBE buffer. 
 
The results revealed that all RPCs at low molecular weight were able to form stable 
polyplexes with DNA as no DNA was released (lane a1-e1). Furthermore, after incubating 
with PAA (lane a2-e2) they did not release DNA, and were more stable than the polyplex 
formed with PEI and PLL (lane f2 and g2, respectively).  
 
 3.4.4.3c  Intracellular reduction studies of polyplexes (Figure 3.1, 
Step 7) 
Stability of the lower molecular weight RPCs polyplexes against physiological 
concentrations of salt and GSH, was assessed by gel electrophoresis by treatment with 
GSH alone (5 mM), salt alone (NaCl 0.15 and 0.5 M), and combination of salt (NaCl 0.15 
and 0.5 M and GSH (5 mM) to assess polyplex destabilisation (Figure 3.23). PLL 
polyplexes at N:P 5 were used as  controls. These gel shift assays demonstrate that: 
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    (a)  Polyplexes produced from lower molecular weight RPCs 2-5 
slightly released the DNA when in the presence of GSH (5mM) without NaCl (Figure 
3.23, lane b), suggesting that they are more easily reducible than polyplexes with higher 
molecular weight RPCs (Figure 3.14, lane e). However,  these lower molecular weight 
RPCs polyplexes were stable in salt alone (0.15-0.5M) as can be seen in Figure 3.23, lane 
c,d which is similar to the high molecular weight RPC polyplexes (Figure 3.14, lane b,c). 
Importantly, however, addition of GSH (5mM) in the presence of salt destabilised the 
polyplexes, leading to a greater release of the DNA in all cases (Figure 3.23, lane e-f), 
relative to the higher molecular weight RPC polyplexes (Figure 3.14, lane f,g).  
 
    (b)  RPC 1(54) produced polyplexes that were stable in GSH alone, 
salt alone and a combination of both as can be seen in lane b, c-d and e-f (Figure 3.23), 
respectively, and are similar to RPC 1(111) (Figure 3.14, lane a-h). These results reveal 
that the molecular weight of RPCs in both cases does not affect the stability of polyplexes: 
Electrostratic interaction dominate the stability it would seem. 
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Figure 3.23.   DNA binding and release demonstrated by gel shift assays of low molecular weight RPC  
polyplexes. All polyplexes formed at N:P 5. Top panel: polyplexes of RPC 1(54), RPC 2(60) and 
RPC 3(40) with pDNA; bottom panel shows RPCs 4(48), RPC 5(42) compared against non-
cleavable polypeptide poly(lysine). Agarose gel electrophoresis was run using 1% agarose gel 
with EtBr (0.5 µg.ml) at 110 V for 60 mins in 0.5x TBE buffer 
 
In combination, the diameters, surface charges and gel shift assays of polyplexes from low 
molecular weight RPCs 2-5 compared to high molecular weight RPCs 2-5 suggest that the 
low molecular weight RPCs could be promising vectors for gene therapy. However, the cell 
transfections of these polyplexes have to be further investigated to confirm (Chapter 4). 
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3.4.4.4    Oligopeptide polyplex formation and characterization (Figure 3.2a, 
Step 2-3) 
 
As shown in the previous section, the DNA polyplexes were synthesized from RPCs with 
molecular weight of approximately 100 kDa. In this section, the DNA polyplexes were 
formed from the oligopeptides (2COPs 1-5) in order to compare their properties with the 
associated RPCs polyplexes. 
  
DNA polyplexes were formed from 2COP 1-5 at N:P ratio 5 as described in section 2.7.1 and 
2.7.2. PEI (25 kDa) was also used to form polyplexes at N:P 10 as control. Briefly, the 
polyplexes were formed by mixing the oligopeptides in HEPES buffer and the DNA in 
HEPES buffer in the appropriate molar ratios. Diameter of the polyplexes were analyzed by 
dynamic light scattering (section 2.8.1) after approximately 6, 24 and 48 hr of the polyplex 
formation. The diameters of the polyplexes over the course of 48 hr are shown in Table 3.7.  
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Table 3.7.  Diameter of polyplexes from 2COPs 1-5 at N:P 5 and PEI at N:P 10 after 6, 24 and 48 hr of the 
formation. 
Diameter (nm) a
Polyplexes 
N:P 
ratio 6 hr 24 hr 48 hr 
2COP 1 
(CK8C) 
5     2848.0   ±   1500.0    1080.8    ±       135.2       741.6    ±         12.4 
2COP 2 
(CK4H4C) 
5     5217.9   ±   1091.5     1563.7   ±     1103.6     7017.2    ±   10211.4 
2COP 3 
(CK2H2K2H2C) 
5     8643.8   ±   3779.3     4438.7   ±     4186.8     2248.6    ±     2669.6 
2COP 4 
(CK2HKHKH2C) 
5     4830.5   ±     640.7     2415.0   ±       990.6     2320.8    ±     1430.1 
2COP 5 
(CKHKHKHKHC) 
5     7116.9  ±    2546.1   11399.1   ±   10939.3     2150.4    ±     2400.5 
PEI 10         98.0   ±         3.8      126.1    ±          4.6         87.7    ±           1.2 
a The hydrodynamic diameters of the polyplexes were measured by dynamic light scattering using a Zetasizer 
3000 (Malvern Instruments, Worcestershire, UK). 
 
As can be seen in Table 3.7 the diameters of polyplexes reduced over the time course of 48 
hrs. 2COP 1 formed the smallest polyplexes (~741 nm) compared to 2COPs 2-5 (greater than 
1 µm diameter in most cases). The polyplexes formed from 2COP 1 are smaller than those 
from 2COPs 2-5 as a result of higher charged on 2COP 1.  Compared to RPC polyplexes 
diameter (~100 nm), the 2COPs polyplexes are much larger suggesting that the 2COPs 
polyplexes are not suitable for use as vectors for gene delivery, because polyplexes that are 
larger than 1 µm more readily interact with blood components or fixed macrophages resulting 
in the clearance from the blood stream before reaching the cells.[35]  
 
References for Chapter 3 are on page 160-163. 
 
150
 
 
3.4.5   Formation and characterization of cross-linked RPCs (Figure 3.2b, step 2-3) 
 
In this section, cross-linked RPCs were synthesized and characterized in order to compare 
their properties with the linear RPCs. 
 
Bis-cysteine containing oligopeptides (2COPs 1-5) were oxidative polymerized with tris-
cysteine containing oligopeptide (3COP 7) to form cross-linked RPCs via disulfide bond 
formation (section 2.5.2). The scheme of the cross-linking polymerization is shown in Figure 
3.24. 
 
Oxidative 
Polymerization 
S-S 
S-S 
SH 
S-S 
S-S 
S-S 
S-S 
S-S 
S-S 
S-S 
S-S 
SH 
HS SH 
SH 
2COP 
3COP 
HS 
S-S 
+ 
S-S 
Cross-linked RPC 
SH 
 
Figure 3.24.  The model of cross-linking polymerization to form cross-linked RPC via disulfide bond 
formation 
 
The reactions were performed at ambient temperature with 30mM concentration of 2COPs 1-
5 containing 3COP 7 at 4% and 32 % mole fractions. The growth of the cross-linked RPC 
molecular weights was monitored by gel permeation chromatography (GPC) (section 2.5.4). 
At various time intervals 5 μl aliquot were removed from the polymerization vessel and AET 
was added to terminate the polymerization. This aliquot was injected onto the GPC eluting 
with 200 mM NaCl with 0.1% TFA. The eluting time was used to determine the molecular 
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weight against calibration data from PLL standards 5.6, 8.3, 21.3, 62.1, and 128.5 kDa. This 
data is plotted in Figure 3.25. 
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Figure 3.25.   Oxidative polymerization of 2COPs 1-5 at 30mM concentration with and without 4% and    
30% mole fraction of 3COP 7 (CK2CK2C) incubated at ambient. The molecular weight was 
analyzed by GPC using PLL as standard curve. 
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The polymerization mixtures of each 2COP without 3COP 7 gave higher molecular weight 
RPCs over an extended time compared to those with 4% and 32% mole fractions of 3COP 7. 
During the first 12 hr the RPCs from 2COP itself grew slowly and increased rapidly after 12 
hr of incubation. The maximum molecular weights of the RPCs (2COP alone) were observed 
between 30 to 36 hr. After 36 hr the molecular weight of the polymers generally reduced. 
However, when 3COP 7 at 4% and 32% mole fractions were present this reduced the growth 
of polymers. For all oligopeptide reactions, the growth of cross-linked RPCs at 32% mole 
fraction of 3COP 7 was lower than those at 4% mole fraction. Therefore, using higher mole 
fraction of 3COP 7 resulted in lower molecular weight of polymers over 4% and 32% 3COP. 
 
The maximum molecular weight of cross-linked RPCs synthesized from all oligopeptides 
varied from approximately 10-35 kDa when carried out with 3COP 7 at 4% mole fraction. 
Synthesis at 32% mole fraction of 3COP 7 in the mixture produced the highest polymer 
molecular weight with 2COP 5 (~30 kDa). The molecular weight of the cross-linked RPCs 
produced from other 2COPs at 32% mole fraction of 3COP 7 are only in the range of 
approximately 5-10 kDa as can be seen in Figure 3.26. 
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Figure 3.26.   Oxidative polymerization compared between 2COPs 1-5 at 30mM concentration with and  
without 4% (a) and 30% (b) mole fraction of 3COP 7 (CK2CK2C) incubated at ambient. 
(all data are an average of the triplicate experiments). 
        [2COP 1        , 2         , 3         , 4    X    and 5   X   ] 
 
Due to the inability of the cross-linking polymerization to produce high molecular weight 
polymers, these cross-linked RPCs were not considered further as vectors.  
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3.5    Conclusions 
 
3.5.1   RPC conclusion 
 
The work presented in this chapter has shown the design of synthetic vectors by 
combining lysine, histidine and cysteine residues to provide the key features to hopefully 
achieve efficient gene delivery. These vectors are designed to bind DNA extracellularly 
(I), achieve cell uptake via endocytosis (III), provide a tunable endosomal release 
mechanism (IV) and provide a degradable backbone in order that the DNA can be 
released once in the cytoplasm (V). 
 
Crude samples of bis-cysteine containing oligopeptides (2COPs 1-6) and tris-cysteine 
contaning oligopeptide (3COP 7) (CK8C (1), CK4H4C (2), CK2H2K2H2C (3), CK2HKHKH2C 
(4), CKHKHKHKHC (5), CH8C (6) and CK2CK2C (7)) synthesized by Alta Bioscience 
(Birmingham, UK) were purified by the preparative reverse phase HPLC. All purified 
oligopeptides were analyzed by analytical RP-HPLC, ESI-MS and 1H NMR to obtain the 
purity and to characterize the oligopeptides. The purity of all oligopeptides is shown to be 
between 97.35-99-64 %. 
 
The pKa values of the oligopeptides 1-7 were determined via 1H NMR titration method. For 
2COP 1 and 3COP 7, the pKa of the lysine residue were 10.51 and 10.81, respectively. For 
2COP 6 (CH8C) and RPCs 2-5 the pKa of the histidine residues were 6.25, 6.20, 6.16, 6.11 
and 6.09, respectively. The increase in the mixing of the constitution of the histidine residues 
in the lysine residues results in the reduction of the pKa for 2COPs 2-5 because of the charge 
repulsion of subphase protons by its proximity to the protonated lysine residues.  
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2COPs 1-6 were oxidative polymerized to form linear reducible polycations (RPCs) via 
disulfide bond formation. The polymerization as a function of oligopeptide concentration 
produced higher molecular weight RPCs at high oligopeptides concentration. The maximum 
RPCs molecular weight obtained for all the oligopeptides at 18 mM, 30mM and 60mM are 
approximately 25-45, 30-65, and 50 -90 kDa, respectively. The maximum molecular weights 
of the RPCs were observed between 30 to 36 hr. After 36 hr the molecular weight of the 
RPCrs generally reduced. The RPCs produced from 2COP 3 did not show this decrease in 
molecular weight after 36 hr and produced the longest RPCs at all oligopeptide 
concentrations. All RPCs were stable to the degradation in the HEPES buffer at  -20°C over a 
period of 2-3 days, with the exception of the RPC formed from 2COP 6 (CH8C) which 
degraded. Therefore, the 2COP 6 was not used for further studies. 
 
The polymerization as a function of temperature revealed that the growth of the RPCs at 40°C 
was more rapid than that at ambient. However, approximately the same maximum molecular 
weight was observed (~45 kDa). The polymerisation proceed only to ~37% (40°C) and 41% 
(ambient), the remaining ~60% of material that was eluted has a retention time of 2COP 1. 
 
DNA polyplexes were then formed from RPCs 1-5 (~100 kDa) at N:P ratios 5 and their 
diameters and surface charges were measured. The polyplexes produced from RPCs-DNA 
condensation showed their diameters were at ~100 nm. However, the RPCs 2-5 introduced 
better compaction of the DNA than RPC 1. We hypothesize RPCs 2-5 are more flexible than 
RPC 1, as a result of the incorporation of histidine residues in the lysine based peptides giving 
them a shorter persistence length.   
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The surface charges were positive for all polyplexes, enabling them to electrostatically 
interact with the negatively charged cell membrane and promote the internalization into cell 
via syndecan-mediated endocytosis.[31] These primary characteristics of RPC polyplexes 
suggested that they are suitable for further cell transfection.  
 
Simulated extracellular stability of these polyplexes was examined. PAA (found in blood 
serum) was used as a competitively polyanionic agent to destabilize the polyplexes.  The 
polyplexes from RPCs 2-5 were stable in this simulated extracellular condition. However, the 
RPC 1 polyplex was slightly unstable in PAA assay. The PEI polyplex was completely 
disrupted under these conditions.  
 
In addition, to the simulated extracellular destabilized conditions, GSH was used as a 
biological intracellular reducing agent, since GSH is present in the cytoplasm (the stability 
under physiological salt concentrations was studied). The polyplexes from RPCs 2-5 were 
stable in salt solution alone in the range 0.15 – 1 M. However, after adding GSH (5 mM), all 
polyplexes released DNA. However, the polyplex from RPC 1 did not release DNA. These 
results suggested that RPCs 2-5 are able to facilitate intracellular reduction resulting in DNA 
releasing for further gene expression mechanisms. Whereas, RPC 1 although probably does 
undergo the disulfide bonds reduction the high net charge on the 2COP 1 that results is still 
bound the DNA more strongly than 2COPs 2-5. 
 
In conclusion, the sizes, surface charges, stability of these polyplexes under simulated 
physiological conditions combined with their sensitivity to levels of GSH which are likely to 
be encountered inside cells (as evidenced by combined gel shift, AFM and DLS) indicated that 
these systems might be effective transfection reagents in vitro.  
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3.5.2   RPC molecular weight conclusion 
 
DNA polyplexes were then formed from low molecular weight RPCs 1-5 (38-60 kDa) at N:P 
5 in order to compare their characteristic as a function of RPC molecular weight. The 
polyplexes produced from low molecular weight RPCs were similar to those from high 
molecular weight RPCs (~100 kDa). The surface charges were similar to polyplexes from 
high molecular weight RPCs. These primary characteristics suggested the lower molecular 
weight RPC polyplexes may also be suitable vectors. 
 
Extracellular stability of these polyplexes were further examined by the PAA assay, and 
revealed that the polyplexes from low molecular weight RPCs 1-5 were stable in this 
simulated extracellular condition.  
 
The intracellular stability of these lower molecular weight RPC polyplexes against 
physiological salt concentrations (0.15-0.5 M) and GSH (5 mM) was studied. The polyplexes 
from RPCs 2-5 were stable in salt solution alone. However, these RPCs polyplexes are less 
stable to GSH compared to the polyplexes from high molecular weight RPCs. Therefore, 
unsurprisingly, when combined salt and GSH in the RPCs polyplex solutions, they released 
more DNA, which might promote enhanced gene delivery over the higher molecular weight 
RPC polyplexes. 
 
In conclusion, the diameters, surface charges and gel shift assays of polyplexes from low 
molecular weight RPCs 2-5 were similar to high molecular weight RPCs 2-5, but had 
enhanced release of DNA when treated with GSH suggesting that the low molecular weight 
RPCs could also be promising vectors for gene therapy. 
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3.5.3 Oligopeptide polyplexes conclusion 
 
DNA polyplexes were then formed from 2COPs 1-5 at N:P 5 and their diameters were 
measured.  All polyplexes from 2COPs 1-5 formed large particles which were greater than 1 
µm diameter over time course of 48 hr. In general, the particle diameter less than 1µm 
circulate longer in the bloodstream than the larger particles if there are no interactions with 
blood components or fixed macrophages.[35] Therefore these polyplexes suggest that they are 
not suitable for further cell transfection. 
 
3.5.4 Cross-linked RPCs conclusion 
 
The oxidative polymerization to form cross-linked RPCs was also studied by mixing between 
2COP 1-5 and 3COP 7 at 4% and 32% mole fraction of 3COP 7. The results showed 
termination in the growth of cross-linked RPCs producing low molecular weight in all cases. 
The higher the mole fraction of 3COP used, the lower the polymer molecular weight 
produced. We believe the 3COP leads to the termination of the cross-linked RPCs during the 
reaction. The maximum molecular weight of cross-linked RPCs for all 2COPs varied from 
approximately 10-35 kDa with 3COP at 4% mole fraction, whereas reacting with 32% mole 
fraction of 3COP the maximum molecular weight was only 5-10 kDa. With such low 
molecular weights of these polymers, they not considered further study as gene delivery 
carriers.  
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CHAPTER 4 
 
Delivery of nucleic acid using lysine, 
histidine and cysteine based oligopeptides 
and reducible polycations (RPCs)  
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4   DELIVERY OF NUCLEIC ACID USING LYSINE, 
HISTIDINE AND CYSTEINE BASED OLIGOPEPTIDES 
AND REDUCIBLE POLYCATIONS (RPCs) 
Abstract 
 
In this chapter the cell transfections based on endosomolytic and 
intracellularly reducible characteristics of the pKa modulated-reducible 
polycations (RPCs) were carried out. These RPCs are not only more active 
at transfection than current systems such as PEI and PLL, but importantly 
are also much better tolerated by two different cell types, bEND3 and A549. 
Furthermore, they can facilitate endosomal buffering and intracellular 
reduction. The highest transfection efficiencies in both cell types were with 
RPC 2. In addition, using low molecular weight RPCs (~50 kDa) as a vector 
induces higher transfection levels than the high molecular weight RPCs 
(~100 kDa). The oligopeptides were shown to be unsuitable to be vectors. 
 
 
4.1    Introduction  
 
 
 
Nature employs a number of highly evolved strategies to package and process nucleic acids. 
Proteins such as histones condense DNA within a cell via the spatially-controlled display of 
protonatable peptide side-chains.[1] Viruses have developed polymeric structures that compact 
nucleic acids for transfer across cellular barriers, then release the ‘foreign’ genetic material 
via specific biological triggers.[2] For the delivery of nucleic acids for therapy, synthetic 
carrier molecules that combine advantageous features of DNA condensing agents, but without 
the infection and immune response problems of viruses are needed.[3-8] The most efficient 
synthetic gene delivery agents for many applications are partially protonated branched 
poly(ethyleneimine)s (PEI), a polycation that can transfect cells in vitro and in vivo.[9-13] 
Unfortunately, PEI exhibits unacceptable toxicity,[14] which arises in part from the 
combination of a non-degradable polymer backbone and a residual high polycation content. 
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As described in Chapter 1, chloroquine has the ability to buffer the endosomal pH, resulting in 
endosomal membrane disruption.[15] Therefore, polyplexes that have no buffering capacity 
such as those contain PLL need chloroquine to promote the endosomal escape.[16, 17] However, 
the use of chloroquine results in cell toxicity.[17] 
 
Therefore in our group’s previous work,[18] The RPC(59) (CH3K3H3C, 59 kDa) and RPC 
(113) (CH6K3H6C, 113 kDa) were developed by incorporating histidine residues which help 
promote the endosomal buffering. These RPCs were synthesized by oxidative polymerization, 
and they have an average pKa of ~5-6. These RPCs formed stable polyplexes with plasmid 
DNA at N:P ratio of 5 with the polyplex sizes ~100 nm in diameter. Addition of chloroquine 
increased the transfection of RPC(59) ~3.2-12.7 fold. However, there was no enhancement in 
RPC(113). These previous results indicated that incorporating histidine improves the 
transfection ability. In addition, RPCs containing disulfide linkages have previously been 
shown to be stable in the extracellular matrix,[18-20] but cleaved efficiently by intracellular 
glutathione, leading to disassemble of the vector to oligomers, which also reduces the toxicity, 
and efficient release of the nucleic acid payload.  
 
However, the coupling of reducible vector backbones with modulated pKa DNA-binding side-
chains has not hitherto been investigated. Therefore, we planned to exploit proximities of 
protonatable groups on a peptide side chain in order to control the pKa range (shown in 
Chapter 3, page 119 and discussed in term of the hypothesis in Chapter 1, page 48). 
Therefore, the pKa of vectors that promotes the endosomal escape in cell transfection will be 
optimized. 
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4.2   Objectives 
 
 
Therefore, the six pKa-moduatable decameric peptides containing lysine and/or histidine and 
terminated with cysteine residues (CK8C (1), CK4H4C (2), CK2H2K2H2C (3), CK2HKHKH2C 
(4), CKHKHKHKHC (5) and CH8C (6)), prepared in Chapter 3, have 4 key criteria to 
enhance gene delivery. These are:  
 
i) Peptide-side-chain functionality provide electrostatic interaction with the DNA 
via the incorporation of lysine residues, which will be fully protonated at physiological pH, 
leading to strong extracellular binding to DNA, 
ii) Modulatable endosome release via buffering by the mixing of lysine and 
histidine residues to modulate the pKa of vectors, 
iii) Biodegradation to promote the release of the DNA, by introducing the 
disulfide backbone, which will be reduced by intracellular GSH, and 
iv) Biodegradation to reduce the toxicity, as the polyplexes can be reduced by 
intracellular GSH, resulting in small fragments of oligopeptides which will be cleared more 
readily than high molecular weight polymers. 
 
Therefore, in this chapter, the cell transfection of these vectors will be studied via experiments 
that manipulate the endosomolysis (addition of CQ) and the intracellular reduction (addition 
of BSO (GSH depleter) and GSH-MEE (GSH raiser)). 
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4.3   Methodology 
 
The transfections were carried out in two representative cell lines, mouse brain endothelial 
cells (bEND3) and human lung carcinoma epithelial cells (A549). These cell lines were 
chosen because for therapeutic applications it is important to consider transduction of both 
endothelial (bEND3) and epithelial cells (A549). The bEND3 cells serve as a model for the 
surfaces that are accessible following bloodstream administration of the polyplexes, while 
A549 cells are representative of most types of common cancer cells. Therefore, for efficient in 
vivo transfection polyplexes should not attach and/or transfect endothelial cells if they are 
injected into bloodstream, otherwise they are unable to reach the target tissue that needs to be 
treated (Figure 4.1). 
 
The controls, PLL and PEI polyplexes, were used, and the background of cell transfection was 
performed by cell lines with no transfection agent (the polyplexes).  
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Figure 4.1.  Physiology of artery, endothelium and capillaries; Image modified from:     
      http://www.webbooks.com/eLibrary/Medicine/Physiology/Cardiovascular/capillary.jpg , and 
                    http://cache-media.britannica.com/eb-media/83/98483-004-FD45DAA5.jpg 
 
The experimental processes in this chapter will be divided into 2 sections as described below 
and shown in Figure 4.2. 
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Figure 4.2.   Schematic overview of cell transfection in this chapter; a) transfection with RPCs polyplexes 
and b) transfection with 2COPs polyplexes  
 
4.3.1  Cell transfections of RPCs polyplexes 
 
The cell transfections of RPC polyplexes were carried out based on four experiments (Figure 
4.2a, step 2). 
 
   Exp  1.  Investigate the cytotoxicity of RPCs polyplexes: The 
cytotoxicity of RPCs polyplexes was investigated using the MTS assay. 
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Exp 2. Investigate the endosomolytic buffering: The transfection of the pKa 
modulated RPCs based on the endosomal buffering and endosomal escape was investigated. 
Chloroquine (CQ) was added to the cell lines for its ability to buffer the endosome. The 
transfection efficiencies of polyplexes with and without CQ were investigated, in order to 
assess the ability of the histidine moieties to buffer the endosome. 
 
Exp 3. Investigate the intracellular reducible property: The intracellular cleavage 
of the disulfide bonds in the RPCs polyplexes by GSH was studied as a function of 
transfection. Intracellular GSH levels were boosted by adding glutathione monoethyl ester 
(GSH-MEE), which is cell permeable and is hydrolysed to GSH intracellularly.[21] In addition, 
an experiment using buthionine sulfoximine (BSO) which inhibits the synthesis of the 
intracellular GSH was studied as a function of transfection. Thus, an assessment of the nature 
of the disulfide bonds can be made on transfection efficiency. 
 
Exp 4. Investigate the endosomolytic buffering and intracellular reducible 
properties: The combination of CQ and GSH-MEE was also carried out in the cell 
transfection studies. The transfections of polyplexes with CQ, GSH-MEE, CQ+GSH-MEE 
and only poplyplexes were investigated, to make a combined assessment of both the nature of 
the histidine moities and the disulfide bonds on the transfection efficiency. 
In addition, the characterization of lower molecular weight RPCs (~40-60 kDa) and their 
polyplexes at N:P 5 studied in Chapter 3 (section 3.3.4.3) also suggested that they were 
suitable for cell transfection. Therefore, the transfection efficiency of RPCs as a function of 
molecular weight will be investigated in this chapter as well. 
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 4.3.2  Cell transfections of oligopeptides polyplexes 
 
Although, the polyplexes produced from 2COPs (see section 3.4.4.4) revealed that they were 
not  suitable for using as vectors as the polyplex diameters were large, the transfection of 
these polyplexes was also investigated (Figure 4.2b) to compare with RPCs. 
 
4.4   Results and discussion 
 
The overview of cytotoxicity and transfection experiments are shown in Figure 4.3 and 
described in detail in section 2.10.1. Briefly, cell lines (104 cells/well) were grown in 96 well 
plates for 18 hr. The cells were washed (step 1) and serum free DMEM medium and CQ (100 
µM), GSH-MEE (5 mM) or BSO (100 µM) (step 2) was added. Cells were incubated for 1, 3 
or 24 hrs with CQ, GSH-MEE or BSO, respectively, before washing and transfecting cells 
with the polyplexes (step 3). Further serum containing DMEM medium was added to the 
washed cells, and the cells were further incubated for 96 or 44 hrs for cytotoxicity 
determination (step 5-6) or transfection level determination (step 7-9), respectively. 
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Figure 4.3.   Schematic processes of cytotoxicity and cell transfection studies of polyplexes with CQ, GSH-
MEE or BSO 
 
 
4.4.1   Cytotoxicity of RPC polyplexes (Figure 4.2a, step 2, Exp 1) 
 
The MTS cell proliferation assay was utilized to determine the cytotoxicity of all polyplexes 
at both high and low molecular weight as described in section 2.10.4. The MTS reagent is 
bioreduced by NAD+ and NADH produced by dehydrogenase enzymes in metabolically 
active cells, producing a yellow/orange formazan product (Figure 4.4). The amount of 
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formazan product is directly proportional to the number of living cells. Thus, the cell 
proliferation or death can be quantified by reading the absorbance of the plate at 490 nm.  
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Figure 4.4.   Schematic diagram showing cellular metabolism resulting in the conversion of MST agent to 
formazan in MTS assay 
 
The process of cytotoxicity determination of the transfected cells is shown in Figure 4.3. 
Briefly, after transfecting cells with polyplexes (step 1-4) with or without the combination 
with the additive compounds (CQ or GSH-MEE), the cells were further incubated for 96 hrs. 
The incubated cells were washed and subjected to the MTS assay by adding the MTS reagent 
(step 5) and further incubated for 45 minutes. The absorbance was then measured at λ = 490 
nm. A blank was also performed by adding the reaction media into empty wells. The blank 
N
OMe
Me
H
OCH2COOH
N N
N
N SO3-
N
S
+
OCH2COOH
N N
N
N SO3-
N
S
H
References for Chapter 4 are on page 210-214. 
 
177
References for Chapter 4 are on page 210-214. 
 
178
was deducted before calculating the percentage of cell viability relative to non-transfected 
cells. 
 
In addition, in order to compare with our group’s previously developed RPCs (CH6K3H6C, 
RPC(113) and CH3K3H3, RPC(59))[18] which shown that they are less toxic to cell (~95% cell 
viability) the same amount of DNA polyplexes (with 0.5 µg DNA per well) was used in this 
thesis.  
 
The cell viability after 96 hours of the transfection is illustrated in Figure 4.5.  
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Figure 4.5.      Cell viability following exposure to RPCs (~50 and ~100 kDa) polyplexes 1-5 at N:P 5, PLL polyplex at N:P 5, PEI polyplex at N:P 10 and 
cell    controls; (a, b) : cell viability of transfected cells with RPCs at lower molecular weight (~50 kDa) in bEND3 and A549, respectively. and 
(a1,b1) : cell viability  of transfected cells with RPCs at high molecular weight (~100 kDa) into bEND3 and A549, respectively. Note: The 
percentage of cell viability shown in this diagrame derived from the average cell viability (%) of cells treated with polyplex alone and in the 
combination of polyplexes and CQ, GSH-MEE and CQ+GSH-MEE in each cases 
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As can be seen in Figure 4.5 the data demonstrated that using RPCs alone at both molecular 
weights as vectors were tolerated well by both cell lines (blue bars), apart from RPC 1 (~100 
kDa) which is slightly toxic to A549 (~75% viability after 96 hours post transfection). In 
addition, GSH-MEE does not decrease the cell viability. However, both CQ (black bars) and 
CQ+GSH-MEE (yellow bars) treated cells are less viable. This data indicates that CQ caused 
toxicity to cells. In addition, there was previous study that also indicated cells may be exposed 
to relative low concentration of chloroquine (100 µM) during the transfection, but the 
concentration within cells is found to be much higher resulting in cell toxicity and substantial 
loss of cell viability.[17] 
 
Furthermore, the average cell viability in the transfections with PLL and PEI polyplexes when 
in combination with CQ, GSH-MEE and GSH-MEE+CQ in both cells showed that they are 
slightly toxic to both cells (~80-87% cell viability).  
 
In summary, the overall cytotoxicity data indicated that RPCs 1-5 at low and high molecular 
weight are less toxic to both cell lines (~84-108% cell viability) and similar to (CH6K3H6C-
RPC113 and CH3K3H3-RPC59)[18] (~95% cell viability)  relative to PLL (77-85% cell viability) 
and PEI (71-91% cell viability) polyplexes.  
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4.4.2 Cell transfection of RPCs polyplexes (Figure 4.2a, step 2) 
 
The process of transfecion experiments is shown in Figure 4.3. Briefly, after transfecting 
cells with polyplexes (step 1-4) with or without the combination with the additive compounds 
(CQ or GSH-MEE), the cells were further incubated for 44 hrs. The cells were washed and 
the cell lysis buffer was added to the cells (step 7). The cell lysate (from freezing and thawing 
the cells were analysed by luciferase assay to obtain the relative light units (RLU) (step 8) 
(section 2.10.2) and the amount of protein produced by the advanced protein assay (step 9) 
(section 2.10.3). Thus, the gene expression will be shown in relative light units per milli gram 
of protein (RLU/mg protein). NB. The luciferase assay is a chemiluminescence assay that is 
directly proportional to the amount of protein that is produced upon transfection.  
 
PLL and PEI polyplexes at N:P 5 and 10, respectively were used as controls.  
 
A background experiment was carried out with cell lines in which the process outlined in 
Figure 4.3 was repeated, but whereby the polyplex was not added in step 3.  
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4.4.2.1 Cell transfection of RPCs polyplexes based on the endosomolytic 
buffering: effect of CQ    (Figure 4.2a, step 2, Exp 2) 
 
The mixing of the position of the constitution of the histidine and lysine in 2COPs 2-5 
provided a subtle way of modulating the pKa of the imidazole residues. The average pKa of 
2COPs 2-5 were 6.2-6.09 (section 3.4.2, page 117), thus at physiological pH (~7.4) they will 
not be fully protonated and will have different buffering capacities when in the early 
endosome, whose pH is ~6. Therefore, using the reducible polycations (RPCs) of these 
2COPs, their buffering will promote modulatable endosomolysis as described earlier (page 
27) under the proton sponge hypothesis.[22]  
 
In this experiment, we investigated the cell transfection with RPCs/pCMV-luc polyplexes. 
The RPCs used as vectors are shown in Table 4.1.  
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Table 4.1.  RPCs, polymers and their polyplexes used in cell transfection studies 
 
RPCs/polymers 
 
pKaa
MW  
of RPCs 
(kDa)b
N:P 
of 
polyplexes 
Diameter  of 
polyplexes 
(nm)c
Zeta potential  of 
polyplexes  
(mV)d
RPC 1 (CK8C) 
RPC 2 (CK4H4C) 
RPC 3 (CK2H2K2H2C) 
RPC 4 (CK2HKHKH2C) 
RPC 5 (CKHKHKHKHC) 
PLL 
PEI 
10.51 
6.20 
6.16 
6.11 
6.09 
- 
- 
111.4 
118.0 
115.1 
102.9 
94.8 
70 
25 
5 
5 
5 
5 
5 
5 
10 
     132.1  ±    4.5 
       98.3  ±    0.6 
       99.8  ±    0.9 
     101.1  ±    2.8 
       95.5  ±    1.1 
       81.0  ±    0.9 
     108.7  ±    8.6 
10.0  ±  10.9 
14.3  ±    9.7 
13.5  ±    7.2 
  5.8  ±    3.6 
 17.4  ±   11.3 
 11.3  ±     9.0 
  3.4   ±     0.2 
a average pKa values analysed by 1H NMR titration  
b  Molecular weight of RPCs was analyzed by GPC using CATSEC300 column compared to PLL standard. 
c Hydrodynamic diameters of the polyplexes measured by dynamic light scattering using a Zetasizer 3000 
(Malvern Instruments, Worcestershire, UK). 
d  Zetapotential measured by using  Zetamaster (Malvern Instruments, Worcestershire, UK). 
 
Chloroquine (CQ) (section 1.1.2.2a), a quinoline base with a protonatable diamine containing 
side-chain, was used for its ability to buffer endosomes.[23] The ability of these polyplexes to 
act as proton sponges for endosome escape could be inferred from the studies with added 
chloroquine: for example if the polyplexes had good buffering capacity, then the addition of 
CQ would have a reduced impact on the transfection than if the polyplexes had poor buffering 
capacity. 
 
Cell lines were incubated with or without CQ (100 µM) for 1 hr (Figure 4.3, step 2) before 
washing and transfecting cells with polyplexes. The transfections of polyplexes with or 
without CQ were compared and shown in Figure 4.6.  
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Figure 4.6.   Transfection based on CQ with RPC polyplexes 1-5 at N:P 5, PLL polyplex at N:P 5, PEI 
polyplex at N:P 10 and cell control; a) transfection in bEND3 and b) transfection in A549 
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 bEND3 cells (Figure 4.5a): 
 
  Without CQ 
 
As can be seen in Figure 4.6a RPCs 1-5 polyplexes alone all transfect with significant levels 
above the background. RPC 1 polyplex gives the lowest level of transfection of the RPCs 1-5, 
indicating the histidine moieties are playing a significant part in the transfection ability, i.e. 
increasing the endosomal release. Furthermore, RPC 1 polyplex has ~2 order of magnitude 
increase transfection over the non-reducible PLL polyplex, i.e. the reducible disulfide bond is 
playing a significant part in the transfection efficiencies. 
 
RPCs 2-5 polyplexes have ~1 to ~4 orders of magnitude greater transfection ability that PEI10 
and PLL, respectively.  
 
  With CQ 
 
The addition of CQ increases the transfection ability by ~1 order of magnitude for all the 
polyplexes studied, indicating that these polyplexes need CQ to promote endosomal buffering. 
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A549 cells (Figure 4.6b): 
 
  Without CQ 
 
The first point to note is that RPC 1 alone does not trasfect the cells (RLU is below 
background), whereas, RPCs 2-5 all transfect the cells. Thus, indicating that RPC 1 does not 
have an efficient mechanism for escaping the endosome. 
 
  With CQ 
 
As expected, there is ~3 orders of magnitude increase in transfection with cells incubated with 
CQ and RPC 1 polyplex relative to the polyplex alone. This enhancement is because the RPC 
1 has no histidine residues which promote the buffering capacity in the endosomes, therefore 
it has no efficient mechanism to escape from the endosome by itself for gene expression.  
 
In contrast, there is a modest increase (less than one order of magnitude) in transfection with 
cells (A549) incubated with CQ and polyplexes of RPCs 2-5 (black bars) than the cells 
incubated with the polyplexes alone (blue bars). This result suggests that RPCs 2-5 are 
buffering the endosome, indicating the importance of the intermediate pKa of these RPCs. 
 
There is only a slight increase in the transfection of cells incubated with CQ and PLL and the 
transfection level is near to the background. This result indicates both the lack of a buffering 
mechanism in the endosome and the lack of DNA release once subsequently in the cytoplasm. 
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In summary, from the results of this transfection study based on the endosomolytic buffering 
capacity of the RPCs 1-5 it can be inferred that histidine moiety is important for gene 
transfection. 
 
4.4.2.2 Cell transfection of RPCs polyplexes based on intracellularly reducible 
property: effect of GSH-MEE/ BSO (Figure 4.2a, step 2, Exp 3) 
 
It was established that the RPCs 1-5 polyplexes are stable in the extracellular matrix (section 
3.4.4.2c), and they are cleavable in GSH and salt solution (section 3.4.4.2d). In this study we 
investigated the intracellular reduction of these polyplexes as a function of transfection. 
Glutathione monoethyl ester (GSH-MEE) (Figure 4.7a) was incubated with the cell lines in 
order to increase the intracellular concentration of GSH. The GSH-MEE is transported into 
cells effectively by incubation, and is converted into GSH intracellularly.[21] Thus, 
transfection efficiency of RPCs 1-5 should be boosted. Conversely, another set of cells was 
incubated with buthionine sulfoximine (BSO) (Figure 4.7b) which inhibits GSH production, 
and hence should knock down the transfection efficiency. 
 
 
 
 
 
 
 
 
 
References for Chapter 4 are on page 210-214. 
 
187
 
a) GSH-MEE b) BSO 
 
HO N
H
H
N
O
O O O
NH2
SH
O
 
S
OH
O
NH
O
NH2
 
 
Figure 4.7.  Structures of Glutathion monoethyl ester (GSH-MEE) (a), and buthionine sulfoximine (BSO) 
(b) 
 
4.4.2.2a Artificially increase the intracellular GSH level: effect of   
               GSH-MEE (5mM) 
The GSH-MEE was used to boost the intracellular GSH in order to probe the reductive 
cleavage mechanism in the cells. Briefly (Figure 4.3), cell lines were incubated with GSH-
MEE (5mM) (step 2) containing medium for 3 hrs before washing and transfecting the cells 
with the polyplexes (section 2.10.1). The transfection cells (bEND3 and A549) with 
polyplexes without (blue bars) and with incubation with GSH-MEE (pink bars) are shown in 
Figure 4.8. 
 
 bEND3 cells (Figure 4.8a): 
 
Transfection of cells incubated with GSH-MEE (pink bars) has in all cases increased the 
transfection ability over no incubation with GSH-MEE (blue bars). This result is as expected 
as we have raised the intracellular GSH levels and hence the DNA should be released more 
efficiently once in the cytoplasm, via more rapid cleavage of the disulfide bonds in the RPCs. 
 
 
 
References for Chapter 4 are on page 210-214. 
 
188
 A549 cells (Figure 4.8b): 
 
The case with A549 cells is not so clear cut as for bEND3 cells. Here polyplexes from RPCs 
1, 2, 4 and PLL observed the expected results of an increase in transfection, whereas RPC 3 
saw a reduction in the transfection and RPC 5 has no change in transfection. However, taken 
as a series we conclude the transfection efficiencies have increased as one might expect. 
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Figure 4.8.  Transfection based on GSH-MEE and BSO with RPC polyplexes 1-5 at N:P 5, PLL polyplex 
at N:P 5, PEI polyplex at N:P 10 and cell control; a) transfection in bEND3 and b) transfection 
in A549 
 
 
 
 
References for Chapter 4 are on page 210-214. 
 
190
4.4.2.2b Artificially depleting the intracellular GSH level: effect of 
BSO 
BSO is a GSH biosynthesis inhibitor by inhibiting the γ-glutamylcysteine synthetase in the 
glutamyl cycle for glutathione synthesis (Figure 4.9).[24] Therefore, BSO was used to deplete 
intracellular GSH.[25] Briefly (Figure 4.3), cell lines were incubated with BSO (100 µM) 
(step 2) containing medium for 24 before washing and transfecting the cells with the 
polyplexes (section 2.10.1).  
 
 
Figure 4.9.    Inhibition of glutathione synthesis by buthionine sulfoximine (BSO) in γ-glutamyl cycle  
 
The transfection cells (bEND3 and A549) with polyplexes without (blue bars) and with BSO 
(green bars) are shown in Figure 4.8. 
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 bEND3 cells (Figure 4.8a): 
 
The transfection ability of cells incubated with BSO (green bars) and treated with the 
polyplexes increased. Clearly, this result is contrary to what was expected as the BSO should 
deplete the amount of intracellular GSH, resulting in poorer release of DNA from the 
polyplex in the cytoplasm and hence reduced transfection. 
 
 A549 cells (Figure 4.8b): 
 
In contrast, the A549 cells behaved as expected and all the transfections were knocked down 
by BSO treatment.  
 
4.4.2.2c Assessing intracellular GSH levels in A549 and bEND3 cells 
treated with GSH-MEE and BSO 
     
As noted ealier (section 4.4.2.2b) the bEND3 cells treated with BSO had increased levels of 
transfection over the cells not treated with BSO. This result appears anomalous, as the BSO 
should knock down intracellular GSH levels and hence the polyplexes should not be degraded 
less efficiently in the cytoplasm. Therefore, we examined the glutathione content of both cell 
lines with and without treatment with GSH-MEE and BSO. Monochlorobimane (mBCl) was 
utilized to probe the intracellular GSH (section 2.10.5) (Figure 4.10). Briefly, after incubating 
cells with GSH-MEE or BSO at appropriate times (step 1, 2), the background fluorescence 
was measured (λex at 355 nm and λem at 460 nm) (step 3). The monochlorobimane (mBCl) 
was added into cells (step 4) and further incubated for 60 minutes before measuring the 
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fluorescence again (step 5). The relative fluorescence was calculated after subtracting the 
background.  
 
Figure 4.10.  The schematic processes of intracellular GSH determination 
 
The intracellular GSH levels of cell lines incubated with GSH-MEE or BSO are shown in 
Figure 4.11. 
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Figure 4.11.    Relative fluorescence of intracellular GSH based on the addition of GSH-MEE and BSO in 
bEND3 and A549 cells 
 
 
There is boosting in intracellular GSH level in both cell lines incubated with GSH-MEE 
(bEND3 and A549, pink bars) relative to the cell control (bEND3 and A549, yellow bars). 
However the effect is more enhanced in bEND3 as the relative fluoresence increases ~ 175% 
compared to ~ 40% in A549.  
 
However, There is no reduction of the intracellular GSH in bEND3 cells incubated with BSO 
(bEND3, green bar) relative to the cell control (bEND3, yellow bar), indeed, there is ~50% 
increase. In contrast, the intracellular GSH in A549 cells incubated with BSO (A549, green 
bar) decreases relative to the cell control (A549, yellow bar) by 75%.  
 
We do not understand why the intracellular GSH levels rise when the bEND3 cells are treated 
with BSO. However, now known this the data present in Figure 4.8a (green bars) is not 
anomalous. 
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4.4.2.3 Cell transfection of RPCs polyplexes based on the combination of 
endosomolytic and intracellularly reducible properties (Figure 4.2a,    
step 2, Exp 4) 
 
 
The transfection of RPCs polyplexes based on endosomolytic and intracellularly reducible 
properties were also investigated. The transfections were carried out by adding CQ alone, 
GSH-MEE alone and the combination of CQ and GSH-MEE into cell lines, as well as 
incubation with the polyplexes alone (section 2.10.1). The transfection processes are shown in 
Figure 4.3. The transfection levels by the polyplexes with CQ alone, GSH-MEE alone, or 
CQ+GSH-MEE and the polyplexes alone are shown in Figure 4.12. 
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Figure 4.12.    Transfection based on CQ and GSH-MEE with RPC polyplexes 1-5 at N:P 5, PLL polyplex 
at N:P 5, PEI polyplex at N:P 10 and cell control; a) transfection in bEND3and b) transfection 
in A549 
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 bEND3 cells (Figure 4.12a): 
 
In all cases addition of CQ alone (black bars) and GSH-MEE alone (pink bars) increases the 
transfection ability of the polyplexes. However, the combination of CQ and GSH-MEE does 
not give a cumulative effect on the transfection ability (yellow bars). 
 
A549 cells (Figure 4.12b): 
 
As with bEND3 cells there is no cumulative effect of adding CQ and GSH-MEE in 
combination. As can be seen in Figure 4.12b for RPCs 2-5, there is no significant change in 
transfection efficiencies of RPCs 2 and 4 in A549 incubated with the combination of CQ and 
GSH-MEE relative to CQ alone and GSH-MEE alone. In addition, for RPCs 2 and RPC 3 
there is a modest increase (less than one order of magnitude) in the transfection ability in cells 
incubated with the combination of CQ and GSH-MEE (yellow bars) relative to the cells 
incubated with the polyplexes alone (blue bars). This result may suggest that RPCs 2 and 3 do 
not require the addition of CQ and extra GSH in the transfection. However, the combination 
of CQ and GSH-MEE appeared to improve the transfection efficiencies of RPCs 4 and 5 
(~one order of magnitude relative to the polyplexes alone). 
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4.4.2.4    Cell transfection of RPCs polyplexes as a function of RPCs molecular 
weight (Figure 4.2a, step 2) 
 
In the previous chapter the set of RPCs based on the oligopeptides were prepared with 
molecular weights of ~50 kDa and ~100 kDa. Characterizations of these polyplexes showed 
that RPCs of lower molecular weight bound DNA as well as the higher molecular weight 
RPCs, but released DNA more efficiently upon treatment with GSH and NaCl, as shown by 
gel shift assay experiments (Chapter 3, Figure 3.14 and 3.22). Therefore, it is expected that 
these lower molecular weight RPCs might induce higher transfection efficiency than the high 
molecular weight RPCs as the DNA is released more efficiently from the polyplexes. The 
properties of these RPCs and their polyplexes are shown in Table 4.2.  
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Table 4.2.  The characteristic of RPCs and their polyplexes 
RPCs/ polymer 
MW 
of RPCs 
(kDa)a
Diameter 
of polyplexes 
(nm)b
Zeta potential 
of polyplexes 
(mV)c
DNA released (%)d  from 
polyplexes by  
GSH (5mM)+NaCl (0.5 mM) 
  53.9      99.9  ±    8.3        16.8  ±  11.0 
          
0 RPC 1 
(CK8C)  111.4    132.1  ±    4.5        10.0  ±  10.9 0 
     60.8      98.4  ±    0.7        10.1  ±  14.0 95 RPC 2 
 (CK4H4C) 118.0      98.3  ±    0.6        14.3  ±    9.7 61 
 40.4      94.7  ±    1.5 
       
       15.5  ±  15.5 
         
95 RPC 3 
 (CK2H2K2H2C) 115.1      99.8  ±    0.9        13.5  ±    7.2 48 
48.5    101.1  ±    2.2 
       
         5.3  ±    5.7 
       
95 RPC 4 
 (CK2HKHKH2C) 102.9    101.1  ±    2.8          5.8  ±    3.6 95 
 42.3      90.7  ±    3.4       12.6  ±   12.3   90 RPC 5  
(CKHKHKHKHC)  94.8      95.5  ±    1.1        17.4  ±   11.3 63 
a  Molecular weight of RPCs was analyzed by GPC using CATSEC300 column compared to PLL standard. 
b  Hydrodynamic diameters of the polyplexes were measured by dynamic light scattering using a Zetasizer 3000    
   (Malvern Instruments, Worcestershire, UK). 
c  Zetapotential was measured by using  Zetamaster (Malvern Instruments, Worcestershire, UK).  
d DNA released (%) was determined by gel electrophoresis. 
 
The transfection levels of lower molecular weight RPCs based on CQ, GSH-MEE, and the 
combination of CQ and GSH-MEE in both cell lines are shown in Figure 4.13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References for Chapter 4 are on page 210-214. 
 
199
 
 
Transfection in bEND3 cells
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
RPC 1(54) RPC 2(60) RPC 3(40) RPC 4(48) RPC 5(42) PLL PEI10 bEND3
R
LU
/m
g 
pr
ot
ei
n
Only polyplexes CQ GSH-MEE CQ+GSH-MEE
 
 
 
 
 
Transfection in A549 cells
1.00E+04
1.00E+05
1.00E+06
1.00E+07
1.00E+08
1.00E+09
1.00E+10
1.00E+11
RPC 1(54) RPC 2(60) RPC 3(40) RPC 4(48) RPC 5(42) PLL PEI10 A549
R
LU
/m
g 
pr
ot
ei
n
Only polyplexes CQ GSH-MEE CQ+GSH-MEE
 
a) 
b) 
Background 
Background 
 
Figure 4.13.   Transfection based on CQ and GSH-MEE with RPC polyplexes 1-5 (~50 kDa) at N:P 5,  
PLL polyplex at N:P 5, PEI polyplex at N:P 10 and cell control; a) transfection into bEND3 
and b) transfection into A549 
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As can be seen in Figure 4.13 there is similar trend of the transfection efficiencies of lower 
molecular weight RPCs compared to high molecular weight RPCs (Figure 4.12). Thus, 
similarity suggests that transfection mechanism is similar for both low and high molecular 
weights (~50 kDa and ~100 kDa). 
 
A plot of transfection levels versus polyplex types is shown in Figure 4.14 for both sets of 
molecular weight. These graphs clearly show that the lower molecular weight RPCs show 
greater transfection levels for both cell types. In addition, all profiles are similar with a 
maximum transfection levels at a pKa between 6.20-6.16.  
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Figure 4.14.   The transfection efficiency in bEND3 and A549 of RPCs polyplexes at different molecular 
weight (~50 and ~100 kDa), PEI and PLL polyplexes; a) Transfection in bEND3 and b) 
Transfection in A549  
 
 
 
 
 
References for Chapter 4 are on page 210-214. 
 
202
The transfection efficiency of the pair of polyplexes from RPCs at different molecular weights 
were carried out based on the endosomolytic (added CQ) and intracellular reducible (added 
GSH-MEE) properties in both A549 and bEND3 cell lines is a similar fashion to the higher 
molecular weight RPC polyplexes (Figure 4.14a and b). The comparisons of the various 
transfection levels of RPCs at low and high molecular weight are shown in Figure 4.15. 
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Figure 4.15.    Transfection in bEND3 and A549 based on CQ and GSH-MEE of polyplexes from the 
RPCs 1-5 at the different molecular weight; (a)-(d): transfections in bEND3, (a1)-(d1): 
transfections in A549 
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As can be seen in Figure 4.15 the transfection results showed the similar trend by using 
different molecular weight RPCs as vectors in most cases of both cell lines.  
  
bEND3 cells (Figure 4.15a-d): 
As can be seen the treatment of the cells with both CQ (Figure 4.15b), GSH-MEE (Figure 
4.15c) and in combination (Figure 4.15d) reduces the differential between the transfection 
levels and molecular weight considerably when compared to no such treatment (Figure 
4.15a). 
 
 A549 cells (Figure 4.15a1-d1): 
In contrast, A549 cells maintain a differential in transfection cells as a function of molecular 
weight when treated with CQ (Figure 4.15b1), GSH-MEE (Figure 4.15c1) and in 
combination (Figure 4.15c1) when compared to no such treatment (Figure 4.15a1) 
 
In summary, lower molecular weight RPC polyplexes (~50kDa) give higher transfection 
levels than high molecular weight RPC polyplexes (~100 kDa).  
 
4.4.3    Cell transfection of oligopeptide polyplexes 
 
Oligopeptide (2COPs 1-5) polyplexes were prepared at N:P 5 (See section 3.6.2), and were 
found that their sizes were greater than 1 µm over the time course of 48 hrs (Table 3.7 and 
Figure 3.23). However, the transfection efficiency of these polyplexes was still determined, 
although it was expected that this would be poor in vivo, because the large polyplexes would 
interact with blood components or macrophages, resulting in the clearance from the blood 
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stream before reaching the cells.[26] In addition, we might expect poor transfection in vitro 
because of polyplex uptake by endocytosis is poor for polyplexes larger than 200 nm.[27]  
 
The PEI polyplexes formed at N:P 10 were utilized as positive control. The human lung 
carcinoma cells, A549, were used in the in vitro transfection (section 2.10.1). The cell 
transfections with these polyplexes were carried out in the same manner as with RPCs 
polyplexes as shown in Figure 4.3. However, the experiments with GSH and CQ were not 
performed. Therefore, after 18 hrs of growing cells, the polyplexes were added directly to the 
washed cells (Figure 4.3, step 3). The relative transfection efficiencies are shown in Figure 
4.16. 
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Figure 4.16.     Relative transfection efficiency of 2COPs, RPCs at N:P 5 and PEI at N:P 10 in A549 cells  
 
 
As predicted the oligopeptides 2COPs were poorly transfecting the cells relative to the RPCs 
that they formed (Figure 4.16). This result is presumably due to the series of the polyplexes 
formed from the 2COPs. 
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4.5 Conclusions 
 
The work presented in this chapter involved evaluating the cytotoxicity and transfection of 
RPCs 1-5 (~50 kDa and ~100 kDa) in order to investigate the endosomolytic and 
intracellularly reducible properties and the affect of different molecular weight RPCs on 
transfection efficiency. The transfection efficiency of 2COPs 1-5 was also investigated in 
comparison with RPCs. 
 
4.5.1  Cytotoxicity of RPCs polyplexes 
 
Transfections in combination with CQ causes toxicity to cells. However, the overall 
cytotoxicity data indicated that RPCs 1-5 at lower and high molecular weight are less toxic to 
both cell lines relative to PLL and PEI polyplexes as its ability to unpackage in the cytoplasm 
suggested a reduced cytotoxicity compared to PEI and PLL, as it would be expected to 
degrade to readily cleared fragments (2COPs). 
 
4.5.2  Cell transfection of RPC polyplexes 
 
Our overall data of both cells indicates that RPCs 2-5 (with 40% histidine content) – which 
are less aided by CQ relative RPC 1 – is behaving in a similar way to PEI, in term of the 
proton sponge mechanism, escaping to the cytoplasm without developing into the lysosome[28] 
and does not require addition of the endosome buffering agent CQ to achieve high 
transfection efficiencies, whereas PLL and RPC 1 polyplexes do. These findings are in 
agreement with the study by Read and colleagues[29] which revealed that RPCs (45, 187 kDa) 
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oxidatively polymerized from CK10C required  combining with CQ or DOTAP for efficient 
transfection because CK10C-RPC itself lacked endosomal buffering capacity. In addition, by 
incorporation of histidine moities in our group’s previous work[18] also indicated that 
histidine-containing RPCs (RPC(59) (CH3K3H3C, 59 kDa) and RPC (113) (CH6K3H6C, 113 
kDa) promote the endosomal escape mechanism. However, using the new strategy to 
modulate the pKa of RPCs in this study revealed that the range of pKa of RPCs 2-5 (6.09-6.20) 
indeed buffer in a similar way to PEI. In addition, the highest transfection efficiencies in both 
cell types were with RPC 2, the ‘poly(diblock)’ [CK4H4C]n polymer, which was 4 orders of 
magnitude better than PEI and 100-fold better than PLL in bEND 3 cells. In addition, 
comparing the pKa of RPCs 2-5 (pKa 6.20-6.09) suggested that the optimum pKa that induced 
the highest transfection efficiency in both cells is at pKa 6.20 (RPC 2) (Figure 4.17). 
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Figure 4.17.  The transfection efficiency in bEND3 and A549 of RPCs polyplexes based on the pKa values 
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From the results of the artificial depletetion and increase of the intracellular GSH level 
studies, it could be shown that these RPCs are reduced by intracellular GSH (vector feature 
V).  
The difference observed between transfection efficiencies in bEND3 and A549 cell lines was 
most likely due to the different rate of cell growth in vitro. Change in growth rates would 
have affected the level of intracellular glutathione and the protein expression. Concomitant 
degradation of the nuclear membrane would, therefore, have led to the release of high level of 
glutathione into cytoplasm. 
 
4.5.3.  Cell transfection of RPCs polyplexes as a function of RPCs molecular weight 
 
The trend of transfection efficiency of lower molecular weight RPCs and high molecular 
weight RPCs were similar in both cells: The lower molecular weight RPCs induced higher 
transfection efficiency. 
 
4.5.4  Cell transfection of oligopeptides polyplexes 
 
As predicted the oligopeptides 2COPs were poor transfection agents relative to the RPCs as 
they formed large polyplexes which are not efficiently internalized into the cells via 
endocytosis effectively.[26] Manpreet and colleagues[30] also revealed that condensing DNA 
with low molecular weight peptides (DiCWK3, AlkCWK8 and K19) failed to produce 
significant gene transfection which was put down to their large particle diameters (724, 2412 
and 3102 nm, respectively). 
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In summary, incorporation of lysine, histidine, and cysteine residues in RPCs provide 
promising vectors that bind DNA extracellularly and protect against nucleases and protein-
mediated disassembly (vector feature I), cell uptake via syndecan mediated endocytosis 
(vector feature III), provide a tunable endosomal release mechanism (vector feature IV), and 
release DNA into the cytoplasm via glutathione reduction mechanisms (vector feature V) 
leading to further gene expression. In addition, these RPCs are non-toxic to cells.  
 
However, using endothelium (bEND3) and epithelium cell lines (A549) in the in vitro 
transfection could suggest these polyplexes may not be suitable to inject into blood vessels as 
they could internalize into endothelium cells that line the interior surface of the blood vessels 
before they get to epithelium cells, which are the tissues to be treated. However, injecting the 
polyplexes to the specific tissue could be the alternative way to overcome this hurdle. 
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5     SYNTHESIS AND CHARACTERIZATION OF 
REDUCIBLE COPOLYCATIONS (RcPCs) CONTAINING 
LYSINE, HISTIDINE AND CYSTEINE BASED 
SEQUENCES AND TAT PEPTIDE 
Abstract 
As shown previously in Chapters 3 and 4 the reducible polycations (RPCs) are 
promising vectors for gene delivery in non-viral system. However, these 
vectors have no nuclear targeting signal. Therefore, in this chapter we design 
to incorporate the nuclear targeting signal (TAT) in the vectors in order to 
potentially improve the transfection ability. The RP-TAT was synthesized via 
oxidative polymerisation of TAT oligopeptide (CRKKRRQRRRC). The RcPCs 
1-5 (~50 kDa) were synthesized via random oxidative polymerisation of 
2COPs 1-5 and TAT oligopeptide at molar ratio 1:1. The RcPC 5 was also 
synthesized at 1:3 molar ratio of 2COP 5:TAT. The DNA polyplexes of RP-
TAT and RcPCs 1-5 were formed at N:P 5 and characterized.  The RP-TAT 
and RcPCs polyplexes are approximately 100 nm in diameter, and are all 
positively charged. Gel shift assay revealed that the RP-TAT and RcPCs 
polyplexes are unpacked by interacting with PAA (extracellularly simulated 
condition) and GSH+NaCl (intracellularly simulated condition). These results 
suggested that the RcPCs have less potential than RPCs to be used as vectors 
as they are less stable to PAA than the RPCs, and hence may be degraded in 
the blood before they are internalized into the cells.  
 
 
5.1    Introduction 
 
 
As described in Chapter 1 (page 22), there are several cellular barriers that need to be 
overcome in order for a gene to be delivered to the nucleus.[1] In Chapters 3 and 4, we have 
shown that the RPCs incorporating lysine, histidine and cysteine residues are promising 
vectors for non-viral gene delivery. In particular, these polyplexes were stable in an 
extracellular environment. The positively charged polyplexes could internalize into cells via 
syndecan-mediated endocytosis,[2,3] whilst the histidine residues help to buffer the endosomes, 
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resulting in endosomal disruption and release of the polyplexes into the cytoplasm.[4] 
Disulfide bonds in the backbone of the polycations provide the reducible property of the 
polyplexes (cleavage by intracellular GSH) leading to release of the nucleic acid for further 
enhancements in the gene expression mechanism.[5,6]  
 
However, there is another key challenge to improve these cationic vectors, which is the 
nuclear import property.[7,8] The DNA must be internalized into the nucleus in order to either 
replace the non-functional gene or transcribe to mRNA for furthering translation to the 
therapeutic protein.[9] The nuclear membrane is a barrier for most macromolecules that are 
greater than 45 kDa, unless they are able to interact with the nuclear pore active transport 
system[10] as described in Chapter 1 (section 1.1.2.2b). The nuclear localization signals (NLS) 
are peptide sequences that are recognized by this nuclear transport system. Therefore, to 
improve the non-viral RPCs 1-5 vectors designed in Chapters 3 and 4, the conjugation of an 
NLS with 2COPs 1-5 to afford reducible copolycations (RcPCs 1-5) has been considered in 
the research described in Chapters 5 and 6.  
 
The most common NLS peptide that has been used in non-viral vectors derives from the 
simian virus 40 large tumor antigen (PKKKRKV) [7,11,12]  that mediates binding of cargo 
protein to the importin-α,  which in turn binds to importin-β. The heterotrimer then binds to 
cytoplasmic filaments of NPCs and translocates through the nucleus pore complex (see 
section 1.1.2.2b).  
 
The basic region (49RKKRRQRRR57) of the TAT protein from human immunodeficiency 
virus 1 (HIV-1) has widely been known as a cell penetrating peptide (CPP)[13-17]. However, 
TAT has also been investigated as a novel class of NLSs. [18,19] The mechanism for its nuclear 
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active transport is different from SV40 NLS. Instead of targeting to importin-α, TAT binds to 
importin-β directly.[19] In addition, recently, it has been found that TAT could trigger the 
nuclear import faster than SV40 NLS and is capable of importing nanoparticles (5-90 nm).[20] 
 
There was a study by Manickam and colleagues[21] in which reducible copolypeptides 
containing histidine-rich peptides (CKHHHKHHHKC) and nuclear localization signal 
peptides (CGAGPKKKRKVC) from SV40, which combined the endosomal buffering 
capacity and nuclear localization capability features. The transfection efficiency of the 
reducible copolypeptides increased when the content of histidine increased. However, it was 
still unclear as to the effect of the NLS sequence in the transfection. Therefore, in our study 
the TAT peptide was used as nuclear importing factor instead of NLS from SV40, and by 
combining with pKa modulation we investigate the effect of the NLS. 
 
5.2 Objectives 
 
In Chapter 4 we have shown that the reducible polycations (RPCs) produced from 2COPs 2-5 
were promising vectors for non-viral delivery system. The incorporation of a nuclear 
localisation signal could improve the transfection efficiency of these polycations even further. 
Therefore, in this Chapter, the basic region of TAT-peptide 49-57 sequence (RKKRRQRRR) 
(Figure 5.1) that functions as a nuclear targeting signal was used, and terminally modified 
with cysteine moieties (CRKKRRQRRRC) in order that it could be copolymerized with 
2COPs 1-5 to form a series of reducible copolycations (RcPCs).  
References for Chapter 5 are on page 244-246. 
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Nuclear localisation signal (TAT) 
 
Figure 5.1.  The amino acid sequence of human immunodeficiency virus 1 (HIV-1) TAT protein 
 
5.3   Methodology 
 
In this chapter we show the synthesis and characterization of the RcPCs and the 
physiochemical properties of the polyplexes. In order to achieve these objectives the 
following overview of the experimental process was devised as shown in Figure 5.2. 
 
   (i) The purification and characterisation of TAT oligopeptide: The crude 
TAT oligopeptide (CRKKRRQRRRC) was purified and characterized (Figure 5.2 step 1) 
using high perfomance liquid chromatography (HPLC), electrospray mass spectrometry 
(ESI-MS) and nuclear magnetic resonance (1H NMR) 
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   (ii) The formation and characterization of TAT polycation and RcPCs: The 
TAT reducible polycation (RP-TAT) was synthesized from TAT oligopeptide 
(CRKKRRQRRRC)  via oxidative polymerisation (Figure 5.2, step 2). In addition, the 
reducible copolycations (RcPCs) were synthesized via random oxidative polymerization 
between TAT and 2COPs 1-5 (Figure 5.2, step 2). The characterisation of the RP-TAT and 
RcPCs was carried out using gel permeation chromatography (GPC), multi-angle laser light 
scattering (MALLS) and amino acid anaysis.  
 
   (iii) The formation and characterization of RcPC and RP-TAT polyplexes: 
The formation of RcPC and RP-TAT polyplexes with the DNA (pCMV-Luc) was 
performed in a condensation reaction (Figure 5.2, step 4), and the stability of the 
polyplexes under extra- and intracellularly simulated conditions was carried out (Figure 
5.2, step 5-7). 
 Step 1 
 
Purification 
and characterization 
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SH 
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Figure 5.2.   Schematic overview of characterisation and analysis of oligopeptides and polyplexes in this chapter 
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5.4   Results and discussion 
 
5.4.1   TAT oligopeptide purification and characterization (Figure 5.2, Step 1) 
 
 
Crude samples of TAT oligopeptide synthesized by Alta Bioscience (Birmingham, UK) using 
Fmoc procedure were purified by preparative reverse phase HPLC as described in section 2.3. 
The final purity of TAT was determined by analytical reverse phase HPLC, the experimental 
and calculated mass was determined by electrospray-MS (Table 5.1). The purity of all 
oligopeptides was between 97.35-99.59 % by analytical RP-HPLC (see appendix). The 
purified oligopeptides were additionally characterized by 1H NMR (500 MHz) (see appendix) 
and ESI-MS to confirm their structures (section 2.3). Selected data of the purified TAT and 
the oligopeptides from Chapter 3 used in this chapter are shown in Table 5.1. 
 
Table 5.1.  The purity and mass of purified oligopeptides 
 
Oligopeptide 
 
Sequencea
 
Purity (%) b
Experimental Mass 
[M]+ (g mol-1) c
Calculated 
Mass  (g mol-1) d
TAT  
2COPs 
1 
2 
3 
4 
5 
CRKKRRQRRRC  
 
CK8C 
CK4H4C 
CK2H2K2H2C 
CK2HKHKH2C 
CKHKHKHKHKHC  
98.73 
 
99.59 
97.42 
98.45 
97.35 
97.41 
1545.40 
 
1249.90 
1285.90 
1285.70 
1285.70 
1285.80 
1545.10 
 
1249.70 
1285.56 
1285.56 
1285.56 
1285.56 
a C = Cysteine, K = Lysine, H = Histidine, R = Arginine, Q = Glutamine   
b Purity determined by analytical RP-HPLC (see appendix) 
c Mass analyzed by ESI-MS 
d Mass from the calculation 
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5.4.2 Formation and characterization of reducible copolycations (RcPCs)  (Figure 5.1, 
Step 2, 3) 
 
Reducible copolycations (RcPCs) were produced from 2COPs 1-5 and the TAT oligopeptide 
(section 2.5.3). Briefly, 2COPs (30 mM) and TAT solution (30 mM) in 5x PBS and 30% 
DMSO at 2COPs:TAT molar ratios of 1:1 for RcPCs 1-5 and also 1:3 for RcPC 5 were 
incubated at room temperature for 48 hrs. In addition, the RP-TAT was synthesized from 60 
mM TAT solution in 5x PBS and 30% DMSO, and was incubated at room temperature form 
48 hrs (Figure 5.3).  
 
SH 
TAT 
HS 
2COPs 
HS 
SH 
HS 
SH 
HS 
S-S 
S-S 
Reducible copolycations (RcPCs) 
S-S 
S-S 
SH 
HS 
SH 
SH 
HS 
S-S 
-S S- 
Oxidative polymerisation  
with DMSO 
 
Figure 5.3. Schematic model of reducible copolycations (RcPCs) synthesis via random oxidative 
polymerization  
 
The growth of the RcPCs and RP-TAT molecular weights was monitored by gel permeation 
chromatography (GPC) (Table 5.2 and Figure 5.4) (section 2.5.4). At various time intervals 
over 48 hrs, 5 μl aliquots were removed and quenched with aminoethanethiol (AET). This 
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aliquot was analysed by GPC eluting with 200 mM NaCl with 0.1% TFA, in order to obtain 
the molecular weight against PLL standards (5.6, 8.3, 21.3, 62.1 and 128.5 kDa). The 
sequence ratio of 2COP and TAT in RcPCs was analysed and calculated using amino acid 
analysis (EZ:faast kits, phenomenex, UK) (section 2.6). 
 
Table 5.2.  RP-TAT and RcPCs produced from TAT and 2COPs 1-5 
2COPs and TAT  
in reaction mixtures 
 
Entry RP-TAT/ 
RcPCs 
2COPs TAT 
2COP : 
TAT  
molar 
ratio 
 
Incubation 
time 
(hr) 
 
MW 
(kDa)a
PDIb
i 
RP-TAT 
(40) - CRKKRRQRRRC 
- 48 39.7 1.260 
ii RcPC 1 (37) 2COP 1 
(CK8C) 
CRKKRRQRRRC 1:1 48 36.8 1.275 
iii RcPC 2 (52) 2COP 2 
CK4H4C 
CRKKRRQRRRC 1:1 48 51.6 1.265 
iv RcPC 3 (45) 2COP 3 
CK2H2K2H2C 
CRKKRRQRRRC 1:1 48 44.7 1.169 
v RcPC 4 (39) 2COP 4 
CK2HKHKH2C 
CRKKRRQRRRC 1:1 48 38.5 1.222 
vi RcPC 5 (45) 2COP 5 
CKHKHKHKHC CRKKRRQRRRC 
1:1 48 45.1 1.211 
vii RcPC 5 (22) 2COP 5 
CKHKHKHKHC CRKKRRQRRRC 
1:1 24 22.3 1.168 
vii RcPC 5 (23) 2COP 5 
CKHKHKHKHC CRKKRRQRRRC 
1:3 24 23.3 1.213 
a  Molecular weight of RP-TAT and RcPCs was analyzed by GPC using CATSEC300 column compared to PLL 
standards. 
b  Polydispersity index (PDI) of TAT and RcPCs was measured by size exclusion chromatography (Anachem 
Ltd., Luton, UK) coupled with multi-angle laser light scattering photometer (Wyatt Technology (Santa 
Barbara, USA). 
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From Table 5.2 and Figure 5.4 the molecular weight of RP-TAT and RcPCs 1-5 (1:1) were 
~40-~50 kDa when synthesized over 48 hrs. In addition, RcPC 5 (1:1) when synthesized over 
24 hrs has molecular weight of ~22 kDa which is similar to RcPC 5 (1:3) synthesized over 24 
hrs. 
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Figure 5.4.  Oxidative polymerization compared between RcPCs 1-5 prepared from 2COPs (1-5) : TAT at 
1:1 and RcPC 5 (1:3) incubated at ambient 
[RP-TAT         , RcPCs 1         , 2    X    , 3   X    , 4        , 5         , RcPC 5 (22)   +   and    
RcPC 5 (23)      -     ]  
 
5.4.3 2COPs and TAT sequence ratio analysis 
 
The ratios of 2COP and TAT content of the RcPCs 1-5 were determined using amino acid 
analysis (section 2.6). Briefly, RcPCs (500 µg) were hydrolysed by liquid phase hydrolysis 
with 6N HCl with 4% of thioglycolic acid.  The reaction mixtures were placed in a heating 
block in a tightly capped vial at 110oC for 22 hr, to break peptide bonds. The sample was then 
placed at -20oC for 24 h, unless stated otherwise. The samples were neutralised and analysed 
using EZ:faast kits (phenomenex, UK). An amino acid calibration standard at 50, 100 and 200 
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nmol ml-1 (Figure 5.5) was run by gas chromatography (GC) to allow quantification of the 
amount of unknown amino acids found in each sample, thereby enabling calculation of the 
quantity of amino acids within the sample to be determined.  
 
 
 
 
 
 
 
 
 
0.0
10.0
20.0
30.0
40.0
 
Figure 5.5. Amino acid standard at 200 nmol ml-1 (EZ:faast kits, phenomenex, UK) run with GC. 
 
 
To determine the ratios of 2COPs and TAT in RcPCs, the quantities of lysine (Lys), histidine 
(His) and glutamic acid (Glu) (glutamine (Gln, Q) is converted to glutamic acid (Glu, E) 
during acid hydrolysis) were considered. Therefore, in case of RcPC 1 (2COP 1 + TAT), the 
ratio of Lys:Glu was determined. In cases of RcPC 2-5 (2COP 2-5 + TAT), the ratios of 
Lys:Glu, Lys:His and His:Glu were determined (Table 5.3). 2COP 2 and TAT were also 
analyzed as controls. 
 
As can be seen in Table 5.3 the ratios of 2COP and TAT were derived from the calculation of 
the number of lysine, histidine and glutamic acid residues obtained from amino acid analysis. 
Using TAT oligopeptide (CRKKRRQRRRC, 2 Lys and 1 Gln) as a control should have 
produced the number of Lys per Glu at 2. Thus, the experimental result from TAT is 
unreliable (the number of Lys per Glu is 4.8). However, using 2COP 2 (CK4H4C, 4 Lys and 4 
His) as a control produced the experimental result (the number of Lys per His is 1.0) as 
expected. Therefore, we presume that the calculation of amino acid ratio between Lys and His 
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is reliable. The glutamic acid analysis is not accurate and may result from the nonquantitative 
conversion of glutamine to glutamic acid. Therefore, in this study we only relied on the 
calculation between Lys and His.  Therefore, as can be seen in Table 5.3, based on the 
number of Lys per His from feed ratio, the calculated numbers of Lys per His from RcPC 2-5 
(~50 kDa) and RcPC 5 (22) indicated that they have 2COP:TAT ratio content  1:1, and  RcPC 
5 (23) has 2COP:TAT ratio content 1:3. We could not indicate the 2COP:TAT ratio content 
for RcPC 1 as the calculated number of Lys per Glu is unreliable. However, we presumed that 
it is 1:1.  
 
Table 5.3.  2COP and TAT sequence ratios of RcPCs 1-5 analyzed by amino acid analysis 
Calculated number of Lys per 
Glu or His based on feed ratio 
Calculated number of Lys per 
Glu/His from experimental data TAT/ 
2COP/RcPC 
Feed ratio 
of 
2COP:TAT 
Number of  
Lys per Glu 
Number of 
Lys per His 
Number of 
Lys per Glu a
Number of 
Lys per His 
2COP:TAT 
ratio 
contentb
TAT 
2COP 2 
RcPC 1 (37) 
RcPC 2 (52) 
RcPC 3 (45) 
RcPC 4 (39) 
RcPC 5 (45) 
RcPC 5 (22) 
RcPC 5 (23) 
0:1 
1:0 
1:1 
1:1 
1:1 
1:1 
1:1 
1:1 
1:3 
2 
- 
6 
6 
6 
6 
6 
6 
3.33 
- 
1 
1.5 
1.5 
1.5 
1.5 
1.5 
1.5 
2.5 
   4.8 ± 1.6 
- 
 17.2 ± 10.6 
 12.3 ±   0.1 
 10.1 ±   0.3 
 11.8 ±   1.2 
 14.9 ±   2.1 
 11.0 ±   0.2 
   5.3 ±   0.1 
- 
1.0 ± 0.1 
- 
1.3 ± 0.1 
1.3 ± 0.1 
1.3 ± 0.1 
1.3 ± 0.6 
1.4 ± 0.1 
2.4 ± 0.2 
- 
- 
1:1c
1:1 
1:1 
1:1 
1:1 
1:1 
1:3 
a The number of Lys per Glu from the experiments are unreliable as they are much higher than the expecting    
number base on feed ratio 
b  2COP:TAT ratio content of RcPCs indicated from the calculated number of Lys per His  
c  The 2COP:TAT ratio content of RcPC 1 is unable to indicate as the experimental number of Lys per Glu is  
unreliable, however, we presumed that it is 1:1. 
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5.4.4    Formation and characterization of TAT and RcPC polyplexes  
 
The polyplexes were prepared by mixing the plasmid DNA (pCMV-Luc) in HEPES buffer, 
pH 7.4, with the vectors RPCs 1-5 (~50kDa), TAT (40) or RcPC s 1-5 in HEPES buffer (pH 
7.4). The ratio of basic groups (lysine (K), imidazole (H) and arginine (R)) of the vectors to 
the negative phosphate group on the DNA backbone (N:P ratio) was calculated. 
5.4.4.1 Weight per charge and N:P ratio calculation 
 
The calculation of weight per charges (wpc) of 2COPs for polyplexes formation at appropriate 
N:P ratio was described previously in Chapter 3 (section 3.4.4.1). However, there is a 
difference in the weight per charge calculation of the RcPCs because there is a mixture of 
2COP and TAT sequences. Therefore, to calculate the wpc of RcPC s the ratio of 2COP and 
TAT sequence was considered. The calculation of wpc was calculated on the actual mass of 
the 2COP and TAT, taking into consideration the counterion associated with the protonation 
of the amino groups on the lysine, histidine and arginine residues at physiological pH.  In 
addition, during the synthesis, the 2COPs and TAT were deprotected in an acidic cocktail 
containing trifluoroacetic acid (TFA), which acts as the counterion forming a TFA salt. 
Therefore, the number of TFA counterions of 2COP 1-5 is 9, due to the TFA counterion 
forming a salt with the 4 ammonium ions of lysine residues and 4 imidazolium ions of 
histidine residues of the 2COP backbone and the protonated N-terminus of the oligopeptide. 
Moreover, the number of TFA counterions of TAT is 9, due to the TFA counterion forming a 
salt with the 9 ammonium ions of the lysine and arginine residues of the TAT backbone and 
the protonated N-terminus of the oligopeptide. Therefore, the number of TFA counterions of 
this polycation is 18. The following calculation was used to determine the wpc of all 
oligopeptides in this study. 
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wpc = 
pHcalphysiologiatupsginine)grostidine/ar(lysine/hibasicpotonatedofnumber
TFAofMWscounterionTFAofnumberpeptideofMW )()( ×+  
 
MW of TFA    = 114 g/mol 
TFA counterion   = CF3COO – 
 
For example, in the case of RcPC 1 (2COP 1 (CK8C):TAT (CRKKRRQRRRC) = 1:1), the 
pKa of lysine (K) and arginine (R) side chain are approximately 10.5 and 12.5, respectively. 
Therefore, the side chains of the lysine (pKa ~10.5) and arginine (pKa ~12.5) residues are fully 
protonated at physiological pH (pH 7.4). Thus, the number of positive amino groups of this 
RcPC 1 is 18. 
 
In the cases of RcPC s 2-5 (2COP 2-5:TAT = 1:1), the basic nitrogen atom on the imidazole 
rings of histidine residues are not fully protonated as shown in the pKa determination in 
Chapter 3 (Figure 3.4). Therefore, the number of protonated amino groups of the histidine 
based sequences was calculated from the average percentage of the chemical shift changing at 
pH 7.4 described in Chapter 3 (Figure 3.10). Weight per charge (wpc) of 2COPs 1-5 (Chapter 
3, section 3.3.4.1), TAT and RcPC 1-5 at 2COPs and TAT for ratios are 1:1 and 1:3 are 
shown in Table 5.4. 
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Table 5.4.  Weight per charge (wpc) of 2COPs, RP-TAT and RcPCs used in this chapter  
 
2COPs 2COP:TAT 
ratio 
 
Number of 
TFA 
counterions 
Number of 
positive 
charges 
at pH 7.4 
Peptide MW 
  (g mol-1) 
wpc 
 (g mol-1) 
2COP 1 
2COP 2 
2COP 3 
2COP 4 
2COP 5 
RP-TAT 
RcPC 1(2COP 1+TAT) 
RcPC 2 (2COP 2+TAT) 
RcPC 3(2COP 3+TAT) 
RcPC 4 (2COP 4+TAT) 
RcPC 5 (2COP 5+TAT) 
RcPC 5 (2COP 5+TAT) 
- 
- 
- 
- 
- 
- 
1:1 
1:1 
1:1 
1:1 
1:1 
1:3 
9 
9 
9 
9 
9 
9 
18 
18 
18 
18 
18 
36 
9 
5.7 
5.2 
5.4 
5.3 
9 
18 
14.7 
14.2 
14.4 
14.3 
32.3 
1249.9 
1285.9 
1285.7 
1285.7 
1285.8 
1545.4 
2793.3 
2829.3 
2829.1 
2829.1 
2829.2 
5916.0 
252.8 
405.6 
444.6 
428.1 
436.2 
285.7 
269.2 
332.1 
343.7 
339.0 
341.3 
310.2 
 
 
The wpc value is used to calculate the N:P ratio, which is the number of possible protonatable 
basic groups with respect to the negative phosphate groups on the backbone of the nucleic 
acid. The concentration of RPCs, RP-TAT or RcPCs calculated to form the polyplexes at final 
concentration of plasmid DNA at 20 µg/ml and at the N:P ratios used in this study is shown 
by the following equation.  
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Peptides conc. (µg ml-1) = wpcPN
groupphosphateperDNAofmassaverage
DNAplasmidofionconcentratFinal ×× :  
 
Final concentration of plasmid DNA              = 20 µg ml-1
Average mass of DNA per phosphate group  = 325 g mol-1 
wpc    = weight per charge 
 
5.4.4.2 TAT and RcPCs polyplex formation and characterization (Figure 5.2,   
step 4-7) 
 
5.4.4.2a  Diameter and zeta potential of polyplexes (Figure 5.2, Step 4-5) 
Polyplexes from RP-TAT, RPCs 1-5 and RcPCs 1-5 were formed with plasmid DNA 
(pCMV-Luc) as described in section 2.7.1 and 2.7.2 at N:P 5. The polyplexes were analysed 
by dynamic light scattering (section 2.8.1) and zeta potentiometry (section 2.8.2) (Table 5.5).  
 
As can be seen in Table 5.5, the diameter of the RP-TAT polyplex was 95.2 nm. The 
polyplex diameters from RcPCs 1-5 (~40-50 kDa), 2COP:TAT at 1:1 ratio, were in the range 
between 98.1-111.4 nm. Comparison of the diameter of RPCs 1-5 polyplexes and RcPC 1-5 
polyplexes reveals only marginal differences of at most ~10%, from the corresponding RPCs. 
Zeta potentials were positive in all cases and were similar for RPCs and RcPCs (Table 5.5), 
which will allow the polyplexes to promote the internalization via syndecan-mediated 
endocytosis[2] (Figure 1.22) by electrostatic interaction between the positively charged 
polyplexes and the negatively charged cell membrane. 
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Table 5.5. Properties of RP-TAT, RPCs, RcPCs and their polyplexes formed at N:P 5 
 
Polymer Polyplexes 
RP-TAT/ RPCs/  
RcPCs 
2COP : 
TAT ratio 
MW 
(kDa)a
Polydispersity 
indexb
Diameter 
(nm)c
Zeta potential 
(mV)d
RP-TAT (40) - 39.7 1.260      95.2  ±    0.3 
 
       14.4  ±    9.3 
RPC 1 (54) 
RcPC 1 (37) 
- 
1:1 
53.9 
36.8 
1.563 
 
1.275 
     99.9  ±    8.3     
 
    104.1 ±    1.4 
 
       16.8  ±  11.0 
          
       13.5  ±  10.0 
RPC 2 (60) 
RcPC 2 (52) 
- 
1:1 
60.8 
51.6 
1.339 
1.265 
     98.4  ±    0.7 
 
   111.4  ±    2.6 
       10.1  ±  14.0 
 
         8.8  ±    8.0 
RPC 3 (40) 
RcPC 3 (45) 
- 
1:1 
40.4 
44.7 
1.318 
1.169 
     94.7  ±    1.5 
       
   105.7  ±    3.7 
       15.5  ±  15.5 
         
       17.8  ±   12.8 
RPC 4 (48) 
RcPC 4 (39) 
- 
1:1 
48.5 
38.5 
1.279 
1.222 
   101.1  ±    2.2 
       
     98.1  ±   3.7 
         5.3  ±    5.7 
       
       10.3  ±     9.1 
RPC 5 (42) 
RcPC 5 (45) 
RcPC 5 (22) 
RcPC 5 (23) 
- 
1:1 
1:1 
1:3 
42.3 
45.1 
22.3 
23. 
1.292 
1.211 
1.168 
1.213 
     90.7  ±    3.4 
 
   108.1  ±    1.6 
 
 98.4   ±   0.9 
  
  110.3   ±   1.1 
       12.6  ±  12.3     
        
       11.6  ±   14.3 
 
       12.6  ±    8.4 
       
       12.9  ±  12.0 
a  Molecular weight of RP-TAT, RPCs and RcPCs were analyzed by GPC using CATSEC300 column compared 
to PLL standard. 
b  Polydispersity index (PDI) of RPCs was measured by size exclusion chromatography (Anachem Ltd., Luton,     
   UK) coupled with multi-angle laser light scattering photometer (Wyatt Technology (Santa Barbara, USA). 
c  Hydrodynamic diameters of the polyplexes were measured by dynamic light scattering with a Zetasizer 3000    
   (Malvern Instruments, Worcestershire, UK). 
d  Zetapotential was measured by with a  Zetamaster (Malvern Instruments, Worcestershire, UK).  
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5.4.4.2b  Extracellular stability studies of polyplexes (Figure 5.2, 
Step  6) 
The extracellular stability of the RP-TAT and RcPCs polyplexes was studied using the gel 
shift assay by incubating the polyplexes with polyaspartic acid (PAA) (Figure 5.6). PEI 
polyplexes at N:P 10 and PLL polyplexes at N:P 5 were used as a control. The results without 
PAA revealed that RP-TAT and all RcPCs were able to form stable polyplexes as shown by 
no loss of DNA in the gel electrophoresis assay (lanes a1-h1).  
 
However, the polyplexes formed with RP-TAT and all RcPCs were found to be unstable after 
incubating with PAA (lanes a2-h2) which is similar to PEI (lane i2) and PLL (lane j2), 
indicating that RP-TAT and RcPCs polyplexes are less stable than RPCs (Chapter 3, Figure 
3.22). Thus, to use RcPCs vectors may not be suitable in vivo as they may unpack and release 
the DNA by blood components before reaching the target cells.  
 
 
 
 
 
 
 
 
 
References for Chapter 5 are on page 244-246. 
 
236
a) 
 
b) 
 
Figure 5.6.   Gel shift assay with (a) and without (b) polyaspartic acid (PAA) of polyplexes formed from  
RP-TAT (N:P 5), RcPCs 1-5 (N:P 5), PEI (N:P 10) and PLL (N:P 5).  Polyaspartic acid at 
250 times of DNA concentration was mixed into the polyplex solution. Lanes a1-j1 on the top 
panel  (a) are for polyplexes without incubating with PAA. Lanes a2-j2 on the bottom panel (b) 
are for polyplexes incubated with PAA. Agarose gel electrophoresis was run using 1% agarose 
gel with EtBr (0.5 µg.ml) at 110 V for 60 mins in 0.5x TBE buffer 
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5.4.4.2c  Intracellular reduction studies of polyplexes (Figure 5.2,  
Step 7) 
Stability of the RP-TAT and RcPCs polyplexes against physiological concentrations of salt 
and GSH, was assessed by gel electrophoresis via treatment with (i) GSH alone (5 mM), 
(ii) salt alone (NaCl 0.15 and 0.5 M), and (iii) combination of NaCl (0.5 and 0.5 M) and 
GSH (5 mM) to assess polyplexes destabilisation (Figure 5.7). PLL polyplexes at N:P 5 
were used as  controls. These gel shift assays demonstrate that: 
 
    (a)   RP-TAT produced polyplexes that were stable in GSH alone, salt 
alone as can be seen from lanes b-d of RP-TAT. Importantly, however, addition of GSH 
(5mM) in the presence of salt destabilised the polyplexes, leading to release of the DNA 
(lanes e-f of RP-TAT). Thus, the combination of GSH under physiological salt 
concentrations was able to both cleave the polydisulfide bonds in the polyplexes leading to 
lower a molecular weight peptides that had a lower affinity for the DNA in the salt 
solution, leading to disassociation of the polyplexes. 
 
    (b)  RcPC 1 produced polyplexes that were both stable in GSH alone, 
salt alone and in the combination of GSH and salt (lanes b-f of RcPC 1). These results are 
probably due to the short oligopeptide 2COP 1 that probably results, after GSH treatment, 
binding strongly to DNA, and therefore does not release the DNA into the gel. This result 
is in contrast to RcPCs 2-5 (described below) presumably due to the lower charge on 2COP 
2-5, that results in weaker electrostatic bindng to the DNA, and hence it release. 
 
    (c)  RcPCs 2-5 produced polyplexes that were stable in GSH alone 
(5mM) as can be seen from lanes b of RcPCs 2-5. Furthermore, these RcPC polyplexes 
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were also stable in salt (0.15-0.5 M) (lanes c, d of RcPCs 2-5). Importantly, however, 
addition of GSH (5mM) in the presence of salt destabilised the polyplexes, leading to 
release of the DNA in all cases (lanes e, f of RcPCs 2-5). Therefore, these results probably 
indicate that the combination of GSH under physiological salt concentrations was able to 
both cleave the disulfide bonds in the polyplexes leading to lower a molecular weight 
peptides that had a lower affinity for the DNA in the salt solution, leading to disassociation 
of the polyplexes. 
 
    (d)  The lower molecular weight RcPC 5 (22) polyplex was stable in 
GSH alone and salt alone as can be seen in Figure 5.7. (lanes b-d of RcPC 5 (22)) which is 
similar to the high molecular weight RcPC 5 (45) polyplex (Figure 5.7, lane b-d of RcPC 
5 (45)). However, the polyplex produced from the lower molecular weight RcPC 5 (22) 
released more DNA than the polyplex with higher molecular weight (RcPC 5 (45)) when 
treated with GSH and NaCl in combination (lanes e, f of RcPC 5(45) and RcPC 5(22)). 
This suggests that the kinetics of release is more rapid, as would be expected, due to small 
fragments of the polycations dissociate more rapidly from the DNA. 
 
    (e) Polyplexes produced from RcPC 5 at different 2COP:TAT ratios 
(RcPC 5 (22, 1:1) and RcPC 5 (23, 1:3) indicated that there is no ratio effect of 2COP to 
TAT, as they are stable in GSH alone (lane b), salt alone (lanes c, d), and released the 
similar amout of DNA in the combination with GSH and salt (lanes e, f). 
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Figure 5.7.      DNA binding and release demonstrated by gel shift assays of RP-TAT and RcPC 
polyplexes. All polyplexes formed at N:P 5. Top panel: polyplexes of RP-TAT (40), RcPC 1 
(37) and RcPC 2 (52, 1:1) with pDNA; middle panel shows RcPC 3 (45, 1:1), RcPC 4 (39, 1:1) 
and RcPC 5 (45, 1:1); bottom panel shows RcPC 5(22, 1:1), RcPC 5(23, 1:3) compared against 
non-cleavable polypeptide poly(lysine). Agarose gel electrophoresis was run using 1% agarose 
gel with EtBr (0.5 µg.ml) at 110 V for 60 mins in 0.5x TBE buffer 
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5.5  Conclusions 
 
 
The work in Chapters 3 and 4 has shown that the reducible polycations (RPCs) are promising 
vectors for non-viral gene delivery. However, these vectors have no nuclear targeting signal. 
Therefore, the work in this chapter has highlighted a vector design that combines 5 vector 
features together (Table 1.4, page 38): the extracellular binding with DNA (I), cell uptake via 
endocytosis (III), endosomal escape (IV), intracellular degradability (V), and nuclear 
targeting (VI).  
 
5.5.1   TAT oligopeptide purification and characterization 
 
TAT oligopeptide (CRKKRRQRRRC) synthesized by Alta Bioscience (Birmingham, UK) 
was purified by the preparative reverse phase HPLC. All purified oligopeptides were analyzed 
by analytical RP-HPLC, ESI-MS and 1H NMR to obtain the purity and to characterize the 
oligopeptides. The purity of TAT oligopeptide is 98.73%. 
 
5.5.2  Formation and characterization of RP-TAT and RcPC  
 
2COPs 1-5 and TAT oligopeptide at 2COP:TAT molar ratio 1:1 were randomly oxidative 
polymerized to form reducible copolycations (RcPCs) via disulfide bond formation. The 
RcPC 1-5 molecular weights obtained are approximately 37-52 kDa with a 2COP:TAT ratio 
is 1:1. RP-TAT was synthesized, and the molecular weight is approximately 40 kDa. RcPC 5 
with 2COP:TAT is 1:1 at molecular weight approximately 22 kDa, and the RcPC 5 with 
2COP:TAT is 1:3 at molecular weight approximately 23 kDa were also synthesized in order 
to investigate the vectors as a function of RcPC molecular weight and 2COP:TAT ratio.  
References for Chapter 5 are on page 244-246. 
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5.5.3   Formation and characterization of RP-TAT and RcPC polyplexes 
 
Polyplexes were formed from RP-TAT and RcPCs 1-5 at N:P 5, and the resultant polyplex 
dispersion were analyzed by zeta potential and dynamic light scattering comparing to RPC 1-
5 from Chapter 3. 
 
  5.5.3.1  Diameter and zeta potential of RP-TAT and RcPC polyplexes 
 
The polyplex diameters of RP-TAT, RcPCs 1-5 (~50 kDa) prepared from 2COP:TAT at 1:1 
ratio and RcPC 5 at ~22 kDa with 2COP:TAT ratios are 1:1 and 1:3 were approximately 100 
nm.  
 
Zeta potentials were positive in all cases, which will allow the polyplexes to promote the 
internalization via syndecan-mediated endocytosis (Figure 1.22) by electrostatic interaction 
between the positively charged polyplexes and the negatively charged cell membrane. 
 
  5.5.3.2  Extracellular stability of RP-TAT and RcPC polyplexes 
 
The extracellular stability of the RP-TAT and RcPCs polyplexes was studied using the gel 
shift assay by incubating the polyplexes with polyaspartic acid (PAA). The results without 
PAA revealed that RP-TAT and all RcPCs were able to form stable polyplexes. However, 
they were unstable with PAA, indicating that RP-TAT and RcPCs polyplexes are less stable 
than RPCs. Thus, to use RcPCs as vectors may not be suitable in vivo as they would unpack 
and release the DNA by blood component before reaching the target cells.  
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  5.5.3.3  Intracellular reduction of RP-TAT and RcPC polyplexes 
 
In addition, GSH was used as a biological intracellular reducing agent, since GSH is present 
in the cytoplasm (the stability under physiological salt concentrations was studied). The 
polyplexes from RP-TAT and RcPCs 2-5 were stable in GSH alone (5mM) and salt solution 
alone (0.15 and 0.5M). However, in combination with GSH (5mM) and salt (0.15 and 0.5M), 
these polyplexes released DNA. However, the polyplex formed from RcPC 1 did not release 
DNA. These results suggested that RP-TAT and RcPCs 2-5 polyplexes are able to facilitate 
intracellular reduction resulting in DNA releasing for further gene expression mechanisms. 
Whereas, RcPC 1 although probably does undergo the disulfide bonds cleavage the high net 
charge on the 2COP 1 that results is still bound to the DNA by strong electrostatic interaction. 
 
Polyplexes produced from lower molecular weight RcPC (RcPC 5 (22)) released more 
DNA than polyplex with higher molecular weight (RcPC 5 (45)) in the combination with 
GSH and NaCl. This result is indicative of the fact that the kinetics of release will be 
quicker with RcPC 5(22), because shorter fragments of polycations will dissociate more 
rapidly from the DNA. 
 
Polyplexes produced from RcPC at different 2COP:TAT ratios ((RcPC 5 (22, 1:1) and 
RcPC 5 (23, 1:3)) indicated that there is no affect of the ratio of 2COP and TAT sequences, 
as they are stable in GSH alone, salt alone, and  released the similar amout of DNA in 
combination with GSH and salt. 
 
In summary, in comparisons between RPCs and RcPCs charateristics by DLS, zeta 
potential and gel shift assay, it might be expected that RcPCs will be less effective vectors 
References for Chapter 5 are on page 244-246. 
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than RPCs, because their polyplexes can be dissociated by PAA. However, the transfection 
efficiencies of RcPCs will be studied in Chapter 6 to compare with RPCs.  
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6  DELIVERY OF NUCLEIC ACID USING REDUCIBLE 
COPOLYCATION (RcPC) CONTAINING LYSINE, 
HISTIDINE AND CYSTEINE BASED SEQUENCES AND 
TAT PEPTIDE 
Abstract 
As shown in Chapter 5 the RcPCs were synthesized via randomly oxidative 
polymerisation in combination of 2COPs and TAT oligopeptides. The RcPC 
polyplexes were characterised and it was revealed that they seemed to be 
suitable vectors for gene delivery in non-viral system as a result of their 
diameters and surface charges and the reducible nature by GSH and NaCl. 
However, they were unstable under simulated extracellular conditions (with 
PAA). In this chapter the transfection efficiencies of RcPC polyplexes were 
investigated and it was revealed that CQ was required to enhance the 
transfection of the RcPCs. In addition, using the lower molecular weight 
RcPCs (22 kDa) showed higher transfection level than higher molecular 
weight RcPCs (45 kDa) as with RPCs. The different ratio of 2COP and TAT 
peptides in RcPCs (1:1 and 1:3) did not affect the transfection levels. 
Furthermore, there is no improvement in transfection of RcPC compared to 
RPCs. Therefore, it may suggest that incorporation of nuclear localization 
signal (TAT) in this study does not improve the transfection.  
 
 
6.1    Introduction 
 
Non-viral vectors are limited for transfection in vivo as they inefficiently transfer DNA into 
nucleus.[1-3] In order to improve nuclear entry of non-viral vectors, there are many strategies 
to couple of NLS peptide to DNA that have been developed. [4-13]  For example, Ciolina and 
colleagues[10] developed a chemical strategy for the covalent coupling of NLS peptides 
(ACGAGPKKKRKV) of  SV40 large T antigen  to plasmid DNA. A p-azido-tetrafluoro-
benzyl-NLS peptide conjugate (Figure 6.1) was synthesized and was used to covalently 
associate NLS peptides to plasmid DNA by photoactivation.  
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Figure 6.1.  p-azido-tetrafluoro-benzyl-NLS peptide conjugate[10] 
 
Zanta and colleagues[5] synthesized capped 3.3-kbp CMVLuciferase-NLS containing a signal 
nuclear localization signal peptide from SV40 (PKKKRKVEDPY) (Figure 6.2). PEI or 
transfectam were used to form polyplexes with CMVLuciferase-NLS. The results revealed 
that only a single NLS peptide per strand of DNA was required to improve the transfection 
efficiencies (10-1000 fold) relative to the polyplexes without NLS.  
References for Chapter 6 are on page 277-279. 
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 Figure 6.2.  Strategy for preparation of CMVLuc-NLS [5]  
 
However, van der Aa and colleagues[6] revealed that covalently linked NLS peptide linked to 
linear DNA did not enhance transfection.  
 
Neves and colleagues[11] developed a strategy for covalent coupling of NLS peptides to 
plasmid DNA at a specific site by triple helix formation. A psoralen, a nucleic acid 
intercalating agent, was used to conjugate with NLS-peptide. A psoralen-oligonucleotide-NLS 
peptide conjugate was synthesized (Figure 6.3) and was used to covalently associate one NLS 
peptide to plasmid DNA by triple helix formation and photoactivation. This conjugate 
References for Chapter 6 are on page 277-279. 
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interacted with the α-importin which is the NLS receptor. The transfection of the plasmid 
DNA coupled with this conjugate indicated that there is no loss of the gene expression 
functionality of the plasmid. The researchers suggested that this site-specific coupling 
technology can be used to couple to a plasmid other ligands targeting to a specific receptor. 
 
O
O
O
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O
O
O
N
S
N
O
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O
O
O
O
5'-oligonucleotide-3'
 
 
Figure 6.3.  psoralen-oligonucleotide-NLS peptide conjugate[11] 
 
The NLS (GGGPKKKRKV) was also chemically attached to psoralen – a nucleic acid-
intercalating agent (Figure 6.4)[4] in order that the conjugate intercalated into the double 
strand DNA. PEI was then used to form the polyplexes with the DNA intercalated with 
psoralen-NLS resulting in enhancement of transfection by ~10 fold relative to PEI/DNA 
polyplex alone.  
References for Chapter 6 are on page 277-279. 
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Figure 6.4.  Schematic conjugation of succinimidyl-[4-(psoralen-8-yloxy)]-butylrate (SPB) to NLS [4] 
 
The condensation between TAT oligomers (C(YGRKKRRQRRRG)2)[7] or TAT polymer 
(CQRKKRRQRRRGC)n, ~100 kDa)[8]  and DNA enhanced transfection activity of DNA 
polyplexes and reduced cytotoxicity. However, they required chloroquine in order for the 
endosomal vesicles to burst.  
 
The reducible copolypeptides[9] containing histidine-rich peptides (CKHHHKHHHKC) and 
nuclear localization signal peptides (CGAGPKKKRKVC) from SV40 were used as vectors in 
order to combine the endosomal buffering capacity and nuclear localization capability 
features. The transfection efficiency of the reducible copolypeptides increased when increased 
the content of histidine-rich peptide. However, it was still unclear as to the effect of the NLS 
sequence in the transfection. 
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6.2    Objectives 
 
We have shown that the RPCs (see chapters 3 and 4) that consist of lysine, histidine and 
cysteine moieties are promising non-viral vectors. However, the vector transfection efficiency 
may be improved by incorporating the NLS peptide in order to promote DNA nuclear 
transport. In this chapter the cytotoxicity and transfection efficiency of RcPCs are investigated 
in order to compare with RPCs and see if there is an improvement in the transfection by 
incorporation with TAT peptide.  
 
6.3     Methodology 
 
The cell transfection of the RP-TAT and RcPCs polyplexes prepared at N:P 5 (Figure 6.5, 
step 1) were carried out based on four experiments (Figure 6.5, step 2) which are similar to 
the transfection experiments of RPCs in Chapter 4 (section 4.3). 
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 Exp 1)   Cytotoxicity (MTS assay) 
Exp 2)   Transfection based on endosomolytic property (CQ) 
Exp 3)   Transfection based on intracellular reducible property  
              (GSH-MEE, BSO) 
Exp 4)   Transfection based on combination of 2) & 3) (CQ, GSH) 
Step 2 
Cell transfections (bEND3 and A549)
Step 1  
(Figure 5.2, step 4) 
DNA polyplex formation 
(N:P 5) 
DNA 
Polyplex
S 
S-S 
S ( )n S 
S-S 
S ( )n
Reducible copolycations (RcPCs) RP-TAT  
or 
TAT  TAT  TAT  2COP 
Figure 6.5. Schematic overview of cell transfection in this chapter 
    
   Exp 1.  Investigating the cytotoxicity of RP-TAT and RcPCs polyplexes: 
The cytotoxicity was investigated using the MTS assay. 
 
Exp 2.  Investigating the endosomolytic buffering: The transfection of 
RP-TAT and RcPCs based on the endosomal buffering and endosomal escape was 
investigated. The transfections of polyplexes with and without CQ were investigated. 
Chloroquine (CQ) was added into cell lines for its ability to buffer the endosome. 
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   Exp 3. Investigating the intracellular reducible property: The 
intracellular cleavage of the disulfide bonds in the RP-TAT and RcPCs polyplexes by GSH 
was studied as a function of transfection. Intracellular GSH level were boosted by adding 
glutathione monoethy ester (GSH-MEE), which is cell permeable and is hydrolyzed to GSH 
intracellularly.[14] In addition, experiment using buthionine sulfoximine (BSO), which inhibits 
the synthesis of the intracellular GSH, was studied as a function of transfection. 
 
   Exp 4. Investigating the endosomolytic buffering and intracellular 
reducible properties: The transfections of polyplexes with CQ, GSH, and CQ+GSH and 
polyplexes alone were investigated. 
    
6.4   Results and discussion 
 
6.4.1  Cytotoxicity of polyplexes (Figure 6.5, step 2, Exp1) 
 
  6.4.1.1 Cytotoxicity of RP-TAT and RcPCs polyplexes 
 
The cytotoxicity of RP-TAT and RcPCs polyplexes based on the effect of CQ, GSH-MEE and 
the combination of CQ and GSH-MEE was investigated using MTS assay. All experiments 
were performed as with RPCs in Chapter 4 (Figure 4.3). The cytotoxicity of RP-TAT and 
RcPC 1-5 in comparison with RPCs 1-5 are shown in Figure 6.6. 
 
As can be seen in Figure 6.6 the data demonstrated that RP-TAT and RcPCs were tolerated 
well by both cell lines in all cases (over 100% cell viability in most cases), and the percentage 
References for Chapter 6 are on page 277-279. 
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of cell viability of cell treated with RcPCs are higher than RPCs in all cases. However, RPCs 
1-5 are less toxic than PEI and PLL in both cells. 
 
In addition, there is toxicity to cells treated with CQ and RPC polyplexes (black bars) and 
CQ+GSH-MEE and polyplexes (yellow bars) relative to cells treated with RPC polyplexes 
alone (blue bars) in most cases. However, there is none or low toxicity to cells treated with 
these additives (CQ, GSH-MEE and CQ+GSH-MEE) and RcPC polyplexes in bEND3. 
However, there is only slight toxicity to cells treated with CQ+GSH-MEE and RcPC 
polyplexes in A549.   
 
The overall cytotoxicity data indicated that RP-TAT (108-140% cell viability) and RcPCs 1-5 
(~86-145% cell viability) are less toxic to both cell lines and are better than PLL (79% cell 
viability) and PEI (69-89% cell viability) polyplexes.  
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Transfection in A549
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Figure 6.6.     Cell viability following exposure to RPC 1-5 , RP-TAT and RcPC 1-5 polyplexes at N:P 5, 
PLL polyplex at N:P 5, PEI polyplex at N:P 10 and cell controls; (a): cell viability of 
transfected cells in bEND3, (b): cell viability of transfected cells in A549. Note: The percentage 
of cell viability shown in this diagramed derived from the average cell viability (%) of cells 
treated with polyplex alone and in the combination of polyplexes and CQ, GSH-MEE and 
CQ+GSH-MEE in each cases 
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6.4.1.2 Cytotoxicity of RcPCs polyplexes as a function of RcPC molecular  
weight and 2COP:TAT ratio 
  
6.4.1.2a Cytotoxicity of RcPCs polyplexes as a function of RcPC 
molecular weight 
As can be seen in Figure 6.7 there is no toxicity to cells of RcPC 5 of different molecular 
weights (45 and 22 kDa) for both bEND3 (Figure 6.7a) and A549 (Figure 6.7b) cells as the 
cell viabilities are over 100% and are better than PLL (78-81% cell viability) and PEI (77-
78% cell viability) polyplexes. 
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Figure 6.7.      Cell viability of cells transfected with RcPC 5 (45 and 22 kDa with 2COP 5:TAT ratio 1:1), 
RcPC 5 (23 kDa with 2COP 5:TAT ratio 1:3) at N:P 5, PLL polyplex at N:P 5, PEI polyplex 
at N:P 10 and cell controls; (a): cell viability of transfected cells in bEND3, (b): cell viability of 
transfected cells in A549. Note: The percentage of cell viability shown in this diagramed derived 
from the average cell viability (%) of cells treated with polyplex alone and in the combination of 
polyplexes and CQ, GSH-MEE and CQ+GSH-MEE in each cases 
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6.4.1.2b Cytotoxicity of RcPCs polyplexes as a function of 2COP:TAT 
ratio 
As can be seen in Figure 6.7 there is no toxicity to cells of RcPC 5 (22 and 23 kDa) in 
different 2COP:TAT ratios (1:1 and 1:3) for both bEND3 (Figure 6.7a) and A549 (Figure 
6.7b) cells as the cell viabilities are over 100% and are better than PLL and PEI polyplexes. 
 
 
6.4.2  Cell transfection of polyplexes (Figure 6.5, step 2, Exp 2-4) 
 
The transfection efficiencies of RP-TAT and RcPCs polyplexes based on endosomolytic 
buffering and intracellular reduction in both cell lines were investigated. All transfection 
experiments were performed as outlined in Chapter 4 (Figure 4.3). The transfection 
efficiencies of RP-TAT and RcPC 1-5 based on the effect of CQ, BSO, GSH-MEE and the 
combination of CQ and GSH-MEE are shown in Figure 6.8. 
 
The first point to note is that the overall transfection efficiency of RP-TAT is similar to 
RcPCs 2-5 in both cells (Figure 6.8). However, RP-TAT polyplexes seemed to induce higher 
transfection efficiency than RcPCs 1-5 in the transfection with polyplexes alone (blue bars). 
RcPC 1 showed the least transfection efficiency relative to other RcPCs polyplexes. 
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Figure 6.8.    Transfection based on CQ, GSH-MEE and BSO with RP-TAT, RcPC polyplexes 1-5 (~50 
kDa) at N:P 5,  PLL polyplex at N:P 5, PEI polyplex at N:P 10 and cell control; a) 
transfection into bEND3 and b) transfection into A549 
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7    CONCLUSIONS  
Abstract  
 
This chapter gives an overview of the conclusions of the experimental results 
presented in this thesis. Also the limitations to our research and potential 
future work to improve the RPC base vectors are described. 
 
 
 
7.1 Conclusions 
 
 
In this thesis we have synthesized and characterised synthetic vectors by combining lysine, 
histidine and cysteine residues (described in Chapter 1, page 44) to provide the key features to 
hopefully achieve efficient gene delivery. These vectors are designed to bind DNA 
extracellularly (I), achieve cell uptake via endocytosis (III), provide a tunable endosomal 
release mechanism (IV), provide a degradable backbone in order that the DNA can be 
released once in the cytoplasm (V), and provide a nuclear localization signal (VI).  
 
The summary results of the physiological and biological properties of vectors studied in this 
thesis are shown in Table 7.1 and the associated text below. 
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Table 7.1.  Summary of physicological and biological properties  
a   Hydrodynamic diameters of the polyplexes (N:P 5) measured by dynamic light scattering with a Zetasizer 3000 (Malvern Instruments, Worcestershire, UK) 
b   Zetapotential measured by with a  Zetamaster (Malvern Instruments, Worcestershire, UK) 
c   DNA released investigated by agarose gel electrophoresis 
d The percentage of cell viability derived from the average cell viability (%) of cells treated with polyplex alone and in the combination of polyplexes and CQ, GSH-MEE and 
CQ+GSH-MEE in each cases 
e   Normalized transfection efficiency of polyplexes to PLL polyplex = transfection level of polyplex/transfection level of PLL polyplex 
f   Relative transfection enhancement by chloroquine (%) = (transfection level of polyplex with CQ/transfection level of polyplex only)*100 
DNA released from 
polyplexc
Cell viability (%)d
 
Normalized transfection 
efficiency of polyplexes to PLL 
polyplexe
Relative  transfection  
enhancement by CQ (%)f
Vectors MW (kDa) Oligopeptides 
pKa of  
2COPs 
Polyplex 
diameter  
(nm)a  
Polyplex 
zetapotential 
(mV)b  
PAA  GSH+NaCl bEND3 A549 bEND3 A549 bEND3 A549 
PLL 
PEI 
70 
25 
- 
- 
- 
- 
  81.0  ±  0.9 
108.7  ±  8.6 
  11.3  ±     9.0 
   3.4   ±     0.2 
√ 
√ 
X 
- 
79 
83 
80 
81 
1.0 
147.0         
        1.0 
    1349.4 
1049 
1268 
161 
271 
RPC 1 (111) 
RPC 2 (118) 
RPC 3 (115) 
RPC 4 (102) 
RPC 5 (94) 
111 
118 
115 
102 
94 
2COP 1 
2COP 2 
2COP 3 
2COP 4 
2COP 5 
10.51 
  6.20 
  6.16 
  6.11 
  6.09 
132.1  ±  4.5 
  98.3  ±  0.6 
  99.8  ±  0.9 
101.1  ±  2.8 
  95.5  ±  1.1 
  10.0  ±  10.9 
  14.3  ±    9.7 
  13.5  ±    7.2 
    5.8  ±    3.6 
  17.4  ±  11.3 
X 
X 
X 
X 
X 
X 
√ 
√ 
√ 
√ 
104 
102 
104 
105 
101 
88 
97 
108 
96 
104 
78.0 
1343.8 
497.9 
431.6 
1204.9 
          0.3 
406.7 
378.4 
32.4 
21.0 
1296 
2492 
2526 
3316 
1381 
257547 
722 
129 
611 
717 
RPC 1 (54) 
RPC 2 (60) 
RPC 3 (40) 
RPC 4 (48) 
RPC 5 (42) 
54 
60 
40 
48 
42 
2COP 1 
2COP 2 
2COP 3 
2COP 4 
2COP 5 
10.51 
  6.20 
  6.16 
  6.11 
  6.09 
  99.9  ±  8.3 
  98.4  ±  0.7 
  94.7  ±  1.5 
101.1  ±  2.2 
  90.7  ±  3.4 
  16.8  ±  11.0 
  10.1  ±  14.0 
  15.5  ±  15.5 
    5.3  ±    5.7 
  12.6  ±  12.3     
X 
X 
X 
X 
X 
X 
√ 
√ 
√ 
√ 
110 
93 
86 
79 
89 
95 
97 
98 
101 
96 
80.6 
6892.5 
5648.7 
1633.4 
4499.3 
5.9 
2434.6 
1519.3 
166.5 
146.5 
836 
186 
130 
32 
283 
12143 
806 
418 
22 
972 
17722 
13242 
2587 
6117 
220532 
2127 
1615 
360 
29 
28 
112 
178 
31 
2055 
4889 
RcPC 1 
RcPC 2 
RcPC 3 
RcPC 4 
RcPC 5  
RcPC 5 
RcPC 5 
RP-TAT 
37 
52 
45 
39 
45 
22 
23 
40 
2COP 1:TAT (1:1) 
2COP 2:TAT (1:1) 
2COP 3:TAT (1:1) 
2COP 4:TAT (1:1) 
2COP 5:TAT (1:1)  
2COP 5:TAT (1:1)  
2COP 5:TAT (1:3)  
TAT 
10.51 
  6.20 
  6.16 
  6.11 
  6.09 
  6.09 
  6.09 
- 
104.1 ±  1.4 
111.4  ±  2.6 
105.7  ±  3.7 
  98.1  ±  3.7 
108.1  ±  1.6     
  98.4  ±  0.9 
110.3  ±  1.1 
 95.2 ±  0.3 
  13.5  ±  10.0 
    8.8  ±    8.0 
  17.8  ±  12.8 
  10.3  ±    9.1 
  11.6  ±  14.3 
  12.6  ±    8.4 
  12.9  ±  12.0 
  14.4  ±    9.3 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
X 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
124 
129 
110 
93 
86 
136 
134 
140 
124 
129 
138 
145 
107 
103 
100 
108 
16.6 
252.6 
1390.0 
14177.4 
12717.5 
2715.4 
2593.8 
21574.6 
11.5 
335.8 
173.1 
107.9 
4.1 
40.1 
36.7 
760.8 1960 
7.1.1 pKa modulation of 2COPs 
 
We have shown that using the new strategy of increasing the mixing of the constitution of the 
histidine residues in the lysine residues we were able to modulate the pKa of 2COPs 1-5 from 
10.51-6.09 (Table 7.1, pKa of 2COPs) because of the charge repulsion of subphase protons 
by its proximity to the protonated lysine residues. The modulation of the pKa of 2COPs 2-5 
(pKa 6.20-6.09) will provide a way to modulate the buffering capacity in the early endosome 
(pH ~6) leading to endosomal disruption, before it develops into the late endosome where 
polyplexes would be degraded (vector feature IV) as described in the hypothesis (Chapter 1, 
page 48).  
 
7.1.2 Diameter and zetapotential of polyplexes 
 
Regarding to the hypothesis in Chapter 1 (page 51), the incorporation of lysine into synthetic 
vectors provides the strong binding of the vector to DNA via electrostatic interactions (Vector 
feature I). The RPCs and RcPCs in this thesis have lysine residues incorporated and not only 
bind strongly to the DNA, but also form polyplexes of ~100 nm (Table 7.1, polyplex 
diameter). 
 
In addition, incorporation of lysine residues into the synthetic vectors resulted in positively 
charged polyplexes (Table 7.1, polyplex zetapotential), which further enabled them to 
electrostatically interact with the negatively charged cell membrane and promote the 
internalization into cells via syndecan-mediated endocytosis[1,2] (vector feature III) as 
described in the hypothesis in Chapter 1 (page 51).  
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7.1.3 Extracellular stability of polyplexes 
 
PLL polyplexes are less stable than RPC 1 when exposed to PAA (Table 7.1, PAA). This 
result indicates RPC 1 binds more strongly to DNA than PLL. We hypothesized that PLL has 
a higher persistent length (Figure 7.1a) than RPC 1 (Figure 7.1b). This reduction in 
persistence length of RPC 1 is a result of the reduction in charge repulsion of the protonated 
lysine groups either side of the reducible disulfide bond from the cysteines, allow the s-s bond 
to act as a molecular hinge. 
 
a) PLL (K20) electrostratic 
repulsion 
 
 
 
 
b) RPC 1 (CK8C)2
electrostratic 
repulsion 
 less electrostratic 
repulsion 
S-S bond acts like 
a molecular hinge 
“+” ‘s Not in plane 
 
 
 
 
 
 
 
 
Figure 7.1.  Disulfide bond backbone in RPC resulting in polymer chain bending compared to PLL (K20) 
with more rigid structure: a) PLL (K20) and b) RPC 1 (CK8C)2
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RPCs 2-5 have inherently more extracellular stability than other polyplexes as they did not 
release the DNA when exposed to PAA (Table 7.1, PAA). This result was a surprise as there 
were only 50% of the fully protonated lysine residues compared to RPC 1, thus, the 
electrostatic interaction would be much weaker. However, continuing the argument around 
persistence length and better compaction of RPC 1 polyplexes, one can envisage that RPCs 2-
5 have even shorter persistent lengths than RPC 1, and hence compact better with DNA, and 
are therefore more stable. This result suggested that polyplexes formed from RPCs 2-5 are 
more stable extracellularly than PLL and RPC 1 polyplexes and, therefore, would be able to 
reach the target cells after blood stream circulation (vector feature I). 
 
7.1.4 Intracellular reduction and toxicity of polyplexes 
 
As described previously in the hypothesis (Chapter 1, page 51), the disulfide backbone in 
RPCs and RcPCs provides the point of cleavage of the reducible polycations by intracellular 
GSH leading to the DNA release in the cytoplasm (vector feature V). The gel shift assay of 
RPCs 2-5 and RcPCs 2-5 polyplexes with GSH in combination with salt revealed that they are 
able to be reduced and release the DNA intracellularly (Table 7.1, GSH+NaCl). However, 
treatment of polyplexes with GSH revealed no release of DNA with RPC 1 and RcPC 1, in 
contrast to RPCs 2-5 and RcPCs 2-5. Presumably, all polyplexes are undergoing disulfide 
bond cleavage, but the enhanced positive charge of 2COP 1 (twice as many lysine residues in 
RPC 1 compared to RPCs 2-5) means the short oligopeptide fragments (2COP 1) remain 
bound to the DNA, unlike 2COPs 2-5. 
 
In addition, all of the intracellular reducible vector systems studied here are less toxic to both 
cell types than the non-degradable polymers (PLL and PEI). Presumably, the RPCs and 
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RcPCs degrade to readily cleared fragments (2COPs) compared to the high molecular weight 
PLL and PEI (Table 7.1, cell viability).  
 
7.1.5 Transfection efficiency of polyplexes 
 
7.1.5.1  Transfection in endothelial (bEND3) and epithelial (A549) cells 
 
bEND3 cells have higher transfection levels than A549 cells (Table 7.1, relative transfection 
efficiency of polyplexes to PLL polyplex). The difference observed between transfection 
efficiencies in bEND3 (mouse brain endothelial cells) and A549 (human lung carcinoma 
epithelial cells) is most likely due to the different rate of cell growth in vitro, as endothelial 
cells grow faster. Change in growth rates would have affected the level of intracellular 
glutathione and the protein expression as described in Chapter 4 (in the transfection results 
with GSH-MEE/BSO). Concomitant degradation of the nuclear membrane would, therefore, 
have led to the release of high level of glutathione into the cytoplasm leading to more efficient 
release of DNA from the polyplexes to the cytoplasm resulting in higher transfection levels 
than in A549, and may result in the different trends of the transfection between bEND3 and 
A549.  
 
The higher transfection rates of the endothelium (bEND3) cells might be a contra-indication 
to support the administration of the RPC polyplexes via intravenous injection if one was 
trying to treat a tumor, as the polyplexes would be internalized by blood vessels before 
reaching the tumor. 
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7.1.5.2 Transfection efficiency of RPC and RcPC  polyplexes  
 
In Table 7.1 we have normalized the transfection data by dividing the PLL polyplex 
transfection level into all the other polyplex transfection levels. Several conclusions can be 
drawn from this if we consider the bEND3 cells and A549 cells both independently and then 
together. 
  
bEND3 cells : 
  
(i)        PLL polyplexes are the worst transfection agents. 
(ii)       RPC 1 (111) and RPC 1 (54) have increased transfection levels over PLL (80.6 
and 16.6 fold increase, respectively).  Therefore, the incorporation of the disulfide bond has 
significantly increased the transfection efficiency. 
(iii)     The histidine containing RPCs (2-5), both high and low molecular weight, have 
increased transfection efficiency over RPC 1, ranging from 431.6 (RPC 4) to 1343.8 (RPC 2) 
for the high molecular weight materials. All of the lower molecular weight materials have 
even better transfection.  Therefore, the incorporation of histidine moieties enhances the 
transfection above and beyond the introduction of the disulfide bonds. 
 (iv)     The lower molecular weight RPCs 2-5 have higher transfection levels than 
the higher molecular weight RPCs 2-5.  Therefore, molecular weight is key determinant in 
transfection levels. We have also shown that the diameters, surface charges and gel shift 
assays of polyplexes from low molecular weight RPCs 2-5 (~50 kDa) were similar to high 
molecular weight RPCs 2-5 (~100 kDa), but had enhanced release of DNA when treated 
with GSH. This result is indicative of the fact that the kinetics of DNA release is quicker 
with low molecular weight RPCs, presumably because shorter fragments of polycations 
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will dissociate more rapidly from the DNA. Therefore, the low molecular weight RPCs 
might induce higher transfection level than high molecular weight RPCs, and indeed this 
was the case. 
(v) Incorporation of TAT (RcPCs 4-5) significantly enhances the transfection of 
the polyplexes, whilst it is variable for RcPCs 2-3.  Thus, TAT potentially has an effect in 
endothelial cells (which is in contrast to A549 epithelial cells). 
(vi) The cell transfections with RcPC 5 polyplexes at different 2COP:TAT ratios 
(1:1 and 1:3) revealed that  the amount of nuclear localization signal (TAT) incorporated in 
the RcPCs does not affect the transfection level as similar transfection levels were determined  
(RcPC 5 (22 (1:1), 23 (1:3)). This result may be due to the RcPC polyplexes upon 
intracellular GSH reduction leading to the DNA dissociating totally from the TAT fragments, 
and therefore no translocation and internalization of the DNA to the nucleus. Therefore, there 
is no improvement in addition of TAT sequence relative to the transfection with RPC 
polyplexes.  
 
A549 cells : 
  
Similar conclusions with respect to the introduction of the disulfide bond, histidine and 
molecular weight can be drawn for A549 as were for bEND3 cells.  However, for RcPC 
polyplexes the transfection levels were lower or about the same for RPCs 2-5.  Therefore, it 
appears that the type of cell – endothelial or epithelial – has a significant effect on the 
transfection levels.  
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7.1.5.3 Relative transfection enhancement by CQ of RPC and RcPC  polyplexes 
 
In Table 7.1 the relative transfection enhancement of polyplexes by CQ are shown. Several 
conclusions can be drawn. 
 
(i)  We were expecting that the transfection levels of RPCs 2-5 would be less 
enhanced by CQ than RPC 1 because of the buffering capacity by histidine residues. 
However, the transfection levels of RPC 2-5 (~100 kDa) in bEND 3 enhanced by CQ were 
about the same or even higher than RPC 1, which are anomalous. These results in bEND 3 are 
in contrast to RPC 1-5 (~100 kDa) in A549, as the transfection levels were less enhanced by 
CQ when incorporation of histidines (RPCs 2-5) compared to RPC 1. Therefore, once again, 
it appears that the type of cell – endothelial or epithelial – has a significant effect on the 
transfection levels.  
 (ii) The lower molecular weight RPCs 1-5 (~50 kDa) have less enhancement by 
CQ than the higher molecular weight RPCs 1-5 (~100 kDa) in both cells. Therefore, the lower 
molecular weight RPCs used in this thesis are better transfection agents than higher molecular 
weight RPCs. 
 (iii) CQ was required to enhance the transfection levels of RcPCs 1-3 compared to 
RPC 1-3 (~50 kDa) in bEND3. However, CQ did not affect the transfection of RcPC 4-5. 
Also these results are in contrast to the transfection in A549, in which all of the RcPCs 2-5 
required CQ to give better transfection levels than corresponding RPCs. Presumably, this is 
because the buffering capacity (proton sponge mechanism) is lower in the RcPCs. 
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7.1.6  2COPs conclusion 
 
DNA polyplexes formed from 2COPs 1-5 at N:P 5 (Chapter 3) formed large particles  (1µm ) 
over a time course of 48 hr (Chapter 3, Table 3.7). In general, particle diameters less than 
1µm survive longer in the bloodstream than the larger particle if there are no interactions with 
blood components or macrophages.[4] Therefore, these polyplexes were not suitable for further 
cell transfection. As predicted the oligopeptides 2COP polyplexes were poor transfection 
agents relative to the RPCs (Chapter 4, Figure 4.16). 
 
7.1.7 Cross-linked RPC conclusions 
 
The oxidative polymerization to form cross-linked RPCs was also studied by oxidatively 
polymerising 2COPs 1-5 and 3COP 7 at 4% and 32% mole fraction of 3COP 7 (Chapter 3, 
section 3.4.5). The results showed termination in the growth of cross-linked RPCs producing 
low molecular weight polymers in all cases. The higher the mole fraction of 3COP used, the 
lower the polymer molecular weight produced. We believe the 3COP leads to the termination 
of the cross-linked RPCs during the reaction.  
 
7.2   Limitations and future work 
 
7.2.1    Improve cell targeting 
 
In our primary vector design the cell targeting ligand was not attached to the vector. 
Therefore, theses non-targeting vectors can not be used effectively in transfection in vivo. To 
improve this vector feature the targeting ligands have to be attached to the vectors as 
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described in Chapter 1 (Section 1.1.2.1b). The targeting ligands that have been widely used 
are transferrin, which specifically targets transferrin receptors that are overexpressed in 
rapidly dividing tissues, such as tumors,[5-13]  and folic acid that specifically target folate 
receptors, which are also overexpressed in proliferating tissues.[13-15] In addition, various 
sacharide ligands such as galactose, manose, fucose, lactose as well as asialoorosomucoid and 
asialoglycoprotein are specifically targeting asialoglycoprotein receptors, which are 
abundantly expressed in hepatocytes.[12,13,16]   
 
In addition, using endothelium (bEND3) and epithelium cell lines (A549) in the in vitro 
transfection studies indicated that the in vivo injection of RPC polyplexes in blood vessel 
would not be a suitable method for delivering genes, as the polyplexes entered into the 
endothelial cells. Therefore, to improve the transfection at the target sites, the administration 
methods have to be considered such as direct injection[17,18] and electroporation[19,20] based on 
formation of membrane pores induced by electric pulses into tissues. 
  
7.2.2 Improve nuclear localization 
 
Another limitation in our studies is that the incorporation of TAT peptide in RcPCs did not 
improve the transfection level compared to RPCs. This result is likely to be due to the free 
DNA being fully released from TAT peptides after the reduction by intracellular GSH. 
Therefore, to improve the nuclear localization the direct covalent/non covalent attachment of 
NLS to DNA is a way of developing RPC based polyplexes.  
 
There are many strategies developed to attaching the NLS to DNA as described in Chapter 6 
(section 6.1). For instance, the attachment of NLS to the hair pin loop at the end of linear 
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DNA.[21] The intercalating agent such as psoralen[22,23] and p-azido-tetrafluoro-benzyl[24] were 
also chemically attached to the NLS peptide, in order that the NLS peptide is covalently 
attached to the DNA by photoactivation.  
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7    CONCLUSIONS  
Abstract  
 
This chapter gives an overview of the conclusions of the experimental results 
presented in this thesis. Also the limitations to our research and potential 
future work to improve the RPC base vectors are described. 
 
 
 
7.1 Conclusions 
 
 
In this thesis we have synthesized and characterised synthetic vectors by combining lysine, 
histidine and cysteine residues (described in Chapter 1, page 44) to provide the key features to 
hopefully achieve efficient gene delivery. These vectors are designed to bind DNA 
extracellularly (I), achieve cell uptake via endocytosis (III), provide a tunable endosomal 
release mechanism (IV), provide a degradable backbone in order that the DNA can be 
released once in the cytoplasm (V), and provide a nuclear localization signal (VI).  
 
The summary results of the physiological and biological properties of vectors studied in this 
thesis are shown in Table 7.1 and the associated text below. 
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Table 7.1.  Summary of physicological and biological properties  
a   Hydrodynamic diameters of the polyplexes (N:P 5) measured by dynamic light scattering with a Zetasizer 3000 (Malvern Instruments, Worcestershire, UK) 
b   Zetapotential measured by with a  Zetamaster (Malvern Instruments, Worcestershire, UK) 
c   DNA released investigated by agarose gel electrophoresis 
d The percentage of cell viability derived from the average cell viability (%) of cells treated with polyplex alone and in the combination of polyplexes and CQ, GSH-MEE and 
CQ+GSH-MEE in each cases 
e   Normalized transfection efficiency of polyplexes to PLL polyplex = transfection level of polyplex/transfection level of PLL polyplex 
f   Relative transfection enhancement by chloroquine (%) = (transfection level of polyplex with CQ/transfection level of polyplex only)*100 
DNA released from 
polyplexc
Cell viability (%)d
 
Normalized transfection 
efficiency of polyplexes to PLL 
polyplexe
Relative  transfection  
enhancement by CQ (%)f
Vectors MW (kDa) Oligopeptides 
pKa of  
2COPs 
Polyplex 
diameter  
(nm)a  
Polyplex 
zetapotential 
(mV)b  
PAA  GSH+NaCl bEND3 A549 bEND3 A549 bEND3 A549 
PLL 
PEI 
70 
25 
- 
- 
- 
- 
  81.0  ±  0.9 
108.7  ±  8.6 
  11.3  ±     9.0 
   3.4   ±     0.2 
√ 
√ 
X 
- 
79 
83 
80 
81 
1.0 
147.0         
        1.0 
    1349.4 
1049 
1268 
161 
271 
RPC 1 (111) 
RPC 2 (118) 
RPC 3 (115) 
RPC 4 (102) 
RPC 5 (94) 
111 
118 
115 
102 
94 
2COP 1 
2COP 2 
2COP 3 
2COP 4 
2COP 5 
10.51 
  6.20 
  6.16 
  6.11 
  6.09 
132.1  ±  4.5 
  98.3  ±  0.6 
  99.8  ±  0.9 
101.1  ±  2.8 
  95.5  ±  1.1 
  10.0  ±  10.9 
  14.3  ±    9.7 
  13.5  ±    7.2 
    5.8  ±    3.6 
  17.4  ±  11.3 
X 
X 
X 
X 
X 
X 
√ 
√ 
√ 
√ 
104 
102 
104 
105 
101 
88 
97 
108 
96 
104 
78.0 
1343.8 
497.9 
431.6 
1204.9 
          0.3 
406.7 
378.4 
32.4 
21.0 
1296 
2492 
2526 
3316 
1381 
257547 
722 
129 
611 
717 
RPC 1 (54) 
RPC 2 (60) 
RPC 3 (40) 
RPC 4 (48) 
RPC 5 (42) 
54 
60 
40 
48 
42 
2COP 1 
2COP 2 
2COP 3 
2COP 4 
2COP 5 
10.51 
  6.20 
  6.16 
  6.11 
  6.09 
  99.9  ±  8.3 
  98.4  ±  0.7 
  94.7  ±  1.5 
101.1  ±  2.2 
  90.7  ±  3.4 
  16.8  ±  11.0 
  10.1  ±  14.0 
  15.5  ±  15.5 
    5.3  ±    5.7 
  12.6  ±  12.3     
X 
X 
X 
X 
X 
X 
√ 
√ 
√ 
√ 
110 
93 
86 
79 
89 
95 
97 
98 
101 
96 
80.6 
6892.5 
5648.7 
1633.4 
4499.3 
5.9 
2434.6 
1519.3 
166.5 
146.5 
836 
186 
130 
32 
283 
12143 
806 
418 
22 
972 
17722 
13242 
2587 
6117 
220532 
2127 
1615 
360 
29 
28 
112 
178 
31 
2055 
4889 
RcPC 1 
RcPC 2 
RcPC 3 
RcPC 4 
RcPC 5  
RcPC 5 
RcPC 5 
RP-TAT 
37 
52 
45 
39 
45 
22 
23 
40 
2COP 1:TAT (1:1) 
2COP 2:TAT (1:1) 
2COP 3:TAT (1:1) 
2COP 4:TAT (1:1) 
2COP 5:TAT (1:1)  
2COP 5:TAT (1:1)  
2COP 5:TAT (1:3)  
TAT 
10.51 
  6.20 
  6.16 
  6.11 
  6.09 
  6.09 
  6.09 
- 
104.1 ±  1.4 
111.4  ±  2.6 
105.7  ±  3.7 
  98.1  ±  3.7 
108.1  ±  1.6     
  98.4  ±  0.9 
110.3  ±  1.1 
 95.2 ±  0.3 
  13.5  ±  10.0 
    8.8  ±    8.0 
  17.8  ±  12.8 
  10.3  ±    9.1 
  11.6  ±  14.3 
  12.6  ±    8.4 
  12.9  ±  12.0 
  14.4  ±    9.3 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
X 
√ 
√ 
√ 
√ 
√ 
√ 
√ 
124 
129 
110 
93 
86 
136 
134 
140 
124 
129 
138 
145 
107 
103 
100 
108 
16.6 
252.6 
1390.0 
14177.4 
12717.5 
2715.4 
2593.8 
21574.6 
11.5 
335.8 
173.1 
107.9 
4.1 
40.1 
36.7 
760.8 1960 
7.1.1 pKa modulation of 2COPs 
 
We have shown that using the new strategy of increasing the mixing of the constitution of the 
histidine residues in the lysine residues we were able to modulate the pKa of 2COPs 1-5 from 
10.51-6.09 (Table 7.1, pKa of 2COPs) because of the charge repulsion of subphase protons 
by its proximity to the protonated lysine residues. The modulation of the pKa of 2COPs 2-5 
(pKa 6.20-6.09) will provide a way to modulate the buffering capacity in the early endosome 
(pH ~6) leading to endosomal disruption, before it develops into the late endosome where 
polyplexes would be degraded (vector feature IV) as described in the hypothesis (Chapter 1, 
page 48).  
 
7.1.2 Diameter and zetapotential of polyplexes 
 
Regarding to the hypothesis in Chapter 1 (page 51), the incorporation of lysine into synthetic 
vectors provides the strong binding of the vector to DNA via electrostatic interactions (Vector 
feature I). The RPCs and RcPCs in this thesis have lysine residues incorporated and not only 
bind strongly to the DNA, but also form polyplexes of ~100 nm (Table 7.1, polyplex 
diameter). 
 
In addition, incorporation of lysine residues into the synthetic vectors resulted in positively 
charged polyplexes (Table 7.1, polyplex zetapotential), which further enabled them to 
electrostatically interact with the negatively charged cell membrane and promote the 
internalization into cells via syndecan-mediated endocytosis[1,2] (vector feature III) as 
described in the hypothesis in Chapter 1 (page 51).  
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7.1.3 Extracellular stability of polyplexes 
 
PLL polyplexes are less stable than RPC 1 when exposed to PAA (Table 7.1, PAA). This 
result indicates RPC 1 binds more strongly to DNA than PLL. We hypothesized that PLL has 
a higher persistent length (Figure 7.1a) than RPC 1 (Figure 7.1b). This reduction in 
persistence length of RPC 1 is a result of the reduction in charge repulsion of the protonated 
lysine groups either side of the reducible disulfide bond from the cysteines, allow the s-s bond 
to act as a molecular hinge. 
 
a) PLL (K20) electrostratic 
repulsion 
 
 
 
 
b) RPC 1 (CK8C)2
electrostratic 
repulsion 
 less electrostratic 
repulsion 
S-S bond acts like 
a molecular hinge 
“+” ‘s Not in plane 
 
 
 
 
 
 
 
 
Figure 7.1.  Disulfide bond backbone in RPC resulting in polymer chain bending compared to PLL (K20) 
with more rigid structure: a) PLL (K20) and b) RPC 1 (CK8C)2
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RPCs 2-5 have inherently more extracellular stability than other polyplexes as they did not 
release the DNA when exposed to PAA (Table 7.1, PAA). This result was a surprise as there 
were only 50% of the fully protonated lysine residues compared to RPC 1, thus, the 
electrostatic interaction would be much weaker. However, continuing the argument around 
persistence length and better compaction of RPC 1 polyplexes, one can envisage that RPCs 2-
5 have even shorter persistent lengths than RPC 1, and hence compact better with DNA, and 
are therefore more stable. This result suggested that polyplexes formed from RPCs 2-5 are 
more stable extracellularly than PLL and RPC 1 polyplexes and, therefore, would be able to 
reach the target cells after blood stream circulation (vector feature I). 
 
7.1.4 Intracellular reduction and toxicity of polyplexes 
 
As described previously in the hypothesis (Chapter 1, page 51), the disulfide backbone in 
RPCs and RcPCs provides the point of cleavage of the reducible polycations by intracellular 
GSH leading to the DNA release in the cytoplasm (vector feature V). The gel shift assay of 
RPCs 2-5 and RcPCs 2-5 polyplexes with GSH in combination with salt revealed that they are 
able to be reduced and release the DNA intracellularly (Table 7.1, GSH+NaCl). However, 
treatment of polyplexes with GSH revealed no release of DNA with RPC 1 and RcPC 1, in 
contrast to RPCs 2-5 and RcPCs 2-5. Presumably, all polyplexes are undergoing disulfide 
bond cleavage, but the enhanced positive charge of 2COP 1 (twice as many lysine residues in 
RPC 1 compared to RPCs 2-5) means the short oligopeptide fragments (2COP 1) remain 
bound to the DNA, unlike 2COPs 2-5. 
 
In addition, all of the intracellular reducible vector systems studied here are less toxic to both 
cell types than the non-degradable polymers (PLL and PEI). Presumably, the RPCs and 
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RcPCs degrade to readily cleared fragments (2COPs) compared to the high molecular weight 
PLL and PEI (Table 7.1, cell viability).  
 
7.1.5 Transfection efficiency of polyplexes 
 
7.1.5.1  Transfection in endothelial (bEND3) and epithelial (A549) cells 
 
bEND3 cells have higher transfection levels than A549 cells (Table 7.1, relative transfection 
efficiency of polyplexes to PLL polyplex). The difference observed between transfection 
efficiencies in bEND3 (mouse brain endothelial cells) and A549 (human lung carcinoma 
epithelial cells) is most likely due to the different rate of cell growth in vitro, as endothelial 
cells grow faster. Change in growth rates would have affected the level of intracellular 
glutathione and the protein expression as described in Chapter 4 (in the transfection results 
with GSH-MEE/BSO). Concomitant degradation of the nuclear membrane would, therefore, 
have led to the release of high level of glutathione into the cytoplasm leading to more efficient 
release of DNA from the polyplexes to the cytoplasm resulting in higher transfection levels 
than in A549, and may result in the different trends of the transfection between bEND3 and 
A549.  
 
The higher transfection rates of the endothelium (bEND3) cells might be a contra-indication 
to support the administration of the RPC polyplexes via intravenous injection if one was 
trying to treat a tumor, as the polyplexes would be internalized by blood vessels before 
reaching the tumor. 
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7.1.5.2 Transfection efficiency of RPC and RcPC  polyplexes  
 
In Table 7.1 we have normalized the transfection data by dividing the PLL polyplex 
transfection level into all the other polyplex transfection levels. Several conclusions can be 
drawn from this if we consider the bEND3 cells and A549 cells both independently and then 
together. 
  
bEND3 cells : 
  
(i)        PLL polyplexes are the worst transfection agents. 
(ii)       RPC 1 (111) and RPC 1 (54) have increased transfection levels over PLL (80.6 
and 16.6 fold increase, respectively).  Therefore, the incorporation of the disulfide bond has 
significantly increased the transfection efficiency. 
(iii)     The histidine containing RPCs (2-5), both high and low molecular weight, have 
increased transfection efficiency over RPC 1, ranging from 431.6 (RPC 4) to 1343.8 (RPC 2) 
for the high molecular weight materials. All of the lower molecular weight materials have 
even better transfection.  Therefore, the incorporation of histidine moieties enhances the 
transfection above and beyond the introduction of the disulfide bonds. 
 (iv)     The lower molecular weight RPCs 2-5 have higher transfection levels than 
the higher molecular weight RPCs 2-5.  Therefore, molecular weight is key 
determinant in transfection levels. We have also shown that the diameters, surface 
charges and gel shift assays of polyplexes from low molecular weight RPCs 2-5 
(~50 kDa) were similar to high molecular weight RPCs 2-5 (~100 kDa), but had 
enhanced release of DNA when treated with GSH. This result is indicative of the 
fact that the kinetics of DNA release is quicker with low molecular weight RPCs, 
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presumably because shorter fragments of polycations will dissociate more rapidly 
from the DNA. Therefore, the low molecular weight RPCs might induce higher 
transfection level than high molecular weight RPCs, and indeed this was the case. 
(v) Incorporation of TAT (RcPCs 4-5) significantly enhances the transfection of 
the polyplexes, whilst it is variable for RcPCs 2-3.  Thus, TAT potentially has an effect in 
endothelial cells (which is in contrast to A549 epithelial cells). 
(vi) The cell transfections with RcPC 5 polyplexes at different 2COP:TAT ratios 
(1:1 and 1:3) revealed that  the amount of nuclear localization signal (TAT) incorporated in 
the RcPCs does not affect the transfection level as similar transfection levels were determined  
(RcPC 5 (22 (1:1), 23 (1:3)). This result may be due to the RcPC polyplexes upon 
intracellular GSH reduction leading to the DNA dissociating totally from the TAT fragments, 
and therefore no translocation and internalization of the DNA to the nucleus. Therefore, there 
is no improvement in addition of TAT sequence relative to the transfection with RPC 
polyplexes.  
 
A549 cells : 
  
Similar conclusions with respect to the introduction of the disulfide bond, histidine and 
molecular weight can be drawn for A549 as were for bEND3 cells.  However, for RcPC 
polyplexes the transfection levels were lower or about the same for RPCs 2-5.  Therefore, it 
appears that the type of cell – endothelial or epithelial – has a significant effect on the 
transfection levels.  
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7.1.5.3 Relative transfection enhancement by CQ of RPC and RcPC  polyplexes 
 
In Table 7.1 the relative transfection enhancement of polyplexes by CQ are shown. Several 
conclusions can be drawn. 
 
(i)  We were expecting that the transfection levels of RPCs 2-5 would be less 
enhanced by CQ than RPC 1 because of the buffering capacity by histidine residues. 
However, the transfection levels of RPC 2-5 (~100 kDa) in bEND 3 enhanced by CQ were 
about the same or even higher than RPC 1, which are anomalous. These results in bEND 3 are 
in contrast to RPC 1-5 (~100 kDa) in A549, as the transfection levels were less enhanced by 
CQ when incorporation of histidines (RPCs 2-5) compared to RPC 1. Therefore, once again, 
it appears that the type of cell – endothelial or epithelial – has a significant effect on the 
transfection levels.  
 (ii) The lower molecular weight RPCs 1-5 (~50 kDa) have less enhancement by 
CQ than the higher molecular weight RPCs 1-5 (~100 kDa) in both cells. Therefore, the lower 
molecular weight RPCs used in this thesis are better transfection agents than higher molecular 
weight RPCs. 
 (iii) CQ was required to enhance the transfection levels of RcPCs 1-3 compared to 
RPC 1-3 (~50 kDa) in bEND3. However, CQ did not affect the transfection of RcPC 4-5. 
Also these results are in contrast to the transfection in A549, in which all of the RcPCs 2-5 
required CQ to give better transfection levels than corresponding RPCs. Presumably, this is 
because the buffering capacity (proton sponge mechanism) is lower in the RcPCs. 
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7.1.6  2COPs conclusion 
 
DNA polyplexes formed from 2COPs 1-5 at N:P 5 (Chapter 3) formed large particles  (1µm ) 
over a time course of 48 hr (Chapter 3, Table 3.7). In general, particle diameters less than 
1µm survive longer in the bloodstream than the larger particle if there are no interactions with 
blood components or macrophages.[4] Therefore, these polyplexes were not suitable for further 
cell transfection. As predicted the oligopeptides 2COP polyplexes were poor transfection 
agents relative to the RPCs (Chapter 4, Figure 4.16). 
 
7.1.7 Cross-linked RPC conclusions 
 
The oxidative polymerization to form cross-linked RPCs was also studied by oxidatively 
polymerising 2COPs 1-5 and 3COP 7 at 4% and 32% mole fraction of 3COP 7 (Chapter 3, 
section 3.4.5). The results showed termination in the growth of cross-linked RPCs producing 
low molecular weight polymers in all cases. The higher the mole fraction of 3COP used, the 
lower the polymer molecular weight produced. We believe the 3COP leads to the termination 
of the cross-linked RPCs during the reaction.  
 
7.2   Limitations and future work 
 
7.2.1    Improve cell targeting 
 
In our primary vector design the cell targeting ligand was not attached to the vector. 
Therefore, theses non-targeting vectors can not be used effectively in transfection in vivo. To 
improve this vector feature the targeting ligands have to be attached to the vectors as 
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described in Chapter 1 (Section 1.1.2.1b). The targeting ligands that have been widely used 
are transferrin, which specifically targets transferrin receptors that are overexpressed in 
rapidly dividing tissues, such as tumors,[5-13]  and folic acid that specifically target folate 
receptors, which are also overexpressed in proliferating tissues.[13-15] In addition, various 
sacharide ligands such as galactose, manose, fucose, lactose as well as asialoorosomucoid and 
asialoglycoprotein are specifically targeting asialoglycoprotein receptors, which are 
abundantly expressed in hepatocytes.[12,13,16]   
 
In addition, using endothelium (bEND3) and epithelium cell lines (A549) in the in vitro 
transfection studies indicated that the in vivo injection of RPC polyplexes in blood vessel 
would not be a suitable method for delivering genes, as the polyplexes entered into the 
endothelial cells. Therefore, to improve the transfection at the target sites, the administration 
methods have to be considered such as direct injection[17,18] and electroporation[19,20] based on 
formation of membrane pores induced by electric pulses into tissues. 
  
7.2.2 Improve nuclear localization 
 
Another limitation in our studies is that the incorporation of TAT peptide in RcPCs did not 
improve the transfection level compared to RPCs. This result is likely to be due to the free 
DNA being fully released from TAT peptides after the reduction by intracellular GSH. 
Therefore, to improve the nuclear localization the direct covalent/non covalent attachment of 
NLS to DNA is a way of developing RPC based polyplexes.  
 
There are many strategies developed to attaching the NLS to DNA as described in Chapter 6 
(section 6.1). For instance, the attachment of NLS to the hair pin loop at the end of linear 
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DNA.[21] The intercalating agent such as psoralen[22,23] and p-azido-tetrafluoro-benzyl[24] were 
also chemically attached to the NLS peptide, in order that the NLS peptide is covalently 
attached to the DNA by photoactivation.  
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8.  APPENDIX 
 
8.1 Preparative HPLC chromatograms of crude oligopeptides and 
analytical HPLC chormatograms of purified oligopeptides 
 
8.1.1 Preparative HPLC and analytical HPLC of 2COP 1 
 
-100
0
100
200
300
400
500
600
0.0 5.0 10.0 15.0 20.0 25.0 30.0 35.0 40.0 45.0 50.0 55.6
mAU
min
M1224A (crude) #1 [modified by BIRMINGHAM UNIV.] M1224A (crude) UV_VIS_1
6.50
10.77
21.58
23.50
25.04
35.56
WVL:210 nm 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
6.505 10.2625 16.462 0.7 
10.768 21.491 39.77 1.47 
21.584 72.4728 33.147 4.96 
23.5 915.8373 509.08 62.65 
25.035 373.135 256.823 25.53 
35.561 68.6066 21.518 4.69 
Figure 8.1.   Preparative HPLC chromatogram of crude 2COP 1 with MeCN (1%) plus TFA (0.05%) as 
an elution solvent at 10 ml/min flow rate for 60 minutes: Preparative RP-HPLC 
(Phenomenex), C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
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Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
2.753 0.0923 2.111 0.07 
4.345 0.4416 1.347 0.34 
10.12 129.9928 199.343 99.59 
 
Figure 8.2.  Analytical HPLC chromatogram of purified 2COP 1 with 1% of MeCN:water (60:40) plus 
TFA (0.05%) as an elution solvent at 10 ml/min flow rate: Analytical RP-HPLC 
(Phenomenex), C18 with 250 mm × 4.60 mm ID and 10 μm pore size 
 302
8.1.2   Preparative HPLC and analytical HPLC of 2COP 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
29.162 618.4015 0.051 14.32 
34.794 3036.87 1719.812 70.3 
37.78 147.7109 148.543 3.42 
50.034 516.8252 739.581 11.96 
 
Figure 8.3.  Preparative HPLC chromatogram of 2COP 2 with the gradient of MeCN (0-5%) plus TFA 
(0.05%) for the first 30 minutes, and with MeCN+TFA (5%) for further 10 minutes as an 
elution solvent at 10 ml/min flow rate: Preparative RP-HPLC (Phenomenex), C18 with 250 
mm × 21.2 mm ID and 10 μm pore size 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
16.173 3.9422 8.923 0.44 
21.308 19.1764 29.486 2.14 
22.107 874.5357 854.936 97.42 
 
 
Figure 8.4.  Analytical HPLC chromatogram of 2COP 2 with 0-5% gradient of MeCN:water (60:40) plus 
TFA (0.05%) as an elution solvent at 10 ml/min flow rate for 40 minutes: Analytical RP-
HPLC (Phenomenex), C18 with 250 mm × 4.60 mm ID and 10 μm pore size 
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8.1.3   Preparative HPLC and analytical HPLC of 2COP 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
6.493 12.9678 35.454 0.27 
15.356 81.0607 91.457 1.68 
23.147 72.938 42.955 1.51 
27.355 61.993 49.589 1.28 
30.919 1660.315 729.83 34.38 
31.909 859.2431 613.991 17.79 
47.143 2081.071 0.008 43.09 
 
Figure 8.5.  Preparative HPLC chromatogram of 2COP 3 with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes: Preparative RP-HPLC (Phenomenex), 
C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
23.734 1.237 1.228 1.55 
26.531 78.7612 56.096 98.45 
 
Figure 8.6.  Analytical HPLC chromatogram of 2COP 3 with 3% of MeCN:water (60:40) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate: Analytical RP-HPLC (Phenomenex), C18 
with 250 mm × 4.60 mm ID and 10 μm pore size 
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8.1.4 Preparative HPLC and analytical HPLC of 2COP 4 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
6.551 2.5335 6.13 0.29 
10.207 15.7244 4.979 1.78 
15.001 14.1372 19.487 1.6 
20.53 2.0093 2.004 0.23 
26.193 6.1545 4.649 0.7 
30.414 27.3071 19.554 3.09 
31.452 47.0425 11.172 5.32 
34.65 338.4223 177.384 38.29 
36.055 430.5263 131.709 48.71 
 
Figure 8.7.  Preparative HPLC chromatogram of 2COP 4 with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes: Preparative RP-HPLC (Phenomenex), 
C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
9.006 1.0138 1.819 0.56 
10.128 0.681 0.991 0.38 
22.948 3.1209 1.806 1.72 
27.925 176.6629 102.104 97.35 
 
Figure 8.8.  Analytical HPLC chromatogram of 2COP 4 with 3% of MeCN:water (60:40) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate: Analytical RP-HPLC (Phenomenex), C18 
with 250 mm × 4.60 mm ID and 10 μm pore size 
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8.1.5 Preparative HPLC and analytical HPLC of 2COP 5 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
6.525 3.3749 8.451 0.29 
15.247 26.5209 29.116 2.25 
20.917 4.2119 4.004 0.36 
23.387 11.3968 10.66 0.97 
27.317 10.083 5.612 0.86 
30.468 69.63 37.784 5.91 
32.583 70.8984 11.716 6.01 
36.913 445.3131 182.781 37.77 
38.111 198.7216 148.707 16.85 
39.708 280.6761 99.729 23.8 
51.127 58.2464 15.338 4.94 
 
Figure 8.9.  Preparative HPLC chromatogram of 2COP 5 with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes: Preparative RP-HPLC (Phenomenex), 
C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
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Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
3.398 1.1046 13.563 0.12 
4.706 1.0048 2.424 0.11 
11.645 5.5597 6.243 0.61 
22.074 15.8503 12.839 1.74 
23.696 885.4355 350.93 97.41 
 
 
Figure 8.10.  Analytical HPLC chromatogram of 2COP 5 with 3% of MeCN:water (60:40) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate: Analytical RP-HPLC (Phenomenex), C18 
with 250 mm × 4.60 mm ID and 10 μm pore size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
-50
100
200
300
400
0.0 2.0 4.0 6.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 22.0 24.0 26.0 28.0 30.0 32.0 35.3
mAU
min
Peptide (3%C) #56 F Fr2 repure (9Mar) UV_VIS_1
1 - 3.3982 - 4.706 3 - 11.644
4 - 22.074
5 - 23.696
WVL:210 nm
 307
8.1.6  Preparative HPLC and analytical HPLC of 2COP 6 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
28.878 16.1422 27.719 1.63 
31.267 11.7999 19.283 1.19 
31.793 74.5133 114.364 7.54 
32.809 32.5065 43.353 3.29 
34.841 26.6092 50.353 2.69 
35.351 132.3657 126.6 13.39 
37.631 694.6778 716.758 70.27 
 
Figure 8.11.  Preparative HPLC chromatogram of 2COP 6 with the gradient of MeCN (0-10%) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate for 40 min: Preparative RP-HPLC 
(Phenomenex), C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
36.435 988.786 1234.293 97.56 
37.631 24.7081 80.372 2.44 
 
 
Figure 8.12.  Analytical HPLC chromatogram of 2COP 6 with 0-10% gradient of MeCN:water (60:40) 
plus TFA (0.05%) as an elution solvent at 10 ml/min flow rate for 40 minutes: Analytical RP-
HPLC (Phenomenex), C18 with 250 mm × 4.60 mm ID and 10 μm pore size 
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8.1.7  Preparative HPLC and analytical HPLC of 3COP 7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
6.514 3.1792 6.801 0.76 
9.59 1.5977 2.294 0.38 
11.025 4.5985 7.098 1.1 
13.636 3.8357 4.191 0.92 
15.141 2.3249 3.398 0.56 
18.027 1.2151 1.767 0.29 
19.713 395.2777 229.826 94.82 
25.945 1.0656 1.273 0.26 
35.193 3.7732 2.57 0.91 
 
Figure 8.13. Preparative HPLC chromatogram of 3COP 7 with MeCN (3%) plus TFA (0.05%) as an 
elution solvent at 10 ml/min flow rate for 50 minutes: Preparative RP-HPLC (Phenomenex), 
C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
2.677 0.8971 12.226 0.36 
8.895 249.2342 473.943 99.64 
 
Figure 8.14.  Analytical HPLC chromatogram of 3COP 7 with 3% of MeCN:water (60:40) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate: Analytical RP-HPLC (Phenomenex), C18 
with 250 mm × 4.60 mm ID and 10 μm pore size 
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8.1.8 Preparative HPLC and analytical HPLC of TAT  
 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
18.243 5.4387 11.66 0.8 
30.876 212.0514 146.898 31.21 
31.94 375.2773 520.296 55.23 
33.288 86.6549 47.511 12.75 
 
Figure 8.15. Preparative HPLC chromatogram of TAT with the gradient of MeCN (0-20%) plus TFA 
(0.05%) as an elution solvent at 10 ml/min flow rate for 60 min: Preparative RP-HPLC 
(Phenomenex), C18 with 250 mm × 21.2 mm ID and 10 μm pore size 
 
 
 
 
 
 
 
Ret.Time (min) Area (mAU*min) Height (mAU) Rel.Area (%) 
21.73 1.5041 7.601 1.27 
22.534 116.876 284.337 98.73 
 
Figure 8.16.  Analytical HPLC chromatogram of TAT with 0-20% gradient of MeCN:water (60:40) plus 
TFA (0.05%) as an elution solvent at 10 ml/min flow rate for 40 minutes: Analytical RP-
HPLC (Phenomenex), C18 with 250 mm × 4.60 mm ID and 10 μm pore size 
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8.2 1H NMR of purified oligopeptides 
 
8.2.1 1H NMR of purified 2COP 1 
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Figure 8.17.  1H NMR spectra of 2COP 1 
 
 
1H NMR δ (ppm) (D2O:H2O = 1:9): 4.61 (t, J = 5.23Hz, 1H, -CO-CH-N-), 4.36-4.24 (m, 9H, -CO-CH-N-), 2.98 
(t, J = 6.99 Hz, 20H, CH-C3H6-CH2-NH2, -CH2-SH), 1.79-1.66 (m, 32H, CH-CH2-CH2-CH2-CH2-NH2, CH-
CH2-CH2-CH2-CH2-NH2), 1.45-1.42 (m, 16H, CH-CH2-CH2-CH2-CH2-NH2) 
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8.2.2 1H NMR of purified 2COP 2 
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Figure 8.18.  1H NMR spectra of 2COP 2 
 
 
1H NMR δ (ppm) (D2O:H2O = 1:9): 8.63-8.61 (m, 4H, Im, -N=CH-NH-), 7.32-7.27 (m, 4H, Im, -C-CH-N-), 
4.69-4.63 (m, 4H, -CO-CH-N-), 4.54 (t, 1H, J = 5.73 Hz,-CO-CH-N-), 4.35 (t, J = 5.73 Hz, 1H, -CO-CH-N-), 
4.33-4.21 (m, 4H, -CO-CH-N-), 3.21-3.10 (m, 10H, -NH-CH-CH2-,-CH2-SH), 3.07-2.92 (m, 10H, CH-C3H6-
CH2-NH2, -CH2-SH), 1.74-1.66 (m, 16H, CH-CH2-CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.45-1.38 
(m, 8H, CH-CH2-CH2-CH2-CH2-NH2) 
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8.2.3 1H NMR of purified 2COP 3 
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Figure 8.19.  1H NMR spectra of 2COP 3 
 
 
1H NMR δ (ppm) (D2O:H2O = 1:9): 8.63-8.62 (m, 4H, Im, -N=CH-NH-), 7.31-7.26 (m, 4H, Im, -C-CH-N-), 
4.67-4.64 (m, 4H, -CO-CH-N-), 4.49 (t, 1H, J = 5.59 Hz,-CO-CH-N-), 4.34-4.21 (m, 5H, -CO-CH-N-), 3.25-
3.10 (m, 10H, -NH-CH-CH2-, -CH2-SH), 3.08-2.89 (m, 10H, CH-C3H6-CH2-NH2, -CH2-SH), 1.77-1.65 (m, 16H, 
CH-CH2-CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.45-1.35 (m, 8H, CH-CH2-CH2-CH2-CH2-NH2) 
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8.2.4 1H NMR of purified 2COP 4 
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Figure 8.20.  1H NMR spectra of 2COP 4 
 
 
1H NMR δ (ppm) (D2O:H2O = 1:9): 8.64-8.62 (m, 4H, im, -N=CH-NH-), 7.32-7.28 (m, 4H, im, -C-CH-N-), 
4.69-4.63 (m, 4H, -CO-CH-N-), 4.53 (t, 1H, J = 5.66 Hz,-CO-CH-N-), 4.35 (m, 1H, -CO-CH-N-), 4.33-4.27 (m, 
4H, -CO-CH-N-), 3.26-3.03 (m, 10H, -NH-CH-CH2-,-CH2-SH), 2.98-2.90 (m, 10 H, CH-C3H6-CH2-NH2, -CH2-
SH), 1.76-1.65 (m, 32H, CH-CH2-CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-CH2-NH2), 1.43-1.35 (m, 8H, CH-
CH2-CH2-CH2-CH2-NH2) 
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8.2.5 1H NMR of purified 2COP 5 
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Figure 8.21.  1H NMR spectra of 2COP 5 
 
 
1H NMR δ (ppm) (D2O:H2O = 1:9): 8.64-8.63 (m, 4H, Im, -N=CH-NH-), 7.34-7.30 (m, 4H, Im, -C-CH-N-), 
4.69-4.63 (m, 4H, -CO-CH-N-), 4.55 (t, 1H, J = 5.62 Hz,-CO-CH-N-), 4.33-4.24 (m, 5H, -CO-CH-N-), 3.22-
3.07 (m, 10H, -NH-CH-CH2-, -CH2-SH), 3.01-2.94 (m, 10 H, CH-C3H6-CH2-NH2, -CH2-SH), 1.74-1.64 (m, 
16H, -CH-CH2-CH2-CH2-CH2-NH2, -CH-CH2-CH2-CH2-CH2-NH2), 1.45-1.38 (m, 8H, -CH-CH2-CH2-CH2-CH2-
NH2) 
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8.2.6 1H NMR of purified 2COP 6 
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Figure 8.22.  1H NMR spectra of 2COP 6 
 
 
1H NMR δ (ppm) (D2O): 8.64-8.63 (m, 8H, Im, -N=CH-NH-), 7.28-726 (m, 8H, Im, -C-CH-N-), 4.73-4.63 (m, 
8H, -CO-CH-N-), 4.45 (t, 1H, J = 5.38 Hz,-CO-CH-N-), 4.17 (t, J = 5.37 Hz, 1H, -CO-CH-N-), 3.00-2.84 (m, 
20H, -NH-CH-CH2-, -CH2-SH) 
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8.2.7 1H NMR of purified 3COP 7 
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Figure 8.23.  1H NMR spectra of 3COP 7 
 
 
1H NMR δ (ppm) (D2O:H2O = 1:9): 4.54-4.49 (m, 2H, -CO-CH-N-), 4.36-4.31 (m, 4H, -CO-CH-N-), 3.13-2.90 
(m, 14H, CH-C3H6-CH2-NH2, -CH2-SH), 1.81-1.66 (m, 16H, CH-CH2-CH2-CH2-CH2-NH2, CH-CH2-CH2-CH2-
CH2-NH2), 1.45-1.42 (m, 8H, CH-CH2-CH2-CH2-CH2-NH) 
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8.2.8 1H NMR of purified TAT 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H
N
O
NH
NH2HN
N
H
O
NH
NH2HN
H
N
O
NH
NH2HN
N
H
O
NH2O
H
N
O
NH
NH2HN
N
H
O
NH
NH2HN
H
N
O
NH2
N
H
O
NH2
H
N
O
NH
NH2HN
HS
NH2
O
OH
O
SH
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0.511.522.533.544.555.566.577.588.599.5
(ppm)
 
Figure 8.24.  1H NMR spectra of TAT 
 
1H NMR δ (ppm) (D2O:H2O=1:9):  8.78 (d, J = 6.41 Hz, 1H, -CH-CO-NH-), 8.48 (m, 9H, -CH-CO-NH-), 7.52 
(m, 4H, -CH-CH2-CH2-CH2-NH2), 7.18-7.16 (m, 6H, -CH-CH2-CH2-CH2-NH-CNH-NH2, -N-CH-CH2-NH2,), 
4.34-4.24 (m, 4H, -CO-CH-N-), 3.20-3.16 (m, 12H, -CH-CH2-CH2-CH2-NH-CNH-NH2), 3.10 (dq, 2H, J = 17.42 
Hz, 5.50 Hz, -N-CH-CH2-SH), 3.04-2.98 (m, 6H, -CH-CH2-CH2-CH2-CH2-NH2, -N-CH-CH2-SH), 2.34 (t, J = 
8.14 Hz, 2H, -CH-CH2-CH2-CO-NH2), 2.06-1.92 (m, 2H, -CH-CH2-CH2-CO-NH2), 1.82-1.61 (m, 32H, CH-
CH2-CH2-CH2-CH2-NH2, -CH-CH2-CH2-CH2-NH-CNH-NH2), 1.44-1.36 (m, 4H, CH-CH2-CH2-CH2-CH2-NH2) 
 
 318
8.3   Samples of 1H NMR spectra at different pH in NMR titration 
experiments of 2COPs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.25. 1H NMR spectra of Hε of 2COP 1 at pH 2.88, 10.37 and 12.75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8.26. 1H NMR spectra of H5 and H6 of 2COP 5 at pH 2.64, 5.84 and 7.55 
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Figure 8.27. 1H NMR spectra of H5 and H6 of 2COP 6 at pH 3.04, 5.54 and 7.00 
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8.4 Samples of GPC chromatograms in oxidative polymerization  
experiments 
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Figure 8.28.  Comparison of the chromatogram of the oxidative polymerization of 2COP 1 at 30 mM   
concentration incubated at ambient for 48 hr analyzed by GPC 
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Figure 8.29.  Comparison of the chromatogram of the oxidative polymerization of 2COP 1 at 60 mM 
concentration incubated at ambient for 48 hr analyzed by GPC 
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Figure 8.30.  Comparison of the chromatogram of the oxidative polymerization of 2COP 1 at 18 mM 
concentration incubated at a) ambient and b) 40°C for 72 hr analyzed by GPC 
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